<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7tmmt7527sb st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="Chapters_1-5.pdf">Chapters_1-5.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">12.4MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> Chapters_1-5.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>CHAPTER 1</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anatomy-and-physiology-of-the-integumentary-system">Anatomy and Physiology of the Integumentary System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anatomy-and-physiology-of-the-integumentary-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Noreen Heer Nicol</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Name the layers and appendages of the skin, which comprise the integumentary system.</li>
<li>Identify key functions of the integumentary system.</li>
<li>List the structures of the epidermis, dermis, and subcutaneous layers.</li>
<li>Name the specialized cells in the epidermis and dermis.</li>
<li>Explain the mechanism of skin cell turnover.</li>
<li>List the key structures and role of the nails, hair, and glands.</li>
<li>Discuss the immunology of the skin and its relationship to skin diseases.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>The skin is the largest and most visible organ of the body.</li>
<li>Skin forms the integumentary system when combined with the accessory structures of hair, nails, and glands.</li>
<li>The five layers of the epidermis in ascending order are basal cell layer (stratum germinativum also called stratum basale), prickle cell layer (stratum spinosum), granular cell layer (stratum granulosum), stratum lucidum, and horny cell layer (stratum corneum).</li>
<li>Knowledge of the anatomy and physiology of the skin and its appendages is essential to accurate patient assessment and treatment.</li>
<li>Alterations in the skin will affect the overall well-being of an individual.</li>
<li>The healthy integumentary system is a complex, dynamic system providing diverse functions including protection, homeostasis, excretion, temperature regulation, vitamin D production, sensory perception, psychosocial effects, and wound healing.</li>
<li>The concept of the skin, especially the epidermis, as barrier to physical, anti-microbial,</li>
</ul>
<p>immunologic, and ultraviolet insult as well as maintaining internal homeostasis is important.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview-and-functions-of-the-integumentary-system">I. OVERVIEW AND FUNCTIONS OF THE INTEGUMENTARY SYSTEM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview-and-functions-of-the-integumentary-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The integumentary system is an extraordinary body system, which includes the largest and most visible organ, the skin. The skin forms the integumentary system when combined with the accessory structures of hair, nails, and glands. As the only organ of the body, which is readily available to be inspected and judged by all, the skin's very visible characteristics play a unique role in every individual's well-being. A conceptual framework for recognizing and understanding diseases of the skin relies on principles of diagnosis common to medicine and nursing, namely, historical and social factors, physical examination, and laboratory techniques. To relate these principles of diagnosis and treatment to clinicopathologic events in dermatology, it is important to start with an overview of the skin. The skin is composed of three layers: epidermis, dermis, and subcutaneous fat accounting for 15% to 20% of the body's weight (Figure 1-1). Disease may localize exclusively in one or all of these layers. There is considerable regional variation in the relative thickness of these layers. The more common skin conditions take into account a diverse spectrum of clinical pathology, which may be characterized by inflammation (noninfectious), pigmentary abnormalities, infection and infestation, benign and malignant cellular proliferations, and disease where the basic mechanisms are relatively obscure. To conceptualize skin disorders effectively, it is essential to consider the changes in the structure and function of the skin and to understand the specific clinical pathology related to the changes. The healthy integumentary system is a complex, dynamic system providing diverse functions (Table 1-1), including:</p>
<p><img src="assets/images/image-20251225-9c6a0e01.jpeg" alt="img-0.jpeg">
FIGURE 1-1. Anatomy of the skin. (From Anatomical Chart Co.)</p>
<p>TABLE 1-1 Function and Structure of the Healthy Integumentary System</p>
<table><thead><tr><th>Layer of the Skin</th><th>Function</th><th>Structure</th></tr></thead><tbody><tr><td>Epidermis</td><td></td><td></td></tr><tr><td>Pain receptors</td><td></td><td></td></tr><tr><td>Touch receptors</td><td></td><td></td></tr><tr><td>Keratin production</td><td></td><td></td></tr><tr><td>Melanin production</td><td></td><td></td></tr><tr><td>Immune system afferent limb</td><td>Water loss barrier</td><td></td></tr><tr><td>Sensory organ</td><td></td><td></td></tr><tr><td>Ultraviolet protection</td><td></td><td></td></tr><tr><td>Infection barrier</td><td></td><td></td></tr><tr><td>Excretion</td><td>Cellular Layers</td><td></td></tr><tr><td>Stratum corneum</td><td></td><td></td></tr><tr><td>Stratum lucidum (on palms and soles only)</td><td></td><td></td></tr><tr><td>Stratum granulosum</td><td></td><td></td></tr><tr><td>Stratum spinosum</td><td></td><td></td></tr><tr><td>Stratum germinativum</td><td></td><td></td></tr><tr><td>Dermis</td><td></td><td></td></tr><tr><td>Temperature receptors</td><td></td><td></td></tr><tr><td>Deep pressure and touch receptors</td><td></td><td></td></tr><tr><td>Hair shaft and follicles</td><td></td><td></td></tr><tr><td>Lymphatic vessels</td><td></td><td></td></tr><tr><td>Sebaceous and sweat glands</td><td></td><td></td></tr><tr><td>Nerves</td><td></td><td></td></tr><tr><td>Arrector pili muscles</td><td>Temperature regulation</td><td></td></tr><tr><td>Immunoregulatory function</td><td></td><td></td></tr><tr><td>Vitamin D production</td><td></td><td></td></tr><tr><td>Integument strength</td><td></td><td></td></tr><tr><td>Elastic tone</td><td>Papillary dermis</td><td></td></tr><tr><td>Reticular dermis</td><td></td><td></td></tr><tr><td>Connective tissue and collagen bundles</td><td></td><td></td></tr><tr><td>Subcutaneous Fat Layer</td><td></td><td></td></tr><tr><td>Bulb and matrix of hair follicle</td><td></td><td></td></tr><tr><td>Larger arteries and veins</td><td></td><td></td></tr><tr><td>Pluripotential cells</td><td>Insulation</td><td></td></tr><tr><td>Shock absorption</td><td></td><td></td></tr><tr><td>Energy storage and fat metabolism</td><td></td><td></td></tr><tr><td>Body topography</td><td>Adipose tissue</td><td></td></tr><tr><td>Loose connective tissue</td><td></td><td></td></tr></tbody></table>
<p>A. Protection</p>
<ol>
<li>An intact stratum corneum provides a physical barrier against foreign substances and bacteria.</li>
<li>Mechanical strength is provided by intercellular bonding in the epidermis and collagen, elastin, and ground substance in the dermis.</li>
<li>Subcutaneous tissue acts as a shock absorber.</li>
<li>Melanin screens and absorbs ultraviolet radiation.</li>
</ol>
<p>B. Homeostasis</p>
<ol>
<li>The skin prevents dehydration through loss of internal fluids and electrolytes.</li>
<li>The skin limits absorption of external fluids and gases.</li>
</ol>
<p>C. Excretion</p>
<ol>
<li>The glands of the skin excrete waste products, in addition to sweat, which is mostly water and electrolytes.</li>
<li>The waste products excreted can include urea, lactic acid, bile, ammonia, and even alcohol.</li>
</ol>
<p>D. Thermoregulation</p>
<ol>
<li>Body temperature is controlled by:
a. Conduction of heat from the skin to the air or other objects
b. Radiation of heat from the body surface
c. Convection of heat by air currents
d. Evaporation of perspiration</li>
<li>The cutaneous vasculature plays an important role in body temperature regulation. Blood vessels:
a. Dilate when the external environment is warm to promote heat loss</li>
</ol>
<p>b. Constrict in a cold environment to conserve heat</p>
<p>E. Vitamin D production</p>
<ol>
<li>Ultraviolet light converts 7-dehydrocholesterol to vitamin D3 in the epidermis.</li>
<li>Vitamin D3 is converted in the kidneys into the active form of vitamin D.</li>
</ol>
<p>F. Sensory perception</p>
<ol>
<li>The system contains mechanoreceptors and unmyelinated nerve fibers.</li>
<li>Touch, pressure, temperature, pain, and itch are transmitted.</li>
</ol>
<p>G. Psychosocial</p>
<ol>
<li>The skin, nails, and hair influence sexual attraction, general well-being, and self-image. Outward expressions of anxiety, fear, and anger are visible through sweating, pallor, and flushing.</li>
<li>Different societies and culture greatly influence how one accepts or rejects outward appearance of this body system.</li>
</ol>
<p>H. Wound healing</p>
<ol>
<li>The skin can repair and regenerate itself.</li>
<li>These important wound healing abilities are influenced by multiple internal and external factors.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-structure-of-the-skin">II. STRUCTURE OF THE SKIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-structure-of-the-skin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Epidermis (Figure 1-2)</p>
<ol>
<li>The epidermis is the outermost structure of the skin. It:</li>
</ol>
<p>a. Contains multiple layers of cells (stratified)
b. Has considerable regional variation, depending on the site:</p>
<p>(1) Thickest on palms and soles, approximately 1.5 mm
(2) Very thin on eyelid, less than 0.4 mm</p>
<p>c. Is without lymphatic and vascular channels, and connective tissue; therefore, it derives its nutritional support from the underlying dermis.</p>
<ol start="2">
<li>Keratinization:</li>
</ol>
<p>a. The epidermis rejuvenates itself through the process of keratinization. Epidermal keratinization is the process of morphological and biochemical differentiation of the keratinocyte, beginning in the basal cell layer and ending in the stratum corneum as a horn or cornified cell.</p>
<ol start="3">
<li>Keratin:</li>
</ol>
<p>a. Keratin, the major product of the cornified cell, is a highly resistant, insoluble, fibrous protein. It represents the end product of a differentiated epidermal keratinocyte.
b. Keratinization also involves synthesis of several other proteins and additional substances such as keratohyalin granules, which act as glue.</p>
<ol start="4">
<li>Layers of the epidermis:</li>
</ol>
<p>a. There are five layers in the epidermis.
b. The layers are named to reflect the stage the keratinocytes are in during the process of keratinization.
c. These layers are not independent of each other but rather are interrelated and</p>
<p>continuous phases of the life of a keratinocyte. Keratinocytes move up as they age (Figure 1-2).</p>
<p>(1) Germinating or basal cell layer (stratum basale, also called stratum germinativum): the basal cell layer is the innermost layer of the epidermis. It consists of a single layer of elongated cells. Each cell divides (mitosis) into two daughter cells. One remains as "basal cell," the other migrates upward through the remainder of the epidermis.</p>
<p>(2) Prickle cell or spiny layer (stratum spinosum): the prickle cell layer consists of many rows of flattened polygonal cells that are held together by "prickles" or "spines." These prickles are desmosomes, which are small thickenings in an intracellular bridge.</p>
<p>(3) Granular cell layer (stratum granulosum): the granular cell layer is most prominent on the palms and soles. It consists of one to three layers of flattened, irregularly shaped cells that have large numbers of keratohyalin granules. Keratohyalin granules comprise particulate materials that have a high sulfur-protein content. Keratinocytes lose their nucleus in this layer, thereby becoming nonviable.</p>
<p>(4) Glassy layer (stratum lucidum): the stratum lucidum is made up of one or more rows of distended irregular cells. It is an even, colorless, translucent, or shiny band. The stratum lucidum is almost nonexistent except on thicker skin areas such as palms and soles.</p>
<p>(5) Horny cell layer (stratum corneum): the horny cell layer consists of anucleated, cornified cells. They are also known as horn cells. The nucleus and other cytoplasmic organelles have been totally degraded. The remaining material is predominantly keratin. Other substances include water, water-insoluble proteins, amino acids, sugars, urea, minerals, and lipids. These act as buffers and lubricants.</p>
<p>(a) Cells of the epidermis are continuously being shed or desquamated from the stratum corneum.</p>
<p>(b) It takes approximately 14 days for the keratinocyte to travel from the basal cell layer to the stratum corneum. Once in the stratum corneum, it takes another 14 days before it is shed.</p>
<p>(c) New cells are formed in the basal cell layer at the same rate cells are shed in the stratum corneum.</p>
<ol start="5">
<li>Functions of the horny cell layer:</li>
</ol>
<p>a. The stratum corneum serves many functions for the epidermis and the skin in general:</p>
<p>(1) It functions as the body's major physical barrier by being relatively impermeable to water and electrolytes.</p>
<p>(2) It resists damaging chemicals, provides physical toughness, impedes passage of electrical currents, and retards the proliferation of microorganisms through its relatively dry surface.</p>
<p>(3) The stratum corneum also functions as a reservoir for topical medications.</p>
<p>b. Although the stratum corneum is an effective barrier to most substances, some are able to pass through. Substances can be transported through the skin by three pathways:</p>
<p>(1) Through adnexal orifices (pilosebaceous unit) and sweat glands
(2) Through the intercellular spaces between the cornified cells
(3) Directly through the cornified cells</p>
<p>B. Cells in the epidermis</p>
<ol>
<li>
<p>Keratinocytes account for at least 80% of the cellular components of the epidermis. They have the specialized function of producing keratin. During keratinization, the keratinocytes change shape (flatten), lose organelles, form fibrous protein (keratin), become dehydrated, and thicken their cell membrane (see discussion above).</p>
</li>
<li>
<p>Melanocyte cells:</p>
</li>
</ol>
<p>a. Embryonic development: melanocytes are the pigment-producing cells of the epidermis. Embryonically, they are derived from the neural crest, and by the 8th week of development, melanocytes enter the epidermis. In the fetal epidermis, melanocytes are found at suprabasal levels. When the fetus is fully developed, they are located in the basal cell layer. Failure of the melanocyte to migrate to the basal cell layer results in entities such as blue nevus and mongolian spots.
b. Regional variation: melanocytes are present on all parts of the body with regional variation. There are more melanocytes on the face than on the abdomen. Ratios of melanocytes to keratinocytes vary from 1:4 to 1:10. Advancing age leads to a greater shift favoring keratinocytes.
c. Melanosome/melanin: within the cytoplasm of melanocytes are special organelles called melanosomes. Melanin is stored in the melanosome and is synthesized through the conversion of the colorless amino acid, tyrosine. There are two types of melanin. Eumelanins account for brown and black colors. Pheomelanins account for yellow to reddish brown colors.
d. Epidermal melanin unit: melanocytes are dendritic cells. Their dendrites extend for long distances in the epidermis. This allows one melanocyte to be in contact with many keratinocytes. The interaction of the melanocyte and keratinocyte forms a biologic unit called the epidermal melanin unit. Melanosomes are transferred from the dendrite of the melanocyte to keratinocytes by a process called apocopation. The keratinocyte phagocytizes the melanin-filled tips of the melanocytes. Once transferred to the keratinocyte, the fully melanized melanosomes are partially degraded by lysosomal enzymes or desquamated with cornified cells.
e. Melanin production: melanin production is controlled by genetics, hormones, and the environment. The number of melanocytes in the epidermis is the same regardless of race or sex:</p>
<p>(1) It is the amount of melanin in the keratinocyte that determines skin color. The difference in the skin color among individuals is the result of the differences in level of synthetic activity including degree of melanization and rate of degradation of the melanosome within the keratinocyte.
(2) There is also evidence that tyrosinase activity also plays a role in melanization. Dark-skinned people produce melanosomes that are larger than light-skinned people, resulting in more melanin synthesis. Tyrosinase activity is also increased in blacks.</p>
<p>(3) The size of melanosomes is the principal factor in determining how they will be distributed in the keratinocyte. The larger melanosomes of dark-skinned people are packaged individually in a membrane within the cytoplasm of the keratinocyte. In light-skinned people, smaller melanosomes are package in membrane-bound complexes in the keratinocyte.</p>
<p>f. Hormonal influence: hormones profoundly influence melanin pigmentation, but their precise action at the cellular level is unknown. It is presently believed that the melanocyte-stimulating hormone (MSH) causes a dispersion of melanosomes within melanocytes. Regional variations exist in the sensitivity of the epidermal melanin units to specific hormones:</p>
<p>(1) In pregnancy, there is increased pigmentation of the nipples and areolae, and to a lesser extent, an increased pigmentation of facial skin, midline of the abdomen, and genitalia. This is due to an increase in the number of active melanocytes. The hormones primarily responsible for the color changes are estrogen, progesterone, and possibly MSH.</p>
<p>(2) The same phenomenon occurs in women taking birth control pills.</p>
<p>g. Pigment variation: areas of leukoderma or "whitening" of the skin can be caused by different phenomena:</p>
<p>(1) In vitiligo, the affected skin becomes white because melanocytes are destroyed, leading to a decrease in their number.</p>
<p>(2) There are different types of albinism in which there is partial or complete absence of pigment in the skin, hair, and eyes. Albinism results from defects in the production and distribution of melanin. These defects can be found in the enzyme tyrosinase, melanosome development, or in the type of melanin produced.</p>
<p>(3) Local areas of increased pigmentation are due to a variety of causes:</p>
<p>(a) The typical freckle is caused by localized increased production of pigment by a normal number of melanocytes.</p>
<p>(b) Nevi are benign proliferations of melanocytes.</p>
<p>(c) Melanomas are the malignant counterparts of nevi.</p>
<p>h. Ultraviolet light: the most important function of melanin is to shield the skin from the sun's ultraviolet rays by absorbing its radiant energy. The absorption spectrum of melanin encompasses the entire range of ultraviolet and visible light.</p>
<ol>
<li>Melanosomes function to scatter and absorb ultraviolet light:</li>
</ol>
<p>(a) Exposure to ultraviolet light expedites the transfer of melanosomes to keratinocytes.</p>
<p>(b) When the skin is tanned by ultraviolet light, an increased number of melanosomes are manufactured and available for transfer to the keratinocyte.</p>
<p>(c) In light-skinned people, chronic sun exposure also "tricks" the melanocyte into producing larger melanosomes.</p>
<p>(d) The pattern of distribution of the melanosome in the keratinocyte then resembles that of dark-skinned people.</p>
<ol start="3">
<li>Langerhans cells:</li>
</ol>
<p>a. Langerhans cell is another dendritic cell found in the epidermis. They are found in the</p>
<p>granular, spinous, and basal cell layers of the epidermis. Occasionally, they are seen in the normal dermis. Langerhans cells are derived from bone marrow precursor cells.</p>
<p>b. The Langerhans cell population is self-maintaining. There is a relatively constant number of these cells being maintained by intraepidermal mitosis and migration from the connective tissue. Langerhans cells account for approximately 4% of the epidermal cell population.</p>
<p>(1) Function of Langerhans cells:</p>
<p>(a) They are immunocompetent cells involved in the uptake, processing, and presentation of antigen to lymphocytes.
(b) It is thought that Langerhans cells are the first line of immunologic defense in the skin acting as initial receptors for the cutaneous response to external antigens.
(c) Experimental evidence shows that Langerhans cells are directly involved in allergic contact hypersensitivity.
(d) There is a decreased number of Langerhans cells in patients with skin diseases such as psoriasis and sarcoidosis.
(e) Langerhans cells are also functionally impaired by ultraviolet radiation. UVB and PUVA treatments lead to morphologic, antigenic, and enzymatic changes within the Langerhans cell. Research is under way to learn the implications of this information.</p>
<ol start="4">
<li>Merkel cells:</li>
</ol>
<p>a. Merkel cells are also found in the basal cell layer. They are collected in specialized structures called tactile discs or touch domes. The most distal part of the Merkel cell is embedded in the dermis. Merkel cells are present in the nonhairy or smooth skin of the digits, lips, regions of the oral cavity, and outer root sheath of hair follicles.</p>
<ol start="5">
<li>Embryonic development:</li>
</ol>
<p>a. Merkel cells originate from either the neural crest or ectoderm. They are joined to keratinocytes by "spines" or desmosomes, which project from their cytoplasm.
b. Merkel cells have characteristic organelles. They are membrane-bound granules that contain neurotransmitter substances. Distal to the granules is an unmyelinated neurite or terminal neuraxon.
c. Function:</p>
<p>(1) The function of Merkel cells is that of slowly adapting mechanoreceptors. The exact mechanism of action remains uncertain.
(2) The contacting membrane of the Merkel cell and the dendrite resemble pre- and postsynaptic units. It is therefore thought that the Merkel cell acts as a receptor that transmits a stimulus to the neurite via a chemical synapse.
(3) The Merkel cell may also serve a trophic (concerned with nourishment) role as well as serving as a common contact point for several associated keratinocytes.
(4) Merkel cells respond to maintained deformation of the skin surface and are involved in sensing touch and pressure.</p>
<p>C. Basement membrane zone (dermal-epidermal junction)</p>
<ol>
<li>The basement membrane zone is found at the junction of the epidermis and dermis. It runs along the base of the epidermal rete ridges as well as the sweat glands, hair shafts, and sebaceous glands.</li>
</ol>
<p>a. Structure:</p>
<p>(1) Basement membrane zone structures are formed from basal keratinocytes and dermal fibroblasts. There are several components of the basement membrane zone that are seen with the electron microscope. The plasma membrane is the most distal surface of the basal keratinocyte.</p>
<p>(2) Hemidesmosomes are specialized attachment plates between the basal keratinocyte and the lamina densa. The lamina densa is immediately above the dermis and comprises a collagen that provides structure and flexibility. The lamina densa also functions as a barrier/filter by the selective restriction of molecules.</p>
<p>(3) The lamina lucida appears as a clear zone and is found between the plasma membrane and the lamina densa.</p>
<p>(4) Anchoring fibrils, dermal microfibrils, and collagen fibers below the lamina densa compose the fibrous component of the basement membrane zone.</p>
<p>b. Function:</p>
<p>(1) The basement zone serves as a porous, semipermeable filter. It:</p>
<p>(a) Permits exchange of cells and fluid between the epidermis and dermis</p>
<p>(b) Functions as a structural support for the epidermis and helps hold the epidermis and dermis together</p>
<p>c. Diseases of the basement membrane zone:</p>
<p>(1) Many genetic diseases involve structural alterations in the basement membrane zone. Separation of the epidermis and dermis results in blistering. This is seen in disorders such as epidermolysis bullosa letalis, generalized atrophic benign epidermolysis bullosa, bullous pemphigoid, and recessive dystrophic epidermolysis bullosa.</p>
<p>D. Dermis (Figure 1-3)</p>
<ol>
<li>The dermis is the principal mass of the skin providing structural integrity and is biologically active. It is composed of collagen bundles and is 1 to 4 mm thick. It encloses the appendages of the epidermis and supports the nerve and vascular network.</li>
</ol>
<p>a. Function:</p>
<p>(1) Functions of the dermis include preventing mechanical trauma and maintenance of homeostasis. The dermis:</p>
<p>(a) Binds large amounts of water and thereby represents a water storage organ</p>
<p>(b) Is also involved with thermoregulation and sensory innervation</p>
<p>b. Composition:</p>
<p>(1) The dermis comprises connective tissue, water, and ground substance. There are three types of connective tissue: collagen, elastic fiber, and reticulum.</p>
<p>(a) Collagen constitutes the majority of fibers in the dermis:</p>
<p>i. It is the major structural protein for the entire body.</p>
<p>ii. Collagen is a fibrous protein synthesized by fibroblasts and degraded by the</p>
<p>proteolytic enzyme, collagenase. Scleroderma is an example of a collagen disease that involves abnormal synthesis or degradation of collagen molecules.</p>
<p>iii. Collagen is the most important stress-resistant material of the skin. It provides us with both tensile strength and the ability to resist stretching.</p>
<p>iv. Individual collagen bundles become thinner in atrophic scars and thicker in keloids.</p>
<p>(b) Elastic fibers represent 5% to 9% of dermal fibers. They:</p>
<p>i. Differ structurally and chemically from collagen
ii. Are made up of protein filaments and elastin
iii. Function to restore the collagen network to a normal position following deformation, stress, or stretching. The skin's resiliency and elegant feel are attributed to the elastic fibers. There is a loss of elastic fibers in stria.</p>
<p>(c) Reticular fibers are young finely formed collagen fibers:</p>
<p>i. They are similar in diameter than mature collagen.
ii. Large numbers are found in the papillary dermis where they serve as anchoring fibrils for the basal lamina.
(d) Ground substance constitutes the interstitial component of the dermis. Ground substance:</p>
<p>i. Is a viscoelastic gel
ii. Molds to irregular objects
iii. Is a small fraction of the dermal weight, but accounts for a substantial portion of the volume
iv. Has a great capacity to bind water</p>
<p>c. Papillary dermis:</p>
<p>(1) The dermis is divided into two areas—the papillary and reticulum dermis.</p>
<p>(a) The papillary dermis is the uppermost area of the dermis beginning at the basement membrane zone:</p>
<p>i. The papillary dermis contains thin, haphazardly arranged collagen fibers, numerous reticular fibers, and delicate branching elastic fibers. There is abundant ground substance and numerous capillaries that extend from the superficial plexus.
ii. The papillary dermis and the epidermis form a morphologic and functional unit. This is evident as the papillary dermis molds to the contour of the epidermal rete ridges. This relationship is seen in common inflammatory diseases when both areas show alteration.</p>
<p>d. Reticular dermis:</p>
<p>(1) The reticular dermis represents the bulk of the dermis. It:</p>
<p>(a) Extends from the base of the papillary dermis to the subcutaneous tissue
(b) Carries most of the physical stress of the skin
(c) Is characterized by thick collagen bundles arranged parallel to the skin surface. Coarse elastic fibers are found around collagen bundles.
(d) Is thicker than the capillary dermis. Proportionally, there are fewer reticular fibers, fibroblasts, and blood vessels and less ground substance in the reticular dermis, as compared to the papillary dermis.</p>
<p>E. Cells in the dermis</p>
<ol>
<li>
<p>Fibroblast:
a. The principal cell of the dermis is the fibroblast. It produces collagen, elastic fibers, reticular fibers, and ground substance. Collagen fibrils are broken down and degraded by collagenase and gelatinase, both of which are also synthesized in the fibroblast.
b. Fibroblasts have indistinct cytoplasm and spindle-shaped nuclei. They are found among and on the surface of fiber bundles.</p>
</li>
<li>
<p>Mast cell:
a. Mast cells are secretory cells most commonly found near the superficial plexus and in the subcutaneous fat:
(1) The cytoplasm of mast cells contain secretory and lysosomal granules. Mediators in the granules are produced that are either vasoactive, stimulate smooth muscle contraction, or function to attract neutrophils and eosinophils.
(2) The secretory granules contain histamine and heparin.
(3) The lysosomal granules are nonsecretory but degrade intracellular proteoglycans and complex glycolipids.
b. Mast cells respond to a number of physical stimuli: light, cold, heat, acute trauma, vibration, and sustained pressure, as well as chemical and immunologic stimuli:
(1) When stimulated, the mast cell releases histamine and heparin. Once released, vasodilation and dermal edema result.
(2) Secondly, there is an infiltration of neutrophils, eosinophils, and basophils.
(3) Immediate hypersensitivity reactions in the skin are due to mast cells.
(4) Subacute and chronic inflammatory disease can also be related to the mast cell.</p>
</li>
<li>
<p>Macrophages:
a. Originates in the bone marrow. It initially circulates as a monocyte in the blood.
b. Macrophages in the dermis function in the immune response.
c. Langerhans cells, along with macrophages, are capable of processing and presenting antigens to immunocompetent lymphocytes.
d. Defend against microorganisms through phagocytosis.
e. Important to wound healing cascade.</p>
</li>
<li>
<p>Histiocytes:
a. Histiocytes are cells found in the dermis, which function as scavengers. They engulf hemosiderin, melanin, lipid, and debris.</p>
</li>
</ol>
<p>F. Dermal vasculature. The epidermis has no intrinsic blood supply so it depends on the diffusion of nutrients and oxygen from vessels in papillary dermis. The vasculature of the skin is arranged into two interconnected horizontal plexuses.</p>
<ol>
<li>
<p>Superficial plexus:
a. The superficial plexus (subpapillary plexus) courses at the junction of the papillary and reticular dermis. It supplies capillaries, end arterioles, and venules to the dermal papillae.</p>
</li>
<li>
<p>Deep plexus:
a. The deep plexus is located in the base of the reticular dermis. The two plexuses are</p>
</li>
</ol>
<p>connected by blood vessels that run perpendicular to the skin surface. The communicating vessels originate from arteries and veins in the subcutaneous tissue.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-functions">3. Functions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-functions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>a. Thermoregulation is the most important function of the skin's vascular system. Blood flow through the dermis varies in response to changes in the core temperature of the body, as well as the temperature of the external environment.</p>
<p>b. Blood pressure: the cutaneous vasculature plays a role in blood pressure regulation. Sympathetic stimulation leads to a constriction of cutaneous blood vessels, thereby, reducing blood flow to the skin. This results in increased venous return, increased cardiac output, and increased blood pressure.</p>
<p>c. Nutrition is also a function of the dermal vasculature. In the capillaries and venules, oxygen, water, nutrients, and hormones are distributed from the blood to the tissues. Carbon dioxide and other products of skin metabolism are diffused for transmission to the excretory organs.</p>
<p>d. Inflammation: blood vessels in the dermis also play a role in inflammation. The microcirculatory units of the papillary dermis dilate in skin diseases characterized by erythema.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="g-lymphatics">G. Lymphatics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#g-lymphatics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>A lymphatic network is also found in the dermis. It parallels the vascular plexuses. The lymphatics act to filter and transport a large amount of capillary transudate or lymph and return it back to the venous system.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="h-nerves">H. Nerves<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#h-nerves" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Autonomic motor:</li>
</ol>
<p>a. Autonomic nerves are sympathetic in nature and can be divided into adrenergic and cholinergic fibers:</p>
<p>(1) Adrenergic fibers regulate vasoconstriction, the apocrine gland, and areteric pili muscles.</p>
<p>(2) Eccrine sweat secretion is controlled by cholinergic fibers.</p>
<ol start="2">
<li>Somatic sensory:</li>
</ol>
<p>a. Somatic sensory nerves are either free nerve endings or corpuscular receptors. Either together or alone, they convey touch, pressure, pain, temperature, and itch from every part of the body.</p>
<p>(1) There is variation in intensity of these senses at different parts of the body. This is because the density and type of receptors are regionally variable and specific.</p>
<p>b. Corpuscular receptors: Meissner and Pacini corpuscles are two mechanoreceptors in the skin conveying touch and pressure. The Meissner corpuscles are found in the papillary dermis, especially on the palms and soles. Pacini corpuscles are located in the deeper dermis of weight-bearing surfaces.</p>
<p>c. Free nerve endings: temperature, pain, and itch are transmitted by unmyelinated nerve fibers, which terminate in the papillary dermis and around the hair follicles. These impulses are conveyed to the central nervous system through the dorsal root ganglion.</p>
<p>d. Dermatome: the sensory nerves are arranged in dermatomal patterns. A dermatome is the cutaneous area supplied by a single spinal nerve. On the trunk, the dermatomes</p>
<p>are horizontal; on the arms and legs, they are more vertical and irregularly distributed. Herpes zoster is an example of a disease in a dermatomal pattern.</p>
<p>I. Subcutaneous tissue (Also referred to as Hypodermis or Fatty Tissue) (Figure 1-3)</p>
<ol>
<li>The third layer of the skin is the subcutaneous tissue. It consists of fat cells or lipocytes (adipocyte). The lobules are separated by fibrous walls (septa) of collagen and large blood vessels. Dermal collagen is continuous with the collagen found in the subcutaneous tissue.</li>
<li>The thickness of the subcutaneous tissue varies in different parts of the body. It is nearly absent in the eyelids, penis, scrotum, nipple, and overlying the tibia. It is thick in the waist, especially in middle-aged people. Distribution of subcutaneous tissue is controlled by circulating sex hormones, heredity, age, and eating habits.</li>
<li>The subcutaneous tissue has three main functions. It:</li>
</ol>
<p>a. Insulates the underlying tissue from extreme hot and cold
b. Functions as a mechanical shock absorber
c. Is a storehouse of energy (calories) used in times of nutritional deprivation</p>
<p><img src="assets/images/image-20251225-21cab616.jpeg" alt="img-1.jpeg">
FIGURE 1-2. Layers of the epidermis. (From Archer, P., Nelson, L. (2012). Applied anatomy &amp; physiology for manual therapists. Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-67520400.jpeg" alt="img-2.jpeg">
FIGURE 1-3. The dermis and its appendages. (From Archer, P., Nelson, L. (2012). Applied anatomy &amp; physiology for manual therapists. Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-appendages-of-the-skin-nails-see-chapter-22-hair-and-nails">III. APPENDAGES OF THE SKIN: NAILS (SEE CHAPTER 22, HAIR AND NAILS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-appendages-of-the-skin-nails-see-chapter-22-hair-and-nails" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Overview: The nail covers the upper surface of each finger and toe and acts as a protective covering to the end of each digit and aid in picking up small objects. Nails serve as scratching organs and have an increasingly important esthetic and cosmetic purpose.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-appendages-of-the-skin-hair-see-chapter-22-hair-and-nails">IV. APPENDAGES OF THE SKIN: HAIR (SEE CHAPTER 22, HAIR AND NAILS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-appendages-of-the-skin-hair-see-chapter-22-hair-and-nails" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Overview: Hair is a keratin structure of the epidermis, which serves no vital function on the human body. It does have physiologic functions including insulation, social and sexual display, camouflage, tactile perception, thermoregulation, and protection from UV light.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-appendages-of-the-skin-glands-figure-1-4">V. APPENDAGES OF THE SKIN: GLANDS (FIGURE 1-4)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-appendages-of-the-skin-glands-figure-1-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="assets/images/image-20251225-665544c8.jpeg" alt="img-3.jpeg">
FIGURE 1-4. Vasculature and glands of the skin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-sebaceous-glands">A. Sebaceous glands<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-sebaceous-glands" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Sebaceous glands are found on all areas of the body except the palms, soles, and dorsum of the feet.</p>
</li>
<li>
<p>Their density varies markedly with location, being most numerous on the face, scalp, upper chest, back, and anogenital regions.</p>
</li>
<li>
<p>Most sebaceous glands are associated with hair follicles (pilosebaceous units). The pilosebaceous unit comprises the hair follicle and one or more sebaceous glands attached to it. Exceptions to this are the sebaceous glands in the following:</p>
</li>
</ol>
<p>a. Buccal mucosa
b. Vermillion border of the lip
c. Areola
d. Prepuce
e. Eyelids</p>
<ol start="4">
<li>Embryonic development:</li>
</ol>
<p>a. Embryonically, sebaceous glands are formed as an outgrowth of the upper portion of the hair follicle. They are fully developed at birth and secrete much of the lipid of the vernix caseosa. Sebaceous glands are small at birth, enlarge between 8 and 10 years of age with maturation continuing through adolescence, and remain unchanged until later years. They decrease in menopause in females and after the 70th decade in males. As people age, sebum secretion decreases even though the size of sebaceous glands increases. Development of sebaceous glands and sebogenesis is hormone dependent (testosterone, androstenedione, dehydroepiandrosterone).</p>
<ol start="5">
<li>Anatomy:</li>
</ol>
<p>a. Germinative cells: sebaceous glands consist of one or more lobules of pale-staining cells called germinative cells. Differentiation of the germinative cells is similar to that of the keratinocyte in the epidermis. As the cells differentiate, lipid droplets accumulate, eventually filling the cytoplasm of the cell. These cells eventually rupture, discharging sebum into the sebaceous duct. Sebum is made up of cellular debris and lipids.
b. Sebaceous duct: the sebaceous duct is the short, narrow, common excretory duct connecting several sebaceous lobules with the wider follicular infundibulum. This follicular canal is very wide throughout the entire length. It is filled not only with sebum, but keratinous materials, bacteria, and yeast.</p>
<ol start="6">
<li>Hormonal effects:</li>
</ol>
<p>a. There are hormonal effects on the sebaceous gland:</p>
<p>(1) Sebaceous gland development is one of the earliest signs of puberty. Androgens are the principal hormonal stimulus. Testicular androgens maintain sebum production in the male and ovarian androgens in the female. Adrenal androgens also play a role.
(2) Estrogen decreases the size of the sebaceous gland and decreases the production of sebum.</p>
<ol start="7">
<li>Sebum production:</li>
</ol>
<p>a. The actual production of sebum varies in relation to age and sex:</p>
<p>(1) It is low in children until the time of puberty.
(2) In adults, sebum production is higher in men than women.
(3) In older men, production falls off slightly.
(4) In women, production significantly decreases after 50 years of age.</p>
<ol start="8">
<li>Functions:</li>
</ol>
<p>a. Functions of the sebaceous gland include:
(1) Waterproofing of the hair and skin
(2) Promoting the absorption of fat-soluble substances
(3) Lubrication and possibly assistance in the synthesis of vitamin D</p>
<p>B. Apocrine gland</p>
<ol>
<li>
<p>The apocrine glands are found in the:
a. Axilla
b. Umbilical region
c. Around the areolae
d. Anogenital region
e. External auditory canal (ceruminous gland)
f. The eyelid (Moll gland)</p>
</li>
<li>
<p>Function:
a. The apocrine gland has a unique scent in each individual and serves as a unique identifier.</p>
</li>
<li>
<p>Anatomy:
a. Apocrine secretory gland:
(1) The coiled secretory gland is located either in the lower dermis or in the subcutaneous tissue. Apocrine gland ducts usually open into the hair follicle above the entrance of the sebaceous glands, but some ducts open directly upon the surface of the skin.
(2) It consists of secretory cells and myoepithelial cells.
(3) Collagen and elastic fibers are found in the surrounding dermis.
b. Apocrine duct:
(1) The apocrine duct is the straight duct that merges with the infundibular portion of the hair follicle.
(2) The apocrine duct consists of an inner periluminal cuticle and two to three layers of cuboidal cells. It has no myoepithelial lining.</p>
</li>
<li>
<p>Secretion composition:
a. Apocrine gland secretions are milky in color, odorless, and sterile. The exact chemical consistency is uncertain as there is difficulty in obtaining uncontaminated specimens.
(1) Bacteria that are present in the infundibular canal of the hair follicle, as well as bacteria on the skin surface, act upon the apocrine secretion to produce odiferous substances.
(2) The odiferous substances contain, in part, short-chain fatty acids and ammonia.
(3) A moist environment, conducive for bacterial proliferations, is provided by the axillary eccrine gland.</p>
</li>
<li>
<p>Stimulation:
a. The mode of secretion of the apocrine gland is assumed to be due to the contraction of the myoepithelial cells surrounding the secretory cells.
b. Myoepithelial contraction and the resulting emptying of the secretory coil are induced by emotional stress that leads to sympathetic nervous discharge.
c. Like sebaceous glands, the activity of the apocrine glands is hormone dependent, but</p>
</li>
</ol>
<p>also stimulated by epinephrine and norepinephrine.</p>
<p>d. Once the gland has been emptied, a refractory period ensues until the secretory gland and duct refill.</p>
<p>C. Eccrine sweat gland</p>
<ol>
<li>Eccrine sweat glands function to help regulate the body's temperature. This is accomplished by the production of eccrine sweat that flows to the skin surface and cools by evaporation. The eccrine sweat glands are present everywhere on the body except in the ear canal, glans penis, labia minora, prepuce, lips, and nail beds. Greatest concentration of these glands is on the palms and soles, forehead, and axilla.</li>
</ol>
<p>a. There are a total of two to five million eccrine sweat glands on the body.
b. No new glands develop after birth.
c. Each gland weighs approximately 30 to 40 mcg, the total mass equaling 100 g.</p>
<ol start="2">
<li>Anatomy:</li>
</ol>
<p>a. Eccrine duct: in the epidermis, the eccrine duct spirals on itself. It is lined by modified epidermal cells thought to be derived from upward migration of the dermal duct cells. There is a straight duct lying in the center of the dermis. The coiled segment of the duct is continuous with the secretory coil. It is approximately one third the length of the coil.</p>
<p>(1) The eccrine duct consists of two layers of cuboidal cells:</p>
<p>(a) Luminal cells: the luminal cells have a periluminal filamentous zone comprising a dense layer of tonofilaments. This adds to the rigidity of the duct.
(b) Basal ductal cells: the basal cells have increased mitochondria and Na-K-ATPase (pump) activity.</p>
<p>b. Eccrine secretory coil: the secretory coil has a larger diameter than the duct and is 2 to 5 mm in length. It makes up one half of the basal coil and lies in the lower one third of the dermis, at the dermal subcutaneous border. The secretory coil consists of three types of cells:</p>
<p>(1) The mucoid or dark cells secrete a dense granule glycoprotein.
(2) The clear or secretory cells are generally believed to be responsible for water and electrolyte secretion. The ATP-dependent NA+ pump is located within this cell. Where two or more clear cells abut, intercellular canaliculi are formed, which open into the lumen of the gland.
(3) The myoepithelial cells lie between the secretory cells and the basement membrane. These add support to the gland. They do not expel sweat as do those in the apocrine glands.</p>
<ol start="3">
<li>Stimulation:</li>
</ol>
<p>a. There are three types of stimuli that promote eccrine gland secretion.</p>
<p>(1) Thermal is the most important stimulus. Sweating occurs over the trunk face and sometimes the entire body. The preoptic area of the anterior hypothalamus is the heat regulating center, and it responds to changes in the core temperature. Afferent input from skin temperature also controls thermal sweating, but is not as important as core temperature.
(2) Mental stimuli usually cause sweating on the palms, soles, and axilla, but</p>
<p>sometimes cause generalized sweating. The frontal region of the brain is involved, but the exact pathway is unknown.</p>
<p>(3) Gustatory produces sweating seen after eating hot or spicy foods. It is controlled by an unknown pathway.</p>
<ol start="4">
<li>Physiology of sweating:</li>
</ol>
<p>a. The physiology of sweating involves a complex process. Very basically, sweating begins in the clear secretory cells.</p>
<p>(1) The intercellular canaliculi transports the solution secreted by the clear cells into the secretory coil. There is then reabsorption of sodium, chloride, and other electrolytes from the lumen of the duct.</p>
<p>(2) The eccrine sweat is then secreted. It is an odorless, colorless, hypotonic solution. It has a specific gravity of approximately 1.005 and a pH between 4.5 and 5.5.</p>
<p>b. Sweat contains:</p>
<p>(1) Sodium
(2) Chloride
(3) Potassium
(4) Urea
(5) Lactate
(6) Bicarbonate
(7) Ammonia
(8) Calcium
(9) Phosphorus
(10) Magnesium
(11) Iodine
(12) Sulfate
(13) Iron
(14) Zinc
(15) Amino acids
(16) Proteins
(17) Immunoglobulins</p>
<p>c. The sweat rate determines the concentration of the solutes.</p>
<p>(1) Increased rates of sweating produce sweat with high pH, increased concentrations of sodium and chloride, and decreased concentrations of potassium, lactate, and urea.</p>
<p>(2) Sweat lactate and urea may be important in controlling desquamation of the stratum corneum and may act as natural skin moisturizers.</p>
<p>(3) The body may produce sweat at the rate of 2 to 4 L an hour. It may produce up to 12 L in 24 hours.</p>
<p>(4) Axillary eccrine sweat glands contribute to the odor-producing secretion of the apocrine glands by providing a moist environment that is conducive to bacterial proliferation.</p>
<p>VI. IMMUNOLOGIC RESPONSES AND CELL TYPES</p>
<p>A. Humoral immunity</p>
<ol>
<li>
<p>Humoral immunity is regulated by B lymphocytes that, when stimulated by antigen, form plasma cells that produce antibodies.</p>
</li>
<li>
<p>Antibodies can be divided into five classes:
a. Immunoglobulin G (IgG)
b. Immunoglobulin A (IgA)
c. Immunoglobulin M (IgM)
d. Immunoglobulin D (IgD)
e. Immunoglobulin E (IgE)</p>
</li>
<li>
<p>Antibodies, with varying degrees of efficiency, can:
a. Fix complement (IgG, IgM)
b. Aid macrophages in cytotoxicity or cell killing and phagocytosis (IgG)
c. Interact with antigen at mucosal surfaces (IgA)
d. Trigger release of mediators from mast cells of immunoreactive (IgE)</p>
</li>
<li>
<p>Antibodies can react to self as well as foreign antigen to cause inflammation, which in the pathogenic state can be harmful.</p>
</li>
</ol>
<p>B. Cellular immunity</p>
<ol>
<li>
<p>Cellular immunity involves T lymphocytes.</p>
</li>
<li>
<p>T lymphocytes divide into at least three subtypes:
a. T-helper cells (CD4 cells):
(1) T-helper cells activate B cells to produce antibody and activate T-cytotoxic cells.
(2) Act as killer cells against invading organisms.
(3) Can be classified as Th1 and Th2 based on cytokine profile.
(4) Secrete cytokines that increase the number of T cells, B cells, natural killer cells, and macrophages.
b. T-cytotoxic cells (CD8):
(1) T-cytotoxic cells kill target cells by binding with antigens on target cell.
(2) Cause lysis of antigen-bearing cells
c. T-memory cells (CD45RO):
(1) Play major role in inflammation seen in allergy and atopy
(2) Involved in contact and delayed hypersensitivity</p>
</li>
<li>
<p>Much T-cell function is accomplished by production of soluble proteins called lymphokines.</p>
</li>
</ol>
<p>C. Complement system</p>
<ol>
<li>
<p>A complex set of proteins that, when activated in the complement cascade, can:
a. Lyse cells
b. Aid in phagocytosis by macrophages
c. Cause mast cells to release histamines
d. Be chemotactic for neutrophils</p>
</li>
<li>
<p>Complement can be activated by:
a. Antibodies
b. Immune complexes through the classic pathway</p>
</li>
<li>
<p>Complement can also be activated by:
a. Bacteria
b. Fungi
c. Immunoglobulins and their fragments
d. Immune complexes
e. Lymphocytes
f. Endotoxins</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vii-immunity-and-skin-disease">VII. IMMUNITY AND SKIN DISEASE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vii-immunity-and-skin-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Diseases in the skin can be caused by an immune response in three ways and in some skin diseases a combination of the three:</p>
<ol>
<li>Immune response to foreign antigen</li>
<li>Response to self-antigen (autoimmunity)</li>
<li>Lack of appropriate immune response (immunodeficiency)</li>
</ol>
<p>B. Response to an antigen (either foreign or self) is divided into four types of hypersensitivity reactions. The four hypersensitivity reactions, according to the Gel and Coombs classification are:</p>
<ol>
<li>
<p>Type I—immediate allergic reaction:
a. Immediate reaction provoked by re-exposure to a specific type of antigen referred to as an allergen.
b. Exposure may be by ingestion, inhalation, injection, or direct contact.
c. An IgE-mediated response
d. Example of disease with this reaction:
(1) Urticaria (hives)
(2) Acute allergic drug reactions</p>
</li>
<li>
<p>Type II—cytotoxicity reaction:
a. Antibody is directed against antigen on cells (such as circulating red blood cells) or extracellular materials (basement membrane).
b. The resulting antigen-antibody complexes activate complement (via the classic pathway), leading to cell lysis or extracellular tissue damage.
c. Example of disease with this reaction:
(1) Transfusion reactions: incompatible RBCs or serum is transfused.
(2) Autoimmune hemolytic anemia: antibody is made against one's own RBCs.</p>
</li>
<li>
<p>Type III—immune complex-mediated reaction:
a. Mediated by circulating immune complexes
b. Often deposited in the vessel walls of the joints and kidney, initiating a local inflammatory reaction
c. Example of disease with this reaction:
(1) Serum sickness</p>
</li>
</ol>
<p>(2) Systemic lupus erythematosus</p>
<ol start="4">
<li>Type IV—delayed-type and cell-mediated reactions:
a. Delayed hypersensitivity
b. T-cell-mediated response
c. Example of disease or testing exhibiting this reaction
(1) Allergic contact dermatitis
(2) Mantoux screening test</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adelman, D. C., Casale, T. B., &amp; Corren, J. (2012). Manual of allergy and immunology (5th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.
Adkinson, N. F., Bocher, B. S., Burks, A., Busse, W. W., Holgate, S. T., Lemanske, R. F., &amp; O'Hehir, R. E. (2014). Middleton's allergy: Principles and practice (8th ed.). Philadelphia, PA: Saunders-Elsevier.
Callen, J. P., Jorizzo, J. L., Zone, J. J., &amp; Piette, W. W. (2009). Dermatological signs of internal disease (4th ed.). Philadelphia, PA: Saunders-Elsevier.
Chu, D. H. (2013). Development and structure of skin. In L. A. Goldsmith, S. I. Katz, B. A. Gilchrest, A. S. Paller, D. J. Leffell, &amp; K. Wolff (Eds.), Fitzpatrick's dermatology in general medicine (8th ed., pp. 58-74). New York, NY: McGraw-Hill.
Garg, A., Levin, N. A., &amp; Bernhard, J. D. (2013). Structure of skin lesions and fundamentals of clinical diagnosis. In L. A. Goldsmith, S. I. Katz, B. A. Gilchrest, A. S. Paller, D. J. Leffell, &amp; K. Wolff (Eds.), Fitzpatrick's dermatology in general medicine (8th ed., pp. 26-41). New York, NY: McGraw-Hill.
Marks, J. G., &amp; Miller, J. J. (2006). Lookingbill and Marks' principles of dermatology (4th ed.). Philadelphia, PA: Saunders-Elsevier.
McCann, S. E., &amp; Huether, S. E. (2014). Structure, function, and disorders of the integument. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Pathophysiology—The biologic basics for disease in adults and children (7th ed., pp. 1616-1652). St. Louis, MO: Mosby-Elsevier.
Nicol, N. H. (2009). Assessment of the integumentary system. In J. M. Black, &amp; J. H. Hawks (Eds.), Medical-surgical nursing: Clinical management for positive outcomes (8th ed., pp. 1186-1198). Philadelphia, PA: WB Saunders Company.
Nicol, N. H., &amp; Huether, S. E. (2012). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Understanding pathophysiology (6th ed., pp. 1070-1082). St. Louis, MO: Mosby-Elsevier.
Nicol, N. H., &amp; Huether, S. E. (2012). Structure, function, and disorders of the integument. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Understanding pathophysiology (6th ed., pp. 1038-1069). St. Louis, MO: Mosby-Elsevier.
Nicol, N. H., &amp; Huether, S. E. (2014). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Pathophysiology—The biologic basics for disease in adults and children (7th ed., pp. 1653-1667). St. Louis, MO: Mosby-Elsevier.
Penzer, R., &amp; Ersser, S. J. (2010). Principles of skin care. Oxford, UK: Wiley-Blackwell.
Schalock, P. C., Hsu, J. T. S., &amp; Arndt, K. A. (2011). Lippincott's primary care dermatology. Philadelphia, PA: Lippincott Williams &amp; Wilkins.
Weinberg, S., Prose, N. S., &amp; Kristal, L. (2008). Color atlas of pediatric dermatology (4th ed.). New York, NY: McGraw-Hill.
Wolff, K., Johnson, R. A., &amp; Saavedra, A. P. (2013). Fitzpatrick's color atlas and synopsis of clinical dermatology (7th ed.). New York, NY: McGraw-Hill.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>All of the following are components of the integumentary systems except:
a. Skin
b. Hair
c. Glands
d. Eyes
e. Nails</p>
</li>
<li>
<p>Which of the following components of the integumentary system acts as the major barrier for the body?
a. Dermis
b. Epidermis
c. Skin appendages
d. Subcutaneous fat</p>
</li>
<li>
<p>The outermost layer of the epidermis is the:
a. Basal cell layer
b. Stratum lucidum
c. Horny cell layer
d. Granular cell layer
e. Prickle cell layer</p>
</li>
<li>
<p>For a cell to move from the basal cell layer to the stratum corneum takes approximately:
a. 8 to 14 days
b. 1 to 7 days
c. 15 to 30 days
d. 6 weeks or more</p>
</li>
<li>
<p>Which of the following is not a structural component of the dermis?
a. Collagen
b. Elastic fibers
c. Reticular fibers
d. Lipocytes</p>
</li>
<li>
<p>Functions of the skin include:
a. Temperature regulation
b. Wound repair
c. Vitamin D production</p>
</li>
</ol>
<p>d. All of the above</p>
<ol start="7">
<li>
<p>The principal cell of the epidermis is the:
a. Keratinocyte
b. Macrophage
c. Mast cell
d. Fibroblast
e. None of the above</p>
</li>
<li>
<p>Accessory structures of the skin include the:
a. Dermis, epidermis, and subcutaneous layers
b. Blood vessels, macrophages, and Merkel cells
c. Hair follicles and the sebaceous and sweat glands
d. Cutaneous and subcutaneous layers</p>
</li>
<li>
<p>Type 1 hypersensitivity classically involves which of the following?
a. IgM
b. IgE
c. Mast cells
d. Macrophages
e. IgD</p>
</li>
<li>
<p>Which of the following diseases displays a classic type IV hypersensitivity?
a. Urticaria
b. Psoriasis
c. Allergic contact dermatitis
d. Systemic lupus erythematosus</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>1.d
2.b
3.c
4.a
5.d
6.d
7.a
8.c
9.b</p>
<p>10.c</p>
<p>CHAPTER 2</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="skin-assessment">Skin Assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#skin-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Noreen Heer Nicol</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Define a holistic and comprehensive patient skin assessment.</li>
<li>List subjective and objective data, which are necessary for a comprehensive assessment of the skin.</li>
<li>Express the appropriate terminology used for primary and secondary lesions.</li>
<li>Describe primary and secondary lesions of the skin and examples of dermatologic conditions exhibiting these features.</li>
<li>Determine how lesion location and distribution help indicate specific diagnoses.</li>
<li>Identify factors influencing professional relationship with patients and other health care professionals.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>A comprehensive, holistic skin assessment includes the history given by the patient (subjective data) and the findings of the physical exam of the skin (objective data).</li>
<li>The preliminary patient history can be abbreviated to three key questions, which evaluate onset and evolution, symptoms, and treatment to date.</li>
<li>Physical examination of the skin needs to be done ensuring privacy and dignity while determining whether the lesions being evaluated are primary or secondary lesions, as well as the configuration and distribution of the lesions.</li>
<li>During the assessment, do not underestimate the significance of pruritus or the changes in the hair and nails.</li>
<li>Specific terminology is used to describe the characteristics of skin lesions (number, color, type of lesion, configuration, distribution pattern, which can then be documented).</li>
<li>Specific standardized terminology provides all care providers with a uniform description and understanding of the patient's condition. This can be especially important in completing consults with specialized providers, electronic communication,</li>
</ul>
<p>and telehealth visits.</p>
<ul>
<li>Documentation and communication with other health care professionals and disciplines at appropriate levels and according to identified standards are important to ensure continuity.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>An initial assessment for patients with skin disorders should be approached as you would any patient. A comprehensive assessment of a dermatologic condition includes the history given by the patient (subjective data) and the findings of the physical examination of the integumentary system (objective data). The patient history and physical examination should also occur in an appropriately private area to ensure privacy and dignity, preferably with natural lighting. A preliminary history of a dermatologic problem can be abbreviated to three key questions, which evaluate onset and evolution, symptoms, and treatment to date (Box 2-1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-2-1-sample-questions-for-initial-assessment-or-triage">Box 2-1. Sample Questions for Initial Assessment or Triage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-2-1-sample-questions-for-initial-assessment-or-triage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-questions-with-initial-history-of-skin-problem">Key questions with initial history of skin problem:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-questions-with-initial-history-of-skin-problem" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Onset and Evolution: How long has the lesion been present? Has it gotten better or worse?</p>
<p>Symptoms: Does it itch? Or how does this bother you?</p>
<p>Treatment to Date: Tell me all the things that you have used to try to treat this?</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="additional-questions">Additional questions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#additional-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>What did it first look like?</p>
<p>Has it changed, grown, bled, itched, or failed to heal?</p>
<p>Have you been out of the country lately?</p>
<p>Does it come and go?</p>
<p>Have you recently started any changes in your daily medicines?</p>
<p>Have you recently started any new medicines?</p>
<p>Any history of similar symptoms for you in the past?</p>
<p>Do any family members have the same or similar symptoms?</p>
<p>Have you used or done anything that seems to make it better?</p>
<p>Skin provides an opportunity for visual inspection. This makes inspection the most important part of the physical examination of the skin. Physical examinations should be done in an orderly manner to insure important diagnostic clues are not missed. The initial key impression</p>
<p>of whether the patient appears ill or not is important to note at the beginning of the physical examination.</p>
<p>Lesions can be defined as primary or secondary. Primary lesions are structural changes in the skin that have specific, visual characteristics and develop without any preceding skin changes (Table 2-1). Secondary lesion is one that has changed due to natural progression or due to physical factors such as rubbing or scratching (Table 2-2). Special or "other" lesions are those that occur in the skin only and in the skin most often or can be perceived most easily on the skin (Table 2-3).</p>
<p>TABLE 2-1 Primary Skin Lesions and Commonly Occurring Dermatologic Conditions</p>
<table><thead><tr><th>Primary Skin Lesions Description</th><th>Example of Dermatologic Condition</th><th>Example of Dermatologic Condition</th></tr></thead><tbody><tr><td>Macule A circumscribed, flat discoloration, which varies widely in size, color, and shape</td><td>Brown Becker nevus Café au lait spot Erythrasma Fixed drug eruption Freckle Junction nevus Lentigo Lentigo maligna Melasma Photoallergic drug eruption Phototoxic drug eruption Stasis dermatitis Tinea nigra palmaris Blue Ink (tattoo) Maculae ceruleae (lice) Mongolian spot Ochronosis</td><td>Red Drug eruptions Juvenile rheumatoid arthritis Still disease Rheumatic fever Secondary syphilis Viral exanthems Hypopigmented Idiopathic guttate hypomelanosis Nevus anemicus Piebaldism Postinflammatory psoriasis Radiation dermatitis Tinea versicolor Tuberous sclerosis Vitiligo</td></tr><tr><td>Papule A solid, elevated palpable lesion on the skin &lt;1 cm. It is round and sometimes pointed, is usually red but can be white, yellow, brown, or black, and may be associated with secondary lesions like scale and crust.</td><td>Flesh colored, yellow, or white Adenoma sebaceum Basal cell epithelioma Closed comedones (acne) Flat warts Granuloma annulare Lichen nitidus Lichen sclerosus et atrophicus Milium Molluscum contagiosum Nevi (dermal) Neurofibroma Pearly penile papules Sebaceous hyperplasia Skin tags Syringoma Brown Dermatofibroma Keratosis follicularis Melanoma Nevi Seborrheic keratosis Urticaria pigmentosa Warts</td><td>Red Acne vulgaris Atopic dermatitis Cholinergic urticaria Chondrodermatitis nodularis chronica helicis Eczema Folliculitis Insect bites Keratosis pilaris Leukocytoclastic vasculitis Miliaria Polymorphic light eruption Psoriasis Scabies Urticaria Blue or violaceous Angiokeratoma Blue nevus Lichen planus Lymphoma Kaposi sarcoma Melanoma Mycosis fungoides Venous lake</td></tr></tbody></table>
<p>A primary lesion is a visually recognized structural change in the skin. It has specific characteristics and develops without any preceding skin change.</p>
<p>Adapted from Habif, T. P. (1996). Clinical dermatology: A color guide to diagnosis and therapy (3rd ed., pp. 3-11). St. Louis, MO: Mosby-Yearbook, Inc.</p>
<p>TABLE 2-2 Secondary Skin Lesions and Commonly Occurring</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dermatologic-conditions">Dermatologic Conditions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermatologic-conditions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Secondary Skin Lesions Description</th><th>Commonly Occurring Dermatologic Conditions</th></tr></thead><tbody><tr><td>Scales Excess dead epidermal cells that are produced by abnormal keratinization and shedding</td><td>Fine to stratified Erythema craquele Ichthyosis (quadrangular) Lupus erythematosus (carpet tack) Pityriasis rosea (collarette) Psoriasis (silvery) Scarlet fever (fine, on trunk) Seborrheic dermatitis Syphilis (secondary) Tinea (dermatophytes) Xerosis (dry skin) Scaling in sheets Scarlet fever (hands and feet) Staphylococcal scalded skin syndrome</td></tr><tr><td>Crusts A collection of dried serum and cellular debris; a scab</td><td>Acute eczematous inflammation Atopic dermatitis (face) Impetigo (honey colored) Pemphigus foliaceus Tinea capitis</td></tr><tr><td>Erosions A focal loss of epidermis; erosions do not penetrate below the dermoepidermal junction and therefore heal without scarring.</td><td>Candidiasis Dermatophyte infection Eczematous diseases Intertrigo Petechiae Senile skin Toxic epidermal necrolysis Vesiculobullous diseases</td></tr><tr><td>Ulcers A focal loss of epidermis and dermis; ulcers heal with scarring.</td><td>Aphthae Chancroid Decubitus Factitial Ischemic Necrobiosis lipoidica diabeticorum Neoplasms Pyoderma gangrenosum Radiodermatitis Syphilis (chancre) Stasis ulcers</td></tr><tr><td>Fissure A linear loss of epidermis and dermis with sharply defined, nearly vertical walls</td><td>Chapping (hands, feet) Eczema (fingertip) Intertrigo Petechiae</td></tr><tr><td>Atrophy A depression in the skin resulting from thinning of the epidermis or dermis</td><td>Aging Dermatomyositis Discoid lupus erythematosus Lichen sclerosus et atrophicus Morphea Necrobiosis lipoidica diabeticorum Radiodermatitis Striae Topical and intralesional steroids overuse</td></tr><tr><td>Scar An abnormal formation of connective tissue implying dermal damage; after injury or surgery, scars are initially thick and pink, but with time, scars become white and atrophic.</td><td>Acne Burns Herpes zoster Hidradenitis suppurativa Porphyria Varicella</td></tr></tbody></table>
<p>A secondary lesion is a lesion that has changed due to its natural evolution or due to physical change (scratching, irritation, or secondary infection).</p>
<p>TABLE 2-3 Special Lesions/Other</p>
<table><thead><tr><th>Petechia</th><th>Hemorrhages from superficial blood vessels, &lt;5 mm</th></tr></thead><tbody><tr><td>Purpura</td><td>Hemorrhages from superficial blood vessels, 5 mm to 5 cm</td></tr><tr><td>Ecchymosis</td><td>Bleeding into the tissue affecting large areas</td></tr><tr><td>Lichenification</td><td>Thickening of the skin with exaggerated markings due to prolonged rubbing or scratching</td></tr><tr><td>Induration</td><td>Dermal hypertrophy causing the skin to become thicker and firmer. The skin markings remain unchanged.</td></tr><tr><td>Sclerosis</td><td>Circumscribed or diffuse hardening or induration of the skin resulting from dermal or subcutaneous edema, cellular infiltration, or collagen proliferation</td></tr><tr><td>Maceration</td><td>Thickening and whitening of the horny cell layer caused by excessive moisture</td></tr><tr><td>Excoriation</td><td>A linear or “dug out” traumatized area, usually self-inflicted</td></tr><tr><td>Cyst</td><td>A sac containing liquid or semisolid material</td></tr><tr><td>Furuncle</td><td>Deep form of folliculitis with pus accumulation</td></tr><tr><td>Abscess</td><td>Localized accumulation of purulent material deep within the dermis</td></tr><tr><td>Burrow</td><td>A characteristic linear lesion caused by tunneling in the stratum corneum produced by an animal parasite</td></tr><tr><td>Comedo</td><td>Mass of keratin and sebum within the dilated orifice of a hair follicle</td></tr></tbody></table>
<p>Specific terminology is used to describe the characteristics of skin lesions (number, color, type of lesion, configuration, distribution pattern, which can then be documented). These descriptive clues aid in diagnosing and managing the patient by healthcare providers. It is important to use generally accepted descriptive terminology for verbal and written documentation to ensure continuity and to assist health care providers to interpret the findings. The general examination of the skin considers normal variants and general changes in the skin.</p>
<p>A wide range of normal variations exist in the skin across the life span, which may be due to age, genetic factors, and environmental influences (Table 2-4).</p>
<p>TABLE 2-4 Normal Skin Findings and Variations Across the Life Span</p>
<table><thead><tr><th>Areas of Concern</th><th>Normal Adult Findings</th><th>Variations in Children</th><th>Variations in Older Adults</th></tr></thead><tbody><tr><td>Color and tone</td><td>Deep to light brown in blacks; whitish pink to ruddy with olive or yellow overtones in whites.</td><td>Newborn reddish first 8 to 24 h and then pale pink with transparent tone; slight jaundice starting 2nd or 3rd day of life; mottled appearance of hands and feet in newborns disappears with warming; in black newborns, melanotic pigmentation not intense with exception of nail beds and scrotum</td><td>Skin of white persons tends to look paler and more opaque.</td></tr><tr><td>Uniformity</td><td>Sun-darkened areas; areas of lighter pigmentation in dark-skinned persons (palms, lips, nail beds); labile pigmentation areas associated with use of hormones or pregnancy; callused areas appear yellow; crinkled skin areas darker (knees and elbows); dark-skinned (Mediterranean origin) persons may have lips with bluish hue; vascular flush areas (cheeks, neck, upper chest, or genital area) may appear red, especially with excitement or anxiety; skin color masked through use of cosmetics or tanning agents</td><td>Upper and lower extremities similar in color</td><td>More freckles; uneven tanning; pigment deposits; hypopigmented patches</td></tr><tr><td>Moisture</td><td>Minimum perspiration or oiliness felt; dampness in skin folds; increased perspiration associated with warm environment of activity; wet palms, scalp, forehead, and axilla associated with anxiety</td><td>Perspiration present in all children over 1 mo of age</td><td>Increased dryness, especially of extremities; decreased perspiration</td></tr><tr><td>Surface temperature</td><td>Cool to warm</td><td></td><td></td></tr><tr><td>Texture</td><td>Smooth, even, and soft; some roughness on exposed areas (elbows and soles of feet)</td><td>Smooth, soft, flexible, dryness, and flakiness of skin in infants &lt;1 mo of age (shedding of vernix caseosa); may appear as white cheesy skin; presence of milia; small white papules over nose and cheeks (plugged sebaceous glands) may remain for 2 mo.</td><td>Flaking and scaling associated with dry skin, especially on lower extremities</td></tr><tr><td>Thickness</td><td>Wide body variation; increased thickness in areas of pressure or rubbing (hands and feet)</td><td>Varying degrees of adipose tissue; dimpling of skin over joint areas</td><td>Thinner skin, especially over dorsal surface of hands and feet, forearms, lower legs, and bony prominences</td></tr><tr><td>Turgor</td><td>Skin moves easily when lifted and returns to place immediately when released.</td><td>Skin moves easily when lifted but falls quickly when released; skin over extremities taut.</td><td>General loss of elasticity; skin moves easily when lifted but does not return to place immediately when released; skin appears lax; increased wrinkle pattern more marked in sun-exposed areas, in fair skin, and in expressive areas of face; pendulous parts sag or droop (under chin, earlobes, breasts, and scrotum).</td></tr><tr><td>Hygiene</td><td>Clean, free of odor</td><td></td><td></td></tr><tr><td>Alterations</td><td>Striae (stretch marks) usually silver or pinkish; freckles (prominent in sun-exposed areas); some birthmarks</td><td>Café au lait spots (light, cream-colored spots on darkened background); some nevi; stork bites (small red or pink spots on back of neck, upper lip, or upper eyelid; usually disappear by 5 y of age)</td><td>Nevi often become lighter or disappear; seborrheic keratoses (pigmented raised, warty, slightly greasy lesions most often found on trunk or face); senile (actinic) keratoses on exposed surfaces; first seen as small reddened areas and then as raised, rough, yellow to brown lesions; senile sebaceous adenomas (yellowish flat papules with central depressions); cherry adenomas (tiny, bright, ruby red, round); may become brown with age</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-patient-history-subjective-data">II. PATIENT HISTORY (SUBJECTIVE DATA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-patient-history-subjective-data" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. The traditional approach to assessment in general is to take the history prior to performing a physical examination. However, in dermatology, some providers prefer to do this in a reverse order to expedite the process. A preliminary history helps to establish rapport and engages the patient in the process. Then, moving to physical examination allows appropriately chosen selective questions to be asked subsequently. The general history of current illness is ideally obtained by allowing patient to use their own words regarding his/her skin condition. This gives the provider a sense of direction as to which triage questions to ask. Initially, try to allow the patient to talk uninterrupted. This preliminary history can be abbreviated to three key questions, which evaluate onset and evolution, symptoms, and treatment to date (Box 2-1). Answers to these questions provide a great deal of information about how the condition has started and evolved over time. Review of systems is indicated by the acute or chronic current condition. Symptoms often drive how far one will go in looking for an etiology. Treatment is so key as oftentimes, regardless whether over-the-counter or prescription medications, it can be the very thing causing or contributing to the problem.</p>
<p>B. Information regarding other family members with similar symptoms, past medical history, previous and current drug therapy (including all over-the-counter preparations like herbs, vitamins, and natural supplements), occupation, and social history are all important parts of the initial interview.</p>
<ol>
<li>
<p>Family history is important. Conditions such as psoriasis, eczema, skin cancer, or even keratosis pilaris have a genetic tendency. Patients may claim that another family member shares similar symptoms. For example, the diagnosis of atopic dermatitis is supported when the child presenting with chronic pruritic rash in antecubital fossa has a family history of atopic diseases (asthma, hay fever, and atopic dermatitis).</p>
</li>
<li>
<p>Medical history is significant, including illnesses—particularly chronic illness, which may manifest in the skin—and surgical procedures, for example, if the patient presents with diffuse hair loss or perhaps an unusual rash that may be due to an unresolved strep infection or recent infections occupied by high fever. In another scenario, a past history of chickenpox is helpful in evaluating the patient suspected with herpes zoster.</p>
</li>
<li>
<p>Medication history and medication allergy can take time to update in a comprehensive manner. Then for example, obtaining information regarding current prescription therapy or medicines recently used, including all topicals; systemic medications including steroids; vitamins, and dietary supplements complementary or over-the-counter medications; and home remedies. Drugs or medications can cause multiple types of skin conditions.</p>
</li>
<li>
<p>Occupational history is important in skin disease when patients have occupation-associated symptoms or those which improve over a weekend or resolve while on vacation. In conditions such as occupational contact dermatitis, significant short- and long-term disability, and legal issues may coexist.</p>
</li>
<li>
<p>Social history can be key in complex conditions. Areas to query include occupation, hobbies, sun exposure, pet exposure, alcohol consumption, recreational drugs, smoking</p>
</li>
</ol>
<p>history, travel, and sexual orientation and exposures. Long-time smokers can have physiologic changes that hinder wound healing as well as increase physical aging, particularly face.</p>
<ol start="6">
<li>
<p>Social factors including type of individual medical insurance or ability to pay for treatments also plays a particularly important role in dermatology. Over-the-counter medications or specialized topical prescriptions are frequently a part of the treatment plan. These can create financial burden to even the average patient. Providers must carefully consider these factors when delivering patient recommendations. Traditional and alternative therapies need to be explored.</p>
</li>
<li>
<p>Psychological factors in a patient's life and patient belief system may influence whether or not he/she will have a favorable or unfavorable response to treatment of a chronic skin disease. If, for example, the person prefers the added attention and sympathy the condition brings, improvement may be slow.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-visual-or-physical-examination-objective-data">III. VISUAL OR PHYSICAL EXAMINATION (OBJECTIVE DATA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-visual-or-physical-examination-objective-data" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. There are many dermatologic maladies where examining the patient from head to toe is both necessary and beneficial. Whenever possible, the patient should undress and be placed in comfortable examination gown and setting. A good source of light is the best way to effectively examine the skin (and mouth). Natural lighting in the exam room improves visualization of most skin changes. Additional bright fluorescent lighting sources also are frequently used to examine the skin, mouth, and additional areas. Side lighting helps detect elevation changes.</p>
<p>B. Examinations should be done in an orderly manner to insure important diagnostic clues are not missed. First, note the overall impression of the patient, well or ill. Second, note weight as normal weight, obese, or cachectic. To insure the physical assessment is done in a systematic way, the general inspection of the skin should precede the lesion-specific exam. The hair, nails, mouth, and other mucous membranes should not be overlooked. All providers should strive to move to general inspections of the skin as well as any lesion-specific exams. It is unfortunate when a general physical examination of the skin is often overlooked because some lesions can be recognized at a glance. The total body examinations is completed to find lesions that may occupy the presenting complaint as well as the completely unrelated but important finding such as a skin cancer.</p>
<p>The general examination of the skin considers normal variants and general changes in the skin. A wide range of normal variations exist in the skin across the life span, which may be due to age, genetic factors, and environmental influences (Table 2-4). General changes can alter color (jaundice, cyanosis, pallor), turgor, thickness, temperature, and vascularity (purpura, petechiae, flushing). General findings can suggest a possible association with systemic disease. The lesion-specific examination follows the general assessment and also requires a systematic approach.</p>
<p>C. Gentle palpation of lesion areas, superficial and deep, should be completed to distinguish diagnostic characteristics.</p>
<ol>
<li>Palpable lesions can be located in the epidermis or extend deep into the dermis or subcutaneous tissue.</li>
<li>Papules, nodules, and tumors may be smooth or rough, soft or firm, and fixed or movable.</li>
<li>Manipulation may elicit tenderness or detect localized heat.
D. Normal skin color alterations are best observed on the lips, earlobeso, oral mucous membranes, nails (fingers and toes), and extremities.</li>
<li>Natural skin color variances occur with not only the amount of melanin present in the skin but also the blood supply (from pallor to flush). Degree of pigmentation, pallor (anemia), and jaundice should be noted.</li>
<li>Abnormal conditions of hypopigmentation or hyperpigmentation may be seen in all skin colors.
E. Skin temperature depends upon the amount of vasoconstriction or vasodilation. Whereby localized inflammation causes dilatation of blood vessels and heat sensation, vasoconstriction occurs as the body tries to conserve heat.
F. When assessing for abnormality, evaluate the skin for moisture, turgor, texture, and elasticity. Note the degree of photoaging in adults.
G. The pattern, distribution, texture, and quality of hair on both the scalp and body are indicators of a person's general state of health.
H. Nails change with age and ill health. Pale nail beds can indicate circulatory impedance, whereas red inflamed nail cuticles or pitting can be a sign of psoriasis, or even bacterial or fungal infection.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-evaluation-of-specific-lesions-primary-lesions">IV. EVALUATION OF SPECIFIC LESIONS: PRIMARY LESIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-evaluation-of-specific-lesions-primary-lesions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Primary lesions are the physical changes caused directly by the disease process. Note the shape, morphology, distribution, and quality of the lesion(s). Also important is an accurate and precise description of the evolution of the disease condition. Some common descriptive terms follow. Table 2-1 outlines primary lesions and dermatologic conditions where they commonly occur.</p>
<p>A. Macule—A circumscribed, flat discoloration that varies widely in size, color, and shape, which cannot be palpated (Figure 2-1).
B. Patch—A flat discoloration that varies widely in size, color, and shape greater than 1 cm, which cannot be palpated (Figure 2-2).
C. Papule—A solid, elevated palpable lesion on the skin less than 1 cm. It is round and sometimes pointed, usually red but can be white, yellow, brown, or black and may be associated with secondary lesions like scale and crust (Figure 2-3).
D. Nodule—A solid, elevated palpable mass that is usually larger than 1 cm located in the epidermis or extend deeper to the dermis or subcutaneous tissue. Sometimes considered a small tumor, as tumors have the same features and are larger than nodules (Figure 2-4).
E. Plaque—A solid lesion that covers more than 1 cm of surface skin, which is often elevated or thickened and often formed by closely clustered papules (Figure 2-5).</p>
<p>F. Wheal—Firm, edematous plaque resulting from infiltration of the dermis with fluid. Wheals are transient and with an irregular shape. Sizes usually range from  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">3\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">12\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span>  (Figure 2-6).
G. Vesicle—A round, raised lesion containing clear or purulent fluid that is up to less than 1 cm. They are either sparsely scattered or specifically grouped (Figure 2-7).
H. Bulla—This is a circumscribed collection of free fluid that is larger than  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">1\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span>  in diameter. They are mostly superficial in nature and ruptures easily (Figure 2-8).
I. Pustule—A circumscribed elevated lesion containing whitish or yellowish elevations of the skin filled with purulent exudate, usually a collection of leukocytes and free fluid. Abscesses have the same features and are larger (Figure 2-9).
J. Telangiectasia—A permanently dilated superficial blood vessel in the skin, often seen in areas of solar damage (Figure 2-10).</p>
<p><img src="assets/images/image-20251225-5a598dad.jpeg" alt="img-4.jpeg">
FIGURE 2-1. Macule, solar lentigines. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-ae0a611d.jpeg" alt="img-5.jpeg">
FIGURE 2-2. Patch, vitiligo. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-94f94226.jpeg" alt="img-6.jpeg">
FIGURE 2-3. Papule, acne keloidalis nuchae. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-0a2e6b2d.jpeg" alt="img-7.jpeg">
FIGURE 2-4. Nodule, keloid. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-66d49a92.jpeg" alt="img-8.jpeg">
FIGURE 2-5. Plague, psoriasis. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-8fae2926.jpeg" alt="img-9.jpeg">
FIGURE 2-6. Wheal, dermatographism. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-e1b07957.jpeg" alt="img-10.jpeg">
FIGURE 2-7. Vesicle, herpes simplex. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-9d706f7f.jpeg" alt="img-11.jpeg">
FIGURE 2-8. Bulla, bullous pemphigoid. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-5e77f9f1.jpeg" alt="img-12.jpeg">
FIGURE 2-9. Pustule, insect sting, fire ant. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-23ffc682.jpeg" alt="img-13.jpeg">
FIGURE 2-10. Telangiectasia, rosacea. (Provided by the American Academy of Dermatology, with permission.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-evaluation-of-specific-lesions-secondary-lesions">V. EVALUATION OF SPECIFIC LESIONS: SECONDARY LESIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-evaluation-of-specific-lesions-secondary-lesions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Secondary lesions are physical changes due to natural evolution over time or environmental factors. This is the patient's response to a disease process. Secondary changes may result from scratching/rubbing, secondary infection, or therapies. Some common descriptive terms follow. Table 2-2 outlines secondary lesions and dermatologic conditions where they commonly occur.</p>
<p>A. Scale—Accumulated compact desquamated layers of stratum corneum, which can appear dry or greasy and range from fine and delicate as in pityriasis rosea to coarse and sheet-like as that found in exfoliative dermatitis. These are caused by abnormal keratinization and shedding (Figure 2-11).
B. Crust—Accumulated dried masses of serum, bacteria, and/or possibly blood, mixed with epithelial debris that is covering damaged skin. They vary in size, thickness, and color depending upon the cause and location (Figure 2-12, lichen simplex chronicus).
C. Fissures—Linear cracks in the epidermis, caused mainly by injury or disease. Excessive dryness of the skin may also cause this lesion. They vary in size from a tiny crack to a cleft several centimeters in length that can extend into the dermis. The hands, toes, and angles of the mouth are most commonly affected (Figure 2-13).</p>
<p>D. Lichenification—Areas of epidermal thickening caused by long-term rubbing or scratching. Underlying inflammation often gives a dark red appearance to the skin with exaggerated skin lines. Patient's with neurodermatitis will have lichenified areas (Figure 2-14).</p>
<p>E. Erosion—A temporary loss or break in the epidermis that unless secondarily infected will heal without a scar. Appearing as a slightly depressed, moist lesion, it does not extend below the epidermal junction in the skin layers. Examples of erosions are a scraped knee or elbow (Figure 2-15).</p>
<p>F. Ulcer—A deep erosion that extends through the epidermis down into the dermis. This type of lesion is likely to scar. The cause and location of the ulcer influence the size and type of discharge produced (Figure 2-16).</p>
<p>G. Excoriation—A superficial linear erosion caused by excessive scratching and other trauma. Usually self-induced and may appear linear. Commonly seen in pruritic conditions, such as patients with eczema, neurodermatitis, and scabies. Fingernails are often the source of trauma, so infection is common (Figure 2-17).</p>
<p>H. Scar—A normal result of skin regeneration following injury or disease. Damage to the dermis results with abnormal connective tissue patterns and frequently pigmentary changes. Scars are usually smooth and firm and appear white over time. Overproduction of collagen during the healing process produces a red, raised thickened scar known as a keloid. Burn scars are frequently keloid (Figure 2-18).</p>
<p>I. Atrophy—A thinning of the superficial skin layers, deeper dermal layers, and/or subcutaneous layers most commonly after injury or inflammation. The skin develops a transparent localized indentation. Some examples are postpregnancy stretch marks or healed lesions in patients with chronic discoid lupus (Figure 2-19).</p>
<p><img src="assets/images/image-20251225-ade13395.jpeg" alt="img-14.jpeg">
FIGURE 2-11. Scales, tinea manus. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-f32f95f3.jpeg" alt="img-15.jpeg">
FIGURE 2-12. Crusts, lichen simplex chronicus. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-9d7580e6.jpeg" alt="img-16.jpeg">
FIGURE 2-13. Fissure, hand dermatitis. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-b03cd6e0.jpeg" alt="img-17.jpeg">
FIGURE 2-14. Lichenification, atopic dermatitis. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-356bc853.jpeg" alt="img-18.jpeg">
FIGURE 2-15. Erosions, oral erosions, pemphigus. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-a427a7b8.jpeg" alt="img-19.jpeg">
FIGURE 2-16. Ulcers, pyoderma gangrenosum. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-c5b7de75.jpeg" alt="img-20.jpeg">
FIGURE 2-17. Excoriation with scarring, neurodermatitis. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-5ca789ad.jpeg" alt="img-21.jpeg">
FIGURE 2-18. Scar, hypertrophic scar. (Provided by the American Academy of Dermatology, with permission.)</p>
<p><img src="assets/images/image-20251225-f1199489.jpeg" alt="img-22.jpeg">
FIGURE 2-19. Atrophy, lichen sclerosus. (Provided by the American Academy of Dermatology, with permission.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vi-evaluation-of-lesions-number-color-configuration-and-distribution">VI. EVALUATION OF LESIONS: NUMBER, COLOR, CONFIGURATION, AND DISTRIBUTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-evaluation-of-lesions-number-color-configuration-and-distribution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The number, color, configuration, and distribution of the lesion(s) are often distinct enough to assist with assessment. The earliest lesion and the arrangement of the lesions in relation to each other are valuable diagnostic clues.</p>
<p>A. Consider the number of lesions. Are they few or numerous? Are they localized in one spot or one region? The lesions may be generalized or universal involving the hair and nails as well.</p>
<ol>
<li>Some lesions affect only one side of the body and follow nerve tracts such as herpes zoster.</li>
<li>Lesion has a ringed (i.e., tinea), crescent (i.e., burn), or linear-shaped pattern (i.e., scabies).</li>
<li>Lesion location is important because some diseases only affect specific areas of the skin. For example, acne most often occurs on the face, chest, and back because of the location of sebaceous glands, whereas eczema is frequently found in the antecubital fossa and</li>
</ol>
<p>posterior knees in adolescents and adults.</p>
<p>a. Lesions under a watchband, necklace, or ring might signify a nickel sensitivity.
b. An eruption isolated where skin is exposed to direct sunlight could likely indicate a polymorphic light eruption.
c. A rash on the "blush" areas of the face might indicate rosacea, if the history coincides.
d. Lesions at the openings of hair follicles on the backs of upper arms likely signify keratosis pilaris.</p>
<p>B. Lesion color is a helpful diagnostic aid but may be confusing also since everyone's perception of color is different. A few basic shades are listed below:</p>
<ol>
<li>Brown—seen with increased epidermal melanin pigmentation</li>
<li>Yellow—lipid skin lesions such as xanthomas</li>
<li>Orange—accumulated carotene in the dermis</li>
<li>Purplish red—extravasation of blood in the dermis</li>
<li>Blue-black—seen in cellular blue nevi</li>
</ol>
<p>C. Configuration refers to the arrangement or shape of lesions in relation to other lesions. Some terms seem similar but have been common terminology for decades. The first three words below are all words for round-type lesions.</p>
<ol>
<li>Annular, circinate—ring shaped with active elevated margins that spread peripherally and regress centrally, seen in granuloma annulare</li>
<li>Discoid—disk shaped seen in discoid lupus erythematosus</li>
<li>Nummular—coin shaped, found in nummular eczema</li>
<li>Linear—in a line as seen in Rhus dermatitis</li>
<li>Arciform—arc shape with an incomplete circle as found in mycosis fungoides</li>
<li>Guttate—resembling a drop as found in guttate psoriasis</li>
<li>Iris, target lesion, or "bull's-eye"—lesion which has an erythematous annular macule or papule with a purplish papular or vesicular center</li>
<li>Herpetiform—in a grouping</li>
<li>Reticulated—having a net-like appearance</li>
<li>Confluent—blending together with adjacent lesions</li>
<li>Discrete—separate lesions from each other as in varicella</li>
<li>Polymorphous or multiform—occurring in several forms</li>
<li>Punctate—marked by points or dots</li>
<li>Serpiginous—snake-like</li>
</ol>
<p>D. Configuration refers to the arrangement or pattern of spread in relation to other lesions.</p>
<ol>
<li>Dermatomal/zosteriform—band-like distributions along dermatome, which follows nerve root distribution</li>
<li>Generalized/diffuse—widely distributed</li>
<li>Localized—limited areas of involvement, which are defined clearly</li>
<li>Symmetrical—distributed in a similar way on both sides of area</li>
<li>Unilateral—affects one side of the area only</li>
<li>Truncal—prone to trunk of body, rarely affects limbs</li>
<li>Solitary—a single lesion</li>
<li>Satellite—single lesion in close proximity to a large grouping</li>
</ol>
<p>VII. HAIR AND NAILS AS DIAGNOSTIC INDICATORS</p>
<p>Changes in a person's hair and nails are not necessarily indicative of a disease process. Limited to the skin, changes may be important diagnostic indicators of overall health.</p>
<p>A. Excessive hair (hypertrichosis) or too little hair (hypotrichosis) are findings worth noting.
B. Generalized thinning or lost patches of scalp hair or generalized hair loss in multiple body locations may be important symptoms of infections (bacterial and fungal), systemic illness, lupus erythematosus, chemicals/drugs, scarring, and many other less-common conditions.
C. Fingernails and toenails protect the digits, and changes in their appearance or color must be considered.</p>
<p>See Chapter 22, Hair and Nails, for more detail.</p>
<p>VIII. PRURITUS</p>
<p>A. Primary symptom found in many pathologic systemic disease processes from simple dry skin to the early symptoms of Hodgkin disease or cutaneous T-cell lymphoma.
B. The itch threshold is lower at night.
C. It is the prominent symptom in many dermatologic disorders, and in some cases, there is no apparent skin eruption.
D. To help break the itch-scratch cycle, hydration, moisturizers, sedating oral antihistamines, antipruritic lotions, and topical and injectable steroids may be used. Topical anesthetics and topical antihistamines are generally to be avoided as they may cause allergic contact dermatitis or other forms of irritation or rash. Simple cool compresses applied to the trigger point, if discernable, may help decrease symptoms.
E. Lab work such as CBC, sed rate, urinalysis, serum glucose, and/or liver/thyroid/renal function tests may be ordered. A chest x-ray, Pap smear, or stool tests for ova and parasites and occult blood might also be useful.
F. Psychologic stress and emotional well-being are considered a contributing factor in pruritus, but not solely the causing influence. Fear, tension, anxiety, stress, boredom, and depression may intensify the itch sensation.
G. Dermatologic conditions where pruritus may be a significant component are multiple. Conditions include scabies, dermatitis herpetiformis, atopic dermatitis, lichen simplex chronicus, pruritus vulvae, pruritus ani, miliaria, insect (flea or bedbug) bites, pediculosis, contact dermatitis, psoriasis (especially on scalp and genitalia), lichen planus, urticaria, and lymphoma.</p>
<p>IX. DOCUMENTATION</p>
<p>Accurate, up-to-date, and clear documentation of the patient's condition is essential to provide safe quality care. Interdisciplinary communication requires that all care providers access and contribute to the medical record in an individual and provider-unique manner. Enhanced and</p>
<p>consistent information shared between healthcare providers promotes a continuum of care. Numerous methods and formats for documenting are available to the dermatology specialty. Many documentation specifics are now determined by the formatting established within an electronic medical record. Variations of the older S-O-A-P (subjective-objective-assessment-plan), P-I-E (problem-intervention-evaluation), D-A-R (data-action-response), freehand illustrations, body stickers, and photography have been incorporated into electronic systems. Charting by exception (CBE) while efficient still lends itself to omissions and incomplete assessment.</p>
<p>A. By standardizing a charting format, important patient information and details are less likely to be neglected or forgotten.</p>
<p>B. Body maps help indicate lesion and surgery locations. These methods work when mapping moles, too.</p>
<p>C. Dermatologic photography entered into the patient record is reassuring to the patient and more reliable than one's memory. A change in an acne condition, scar development, mole mapping, and hair loss or regrowth are examples of when photographic documentation are valuable.</p>
<p>D. Dermatologic photography is also used when teaching medical/nursing students, special courses, or relaying information to other medical associates. Written consent from the patient is necessary.</p>
<p>E. Photo documentation of skin surgery before, during, and after the repair is useful for the referring physician, insurance company, and dermatologist for medicolegal reasons.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adelman, D. C., Casale, T. B., &amp; Corren, J. (2012). Manual of allergy and immunology (5th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Adkinson, N. F., Bocher, B. S., Burks, A., Busse, W. W., Holgate, S. T., Lemanske, R. F., &amp; O'Hehir, R. E. (2014). Middleton's allergy: Principles and practice (8th ed.). Philadelphia, PA: Saunders-Elsevier.</p>
<p>Arndt, K. A., &amp; Hsu, J. T. S. (2007). Manual of dermatologic therapeutics (7th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Callen, J. P., Jorizzo, J. L., Zone, J. J., &amp; Piette, W. W. (2009). Dermatological signs of internal disease (4th ed.). Philadelphia, PA: Saunders-Elsevier.</p>
<p>Craven, R., Hirnle, C., &amp; Jensen, S. (2013). Fundamentals of nursing: Human health and function (7th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Desai, S., &amp; Hsu, J. T. S. (2011). Basic definitions and differential diagnosis. In P. C. Schalock, J. T. S. Hsu, &amp; K. A. Arndt (Eds.), Lippincott's primary care dermatology. Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Garg, A., Levin, N. A., &amp; Bernhard, J. D. (2012). Structure of skin lesions and fundamentals of clinical diagnosis. In L. A. Goldsmith, S. I. Katz, B. A. Gilchrest, A. S. Paller, D. J. Leffell, &amp; K. Wolff (Eds.), Fitzpatrick's dermatology in general medicine (8th ed., pp. 26-42). New York, NY: McGraw-Hill.</p>
<p>Garg, A., Levin, N. A., &amp; Bernhard, J. D. (2013). Structure of skin lesions and fundamentals of clinical diagnosis. In L. A. Goldsmith, S. I. Katz, B. A. Gilchrest, A. S. Paller, D. J. Leffell, &amp; K. Wolff (Eds.), Fitzpatrick's dermatology in general medicine (8th ed., pp. 26-41). New York, NY: McGraw-Hill.</p>
<p>Marks, J. G., &amp; Miller, J. J. (2006). Lookingbill and Marks' principles of dermatology (4th ed.). Philadelphia, PA: Saunders-Elsevier.</p>
<p>McCann, S. E., &amp; Huether, S. E. (2014). Structure, function, and disorders of the integument. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Pathophysiology—The biologic basics for disease in adults and children (7th ed., pp. 1616-1652). St. Louis, MO: Mosby-Elsevier.</p>
<p>Nicol, N. H. (2009). Assessment of the integumentary system. In J. M. Black, &amp; J. H. Hawks (Eds.), Medical-surgical</p>
<p>nursing: Clinical management for positive outcomes (8th ed., pp. 1186–1198). Philadelphia, PA: WB Saunders Company.</p>
<p>Nicol, N. H., &amp; Huether, S. E. (2012). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), <em>Understanding pathophysiology</em> (6th ed., pp. 1070–1082). St. Louis, MO: Mosby-Elsevier.</p>
<p>Nicol, N. H., &amp; Huether, S. E. (2012). Structure, function, and disorders of the integument. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), <em>Understanding pathophysiology</em> (6th ed., pp. 1038–1069). St. Louis, MO: Mosby-Elsevier.</p>
<p>Nicol, N. H., &amp; Huether, S. E. (2014). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), <em>Pathophysiology—The biologic basics for disease in adults and children</em> (7th ed., pp. 1653–1667). St. Louis, MO: Mosby-Elsevier.</p>
<p>Penzer, R., &amp; Ersser, S.J. (2010). <em>Principles of skin care</em>. Oxford, UK: Wiley-Blackwell.</p>
<p>Perry, A. G., &amp; Potter, P. A. (2002). Documenting nurses’ progress notes. In A. G. Perry, &amp; P. A. Potter (Eds.), <em>Clinical nursing skills &amp; techniques</em> (5th ed., p. 53). St. Louis, MO: Mosby, Inc.</p>
<p>Weinberg, S., Prose, N. S., &amp; Kristal, L. (2008). <em>Color atlas of pediatric dermatology</em> (4th ed.). New York, NY: McGraw-Hill.</p>
<p>Wolff, K., Johnson, R. A., &amp; Saavedra, A. P. (2013). <em>Fitzpatrick’s color atlas and synopsis of clinical dermatology</em> (7th ed.). New York, NY: McGraw-Hill.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Which of the following is not one of the three general questions important when taking the initial abbreviated history of a new dermatologic problem?</li>
</ol>
<p>a. How long have you had it?</p>
<p>b. Does it itch?</p>
<p>c. What blood tests have you had recently?</p>
<p>d. How have you treated it?</p>
<ol start="2">
<li>Which of the following is a solid, elevated palpable mass that is usually larger than 1 cm?</li>
</ol>
<p>a. Plaque</p>
<p>b. Nodule</p>
<p>c. Patch</p>
<p>d. Papule</p>
<ol start="3">
<li>The pattern, distribution, and texture of which of the following on the body is an indicator of a person’s general state of health?</li>
</ol>
<p>a. Seborrheic keratosis</p>
<p>b. Moles</p>
<p>c. Hair</p>
<p>d. Warts</p>
<ol start="4">
<li>A circumscribed, flat discoloration that could be brown, blue, red, or hypopigmented is a:</li>
</ol>
<p>a. Macule
b. Bulla
c. Nodule
d. Plaque</p>
<ol start="5">
<li>
<p>Lichenification is the accumulation of dried masses of serum, bacteria, and possible blood mixed with epithelial debris that covers damaged epidermis.
a. True
b. False</p>
</li>
<li>
<p>Which of the following primary lesions is caused directly by a disease process?
a. Scales
b. Erosion
c. Pustule
d. Ulcer</p>
</li>
<li>
<p>A lesion that is a response to a disease process is a secondary lesion. Which of the following is an example of a secondary lesion?
a. Wheal
b. Crust
c. Vesicle
d. Plaque</p>
</li>
<li>
<p>A configuration that can be described as coin-like is:
a. Satellite
b. Discoid
c. Gyrate
d. Confluent</p>
</li>
<li>
<p>Pruritis is a major symptom of:
a. Rosacea
b. Keratosis pilaris
c. Herpes zoster
d. Atopic dermatitis</p>
</li>
<li>
<p>The itch or pruritus threshold is lower:
a. First thing in the morning
b. Around noontime
c. During the evening meal</p>
</li>
</ol>
<p>d. In the evening during bedtime hours</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.c
2.b
3.c
4.a
5.b
6.c
7.b
8.b
9.d
10.d</p>
<p>CHAPTER 3</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dermatologic-diagnostic-tests-and-procedures">Dermatologic Diagnostic Tests and Procedures<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermatologic-diagnostic-tests-and-procedures" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Anne Marie Ruszkowski Lord • Noreen Heer Nicol</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Identify diagnostic tests and procedures commonly used on the skin, including microscopic examination, cultures, biopsy for removal and/or pathology, and patch testing.</li>
<li>Describe important steps of above tests and procedures, including scrapings and swabs for microbiology, virology, and mycology.</li>
<li>Describe techniques and application for patch testing in the evaluation of contact dermatitis.</li>
<li>Provide effective education to patients and families to prepare them for tests and procedures.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>The skin is a highly accessible organ, making it available for several diagnostic tests that can help identify specific skin diseases.</li>
<li>Diagnostic tests performed directly on the skin that are usually minimally traumatic and often highly rewarding diagnostically include microscopic examinations, cultures, biopsies, and patch testing.</li>
<li>Blood, urine, and radiograph testing remain helpful when systemic disease is suspected.</li>
<li>Sample selection is extremely important in obtaining the proper diagnostic specimen.</li>
<li>Nursing staff is encouraged to understand each procedure and the benefit versus risk of each to teach and care for their patients more effectively.</li>
<li>Patch testing is an essential tool used in diagnosing allergic contact dermatitis.</li>
<li>Nursing and allied health staff are frequently key personnel participating in the preparation, interpretation, and placement of patch tests.</li>
</ul>
<p>I. DIAGNOSTIC AIDS</p>
<p>As adjuncts to what is seen with the eyes or palpated with the hands, numerous diagnostic tools offer key information in making a diagnosis. Nursing staff rarely perform all steps independently in diagnostic procedures used to establish skin disorders. Therefore, this section is meant to provide an overview. Correct visualization and sample selection are critically important in obtaining the proper diagnostic specimen.</p>
<p>A. An alcohol wipe swept across a lesion is a method used to elucidate the small, delicate telangiectasia and translucence of that lesion, such as with a basal cell carcinoma.</p>
<p>B. Diascopy examination of the skin is completed by gentle pressure utilizing a translucent object, such as a glass slide, to observe the effect upon the color (erythema) of the skin.</p>
<ol>
<li>
<p>Pressure producing a reduction in erythema or pigmentation indicates blood vessel dilation.</p>
</li>
<li>
<p>Pressure that does not produce a change in erythema or pigment indicates increased extravasation of blood, or simply an increased amount of pigment.</p>
</li>
</ol>
<p>C. Mineral oil applied to a glass slide before using magnification helps visualize certain specimens, such as the scabies mite.</p>
<p>D. The microbe is stained for visibility in many microscopic examinations. In dark-field examination, the slide background is darkened to visualize the causative spirochete for syphilis. Specimens for dark-field examinations must be examined immediately.</p>
<p>II. DIAGNOSTIC TESTS</p>
<p>KOH (potassium hydroxide) preparation is a diagnostic method used to confirm the presence or absence of hyphae, spores, and pseudospores. A 10% to 20% KOH solution will digest the keratin in tissue but leave most fungal forms intact for visualization under the microscope (Figure 3-1).</p>
<p><img src="assets/images/image-20251225-bb1d8803.jpeg" alt="img-23.jpeg">
FIGURE 3-1. KOH solution and slide. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p>A. Certain fungi have characteristic appearances.</p>
<ol>
<li>A no. 15 blade is used to scrape skin/scale from the edge of a scaling lesion onto a glass slide. The extremely thick pieces of scale should be avoided. If Candida infection is suspected, a pustule can be a good source of material for the exam.</li>
<li>With the edge of the no. 15 blade, sweep scale or matter into a small pile in the center of the slide.</li>
<li>One or two drops of  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>  KOH are placed on the slide.</li>
<li>A glass coverslip is applied over specimens. Blot out the excess KOH by firmly pressing a paper towel on top of the coverslip and slide.</li>
<li>The slide is gently heated to dissolve the keratin, and the coverslip is gently squeezed and then examined under the microscope using low illumination. If a heat source is not available, leave the specimen set for a minimum of 30 minutes after applying the KOH prior to examination. Scan the entire coverslip first under low (X10) power and then move to higher (X45) power for confirmation.</li>
<li>Repeat the process with a new specimen if the test is negative and a high degree of</li>
</ol>
<p>suspicion remains for a fungal disorder.</p>
<p>B. Fungal cultures are a frequent next step when exact fungal species need to be determined to assist in treatment or the KOH test is negative in light of high suspicion of fungal disease. Scrapings obtained as above with a no. 15 blade from a dry patch of skin, intact pustule, or nail plate or from under the nail can be introduced onto a dermatophyte culture medium and aerobically incubated for a minimum of 7 to 10 days or per the specific media directions. The time required for results depends greatly on the media, lab, or process.</p>
<p>C. Wood's Fluorescence lamp is another simple, but less used, diagnostic tool. This handheld lamp has ultraviolet bulbs (365 nm) that cause certain microorganisms to appear colorful when illuminated. The use of this test has become limited because some common organisms do not fluoresce. This includes <em>T. tonsurans</em> which is now the most common cause of tinea capitis in the U.S. (Figure 3-2).</p>
<ol>
<li>Certain fungus or ringworms glow blue-gray or yellow-green.</li>
<li>Tinea versicolor can appear gold.</li>
<li>Urine screen for porphyrins fluoresces orange.</li>
</ol>
<p>D. Tzanck smear uses a microscope and special stain including Giemsa, methylene blue, or Wright stain. The specimen is best taken from the base of a new vesicle. The specimen slide is colored with a special dye and examined under a microscope, either at the practice office or at a pathology laboratory. The examiner looks for abnormally large cells (called giant cells) that are characteristic of herpes virus infections. This tool aids in the diagnosis of herpes simplex (which causes fever blisters) or herpes zoster (which causes chickenpox and shingles), but does not distinguish between the two.</p>
<p>E. Viral culture, like Tzanck smear, is ideally taken from intact vesicles and transported in a viral transport media. A vesicle is opened or crust removed and underlying serum is swabbed. The swab is placed in the viral media. Human virus types that can be identified by viral culture include adenoviruses, Cytomegalovirus, enteroviruses, herpes simplex virus, influenza viruses, parainfluenza viruses, varicella–zoster virus, measles, and mumps. Viral PCR (polymerase chain reaction) test is also frequently used.</p>
<p>F. Bacterial culture or microbiological culture is a method of multiplying microbial organisms by letting them reproduce in predetermined culture media under controlled laboratory conditions. The ideal specimen sources for bacterial cultures include intact pustules, bullae, and abscesses. The specimen can be obtained by a variety of methods ranging from swabbing, scrapping, aspiration, or biopsy. The cultures are used to determine the type of organism, its abundance in the sample being tested, or both.</p>
<p>G. Scabies scrapings are done with an oil-moistened no. 15 blade. Vigorously scrape small papules or questionable burrows, transfer to a glass slide, cover with coverslip, and examine microscopically.</p>
<p>H. Direct immunofluorescence of tissue is an option when trying to diagnose immunologic abnormalities in the skin. Bullous diseases and connective tissue disorders are two examples. Special tissue preparations and stains are done at a lab to microscopically visualize immunoglobulins, complement, and fibrin found in the skin or circulation.</p>
<p>I. Gram stain allows for identification of Gram-negative or Gram-positive organisms. Exudate from the site is smeared onto a glass slide, then stained, dried, and examined under oil</p>
<p>immersion.</p>
<p>J. Hair pull (pluck) is the most accurate technique to evaluate the anagen/telogen ratio. Approximately 50 hairs of the same length are extracted using a rubber-tipped needle holder and plucked with a quick motion. Hairs are floated on a wet microscope slide or Petri dish for examination. Dyes will be applied to determine phase of growth—anagen reacts with citrulline; telogen hairs do not stain. Hair can also be examined under a microscope to evaluate for disorders such as Netherton disease.</p>
<p><img src="assets/images/image-20251225-c513a31d.jpeg" alt="img-24.jpeg">
FIGURE 3-2. Vitiligo as seen with Wood's lamp. (From Goodheart, H. P. 2010. Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-skin-biopsies">III. SKIN BIOPSIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-skin-biopsies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Shave, punch, and ellipse are biopsy techniques used in both diagnosis and treatment of skin diseases.</p>
<p>A. Shave biopsy/excision is a tangential specimen of tissue for pathology, resulting in minimal to no scarring.</p>
<ol>
<li>The shave biopsy/excision is indicated for dome-shaped intradermal nevi, fibromas,</li>
</ol>
<p>warts, seborrheic keratoses, and actinic keratoses.</p>
<ol start="2">
<li>A portion of the epidermis and underlying papillary dermis is primarily involved.</li>
<li>The procedure can be both an excisional and incisional biopsy depending on whether part or all of the lesion is removed. Extremely superficial lesions are frequently removed with this method.</li>
<li>The equipment needed includes local anesthesia, gentian marker, a single-edged blade (Figure 3-3), curette (optional), hemostatic agent, pathology bottle, and appropriate dressing.</li>
<li>Postbiopsy wound care or dressings are optional depending upon the shave location and patient compliance.</li>
<li>Hypopigmentation at the shave site and localized infection are two potential complications.</li>
</ol>
<p>B. Punch biopsy has multiple uses: diagnosing a disease or an eruption, or simply excising a lesion. The punch instrument can be either circular or elliptical with a razor-sharp cutting edge (see Figure 3-3).</p>
<ol>
<li>An early lesion is selected when an eruption needs diagnosing. If a vesicle is to be studied, a fully intact one is preferred.</li>
<li>An older lesion is needed if discoid lupus erythematosus is suspected.</li>
<li>A punch tool is advantageous in the removal of small nevi because the scar will be smaller than one from the elliptical method.</li>
<li>A punch biopsy is commonly used in diagnosing basal and squamous cell carcinomas, granuloma annulare, and other diseases that involve the deeper dermis.</li>
<li>Punch diameters are available in multiple sizes. Those most frequently used in dermatology range from 2.0 to 8.0 mm.</li>
<li>For local anesthesia, lidocaine 1%, usually with epinephrine for less bleeding depending on the site location, is administered with a 30-gauge needle by raising a wheal prior to biopsy.</li>
<li>Depth extends from the stratum corneum (outermost skin layer) to the underlying fat, providing the entire dermis for evaluation. If nonabsorbable suture is used, the patient returns for suture removal. The punch is twisted while obtaining the biopsy to sample the epidermal and deeper dermal tissue.</li>
<li>Complications to consider are infection, scarring, and nerve damage.</li>
</ol>
<p>C. Elliptical excision/wedge biopsy is used when both normal skin and lesional skin junctions are needed for study, such as evaluating basal and squamous cell malignancies and nevi.</p>
<ol>
<li>The biopsy offers greater tissue depth down to and, if necessary, into the subcutaneous fat.</li>
<li>The equipment needed includes local anesthesia, gentian marker, sterile gloves, a single-edged blade with handle, needle holder, small forceps, skin hook, small clamp, small pointed scissors, suture, curette (optional), hemostatic agent, pathology bottle, gauze, and appropriate dressing.</li>
<li>The incision length is normally 2.5 to 3 times the width of the incision.</li>
<li>Repairs require suturing, and layered closures are frequently necessary.</li>
<li>With so many different types of absorbable suture material available, patients may not need to return for suture removal, making skin surgery more convenient for their</li>
</ol>
<p>schedules. Nonabsorbable suture must be removed. The number of days until removal of nonabsorbable suture is dependent on the area of incision. For instance, facial sutures are removed earlier at 5 to 6 days versus trunk or extremity sutures, which might be left in place 1 to 2 weeks.</p>
<ol start="6">
<li>Flaps and grafts are additional options for closing large and/or inelastic skin surgery sites.</li>
<li>Scarring, possible nerve damage, and infection are the most common complications.</li>
<li>Mohs technique is a specialized procedure involving serial excisions of tissue that are systematically mapped and microscopically examined. This technique done by specially trained Mohs surgeons is used to treat basal cell and squamous cell carcinomas. It defines the extent of the cancer and ensures that the surgical margins are free of tumor.</li>
</ol>
<p><img src="assets/images/image-20251225-db1b1632.jpeg" alt="img-25.jpeg">
FIGURE 3-3. Straight blade and punch tools. A: Shave biopsy. A scalpel blade is manipulated by the operator to adjust the depth of the biopsy. Hemostasis is achieved with topical application of aqueous aluminum chloride, ferrous subsulfate, or electrocautery. B: Punch biopsy. The operator makes a circular incision to the level of the superficial fat, using a rotating or twisting motion of the trephine. Traction applied perpendicularly to the relaxed skin tension lines minimizes redundancy at closure. Hemostasis is commonly achieved by</p>
<p>placement of sutures. (From DeVita, V. T., et al. 2014. DeVita, Hellman, and Rosenberg's cancer: Principles &amp; practice of oncology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-cryosurgery">IV. CRYOSURGERY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-cryosurgery" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition. The destruction of tissue through freezing, most commonly with liquid nitrogen; it causes less scarring because of the ability to control the depth of tissue destruction. It is the simplest and least invasive method of lesion destruction, but one that yields no tissue for pathology.</p>
<p>B. Cryosurgery is the process of destruction by applying extreme cold to a localized site, causing ice formation at the cellular level, thermal shock to the cell, and vascular stasis, resulting in necrosis. Liquid nitrogen at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mn>195.6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">-195.6^{\circ}\mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">195.</span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> is the standard agent used because of its availability and low cost, and because it is noncombustible (Figure 3-4).</p>
<ol>
<li>
<p>The liquid nitrogen invokes rapid cooling and slow thawing and may be applied using a direct spray or cotton-tipped applicator.</p>
</li>
<li>
<p>Treatment causes intense stinging and burning that generally peaks 2 minutes later.</p>
</li>
</ol>
<p>C. Indications</p>
<ol>
<li>
<p>Actinic keratoses</p>
</li>
<li>
<p>Thin seborrheic keratosis</p>
</li>
<li>
<p>Leukoplakia</p>
</li>
<li>
<p>Molluscum contagiosum</p>
</li>
<li>
<p>Common and genital warts</p>
</li>
<li>
<p>Superficial basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in situ (rarely)</p>
</li>
</ol>
<p>D. Nursing considerations</p>
<ol>
<li>
<p>Good cosmetic results with little anesthesia.</p>
</li>
<li>
<p>Painful when used to treat lesions on nose, lips, ears, or eyelids; severe pain if palms, soles, or confined areas such as the area around the nails are treated; these may be better treated by another method.</p>
</li>
<li>
<p>Few side effects, but can damage vital vessels and tear ducts; hyperpigmentation in darker skin is possible.</p>
</li>
<li>
<p>Application with cotton-tipped applicator allows for more control of tissue depth.</p>
</li>
<li>
<p>Blisters form in 3 to 6 hours after application, flatten in 2 to 3 days, and peel off in approximately 2 to 3 weeks.</p>
</li>
<li>
<p>If the site is kept clean, infection is rare.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-ad99af07.jpeg" alt="img-26.jpeg">
FIGURE 3-4. Liquid nitrogen as used for cryosurgery. (From Goodheart, H. P. 2010. Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-0d5fe324.jpeg" alt="img-27.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cryosurgery">Cryosurgery<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cryosurgery" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Understand the objective of procedures and treatment and if unclear, ask questions.</li>
<li>Acknowledge there will be some discomfort associated with the treatment.</li>
<li>Understand the sequence of skin changes associated with treatment; blistering, color changes, crusts, peeling.</li>
<li>Keep site clean and covered after wound occurs.</li>
<li>Acknowledge there will be a possible need for repeat treatments.</li>
</ul>
<p>V. HEMOSTASIS DURING AND AFTER SURGERY</p>
<p>Methods frequently used to achieve hemostasis during or at the end of a surgical procedure are</p>
<p>A. Simple direct pressure, which is the easiest and least traumatizing to tissue.</p>
<p>B. Hemostatic agents such as aluminum chloride or ferric subsulfate, used after shave or curettage procedures.</p>
<p>C. Electrocautery or electrodesiccation using high-frequency radio current during surgical procedures. The lowest current required to achieve hemostasis is recommended.</p>
<p>D. Electrodesiccation and curettage is frequently used to treat selected small basal cell and squamous cell carcinomas. Selection of lesion and methodology is important to avoid reoccurrence of lesions. The practitioner needs to be sure to remove all soft cancerous tissue with curette prior to destroying the rest of the tumor with electrodesiccation and achieving hemostasis. The wound heals by secondary intention usually in 2 to 3 weeks.</p>
<p>VI. PATCH TESTING OVERVIEW</p>
<p>A. History and overview</p>
<ol>
<li>
<p>Patch testing is an essential diagnostic tool used to diagnose allergic contact dermatitis. These tests detect a type IV hypersensitivity response to contact allergens. Patients who present with dermatitis or eczema are potential candidates for patch testing.</p>
</li>
<li>
<p>Jadassohn, a German dermatologist, is considered the father of patch testing. The first scientifically derived connection between a sensitizing substance and a dermatologic hypersensitivity reaction was made by Jadassohn in 1895.</p>
</li>
</ol>
<p>B. Available techniques</p>
<ol>
<li>
<p>Finn chamber/Scanpor tape is one method to test allergens. The chambers consist of shallow aluminum cups or chambers ranging from 8 to 12 mm in diameter that are affixed to a strip of Scanpor tape. Allergens, chambers, and tape are supplied separately (Figure 3-5).</p>
</li>
<li>
<p>Al-test filament paper discs affixed to a strip of plastic-coated aluminum may also be used to test the allergens.</p>
</li>
<li>
<p>T.R.U.E. TEST (Thin-layer Rapid Use Epicutaneous Test) is the first standardized, ready-to-use patch test system approved in the United States. This system delivers 35 common allergens and allergen mixes, which are incorporated into hydrophilic gels, printed on a water-impermeable sheet of polyester, and mounted on nonwoven cellulose tape and one negative control patch (Figure 3-6).</p>
</li>
</ol>
<p>C. Patient selection: Morphology of disease warranting patch testing</p>
<ol>
<li>
<p>Dermatitis or eczema</p>
</li>
<li>
<p>Erythroderma</p>
</li>
<li>
<p>Urticaria</p>
</li>
<li>
<p>Photosensitivity</p>
</li>
<li>
<p>Dermal inflammatory reaction</p>
</li>
<li>
<p>Burning and itching skin with no visible pathology</p>
</li>
</ol>
<p>D. Patient selection: Presentation that may suggest allergic contact dermatitis</p>
<ol>
<li>Highly suggestive history or distribution</li>
<li>Suspected specific antigen or substance</li>
<li>Other dermatitis or conditions that flare or do not respond to treatment
a. Atopic eczema with unusual distribution
b. Stasis dermatitis
c. Hand dermatitis
d. Irritant contact dermatitis
e. Dyshidrotic eczema
f. Seborrheic dermatitis
g. Chronic tinea of the hands and/or feet
h. Nummular eczema
i. Occupationally related dermatitis</li>
</ol>
<p><img src="assets/images/image-20251225-e0a14f24.jpeg" alt="img-28.jpeg">
A</p>
<p><img src="assets/images/image-20251225-fa7835a5.jpeg" alt="img-29.jpeg">
B
FIGURE 3-5. A: Finn chamber patch test supplies with Scanpor tape. B: Finn chambers empty to fill on Scanpor tape. (Courtesy of Noreen Heer Nicol and Anne Marie Ruskowski Lord.)</p>
<p><img src="assets/images/image-20251225-8c59131b.jpeg" alt="img-30.jpeg">
FIGURE 3-6. T.R.U.E TEST panel of 12 allergens peeled from backing. (Courtesy of Noreen Heer Nicol and Anne Marie Ruskowski Lord.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vii-patch-testing-application-techniques">VII. PATCH TESTING APPLICATION TECHNIQUES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vii-patch-testing-application-techniques" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. General considerations (Box 3-1)</p>
<ol>
<li>Patches should be applied to clean skin that is free of dermatitis.</li>
<li>The preferable testing site is the upper back, avoiding midline.</li>
<li>Patches should not be applied on hairy areas.</li>
<li>Patients should not have recently taken oral steroids, had recent intramuscular injection of corticosteroid, used medium- to high-potency topical corticosteroids to test areas, used topical calcineurin inhibitors to testing areas, or had intense sun exposure or phototherapy to testing areas. If the patient has been exposed to these in recent weeks, individual determination of appropriateness for testing must occur, as there may be a high potential for false-negative patch testing response.</li>
<li>Patch testing to unknown substances should never occur.</li>
<li>All patients should have two readings of patches.</li>
</ol>
<p>a. First reading must be 48 hours after initial application for the test to use the standardized parameters on which it is based.
b. Second reading must be 24 to 96 hours after removal of patches, as the reactions are</p>
<p>delayed and may take several days to develop.</p>
<ol start="7">
<li>Patch testing area should be kept dry during testing.</li>
<li>Patients should be instructed to remove patches if "unbearable" to wear for 48 hours. This may include severe burning, stinging, or pruritus at testing areas.</li>
</ol>
<p>B. Finn chamber/Scanpor tape method/standard allergens</p>
<ol>
<li>
<p>Preparing patches for application
a. Allergens are kept refrigerated before use.
b. Anchor strips of Scanpor tape to a hard surface and then apply Finn chambers directly to tape.
c. For aqueous allergens, a filter paper disk is placed into the chamber and one drop of solution is placed on the disk immediately before application (Figure 3-7A).
d. For allergens in an ointment vehicle, the clinician applies a 5-mm ribbon of each petroleum-base allergen directly into individual Finn chambers (Figure 3-7B).</p>
</li>
<li>
<p>Applying patches
a. Allergen patches are placed on the patient's upper back.
b. Patches are smoothed into place, smoothing from bottom to top (Figure 3-7C).
c. Additional Scanpor tape may be necessary to keep patches secure.</p>
</li>
</ol>
<p>C. T.R.U.E. TEST standard allergens (Table 3-1)</p>
<ol>
<li>
<p>Preparing patches for application
a. Standardized, ready-to-use system consists of three panels of patches with 12 allergens per test strip. Panel one contains 11 allergens and 1 negative control.
b. Allergens should be stored in refrigerator before application.
c. Remove test strip from the foil outer sleeve and take off the protective plastic cover.</p>
</li>
<li>
<p>Applying the patches
a. Position test panel #1 on the upper part of the patient's back so that allergen #1 is in the upper left corner.
b. Smooth the panel from the center outward toward the edges.
c. Indicate the location on the skin by using a medical marking pen to make marks on the two notches found on the panel.
d. Repeat the same procedure with panel #2 on the same side of the upper back so allergen #13 is in the upper left corner.
e. Repeat the same procedure with panel #3 on the other side of the upper back so allergen #25 is in the upper left corner.
f. Double-check that the location of all three panels on the skin is marked by using a medical marking pen to make marks on the two notches found on the panel (Figure 3-8).</p>
</li>
</ol>
<p>D. Removing the patches: All patches must be removed 48 hours after application in standardized patch testing.</p>
<ol>
<li>
<p>Supplies needed
a. Recording tool
b. Surgical marking pen or permanent marker
c. Adhesive remover
d. Template</p>
</li>
<li>
<p>Finn chamber method</p>
</li>
</ol>
<p>a. Remove test strips so that the top portion of each strip remains in place (when using template) or
b. Remove test strips and individually mark each individual patch area (Figure 3-9).
c. Wait 20 to 30 minutes before reading patches.</p>
<ol start="3">
<li>T.R.U.E TEST method</li>
</ol>
<p>a. Check that notches on test strip are marked before removing testing panels.
b. Position notches on template to correlate with the notch marks on the skin during application.
c. Wait 20 to 30 minutes before reading patches.</p>
<p>E. Interpreting patch test results</p>
<ol>
<li>Timing</li>
</ol>
<p>a. All patches should be read initially at removal time (48 hours).
b. A second reading is critical 72 to 96 hours after patch application.</p>
<ol start="2">
<li>Irritant versus allergic reaction (Table 3-2)</li>
<li>Morphology codes for patch test interpretation (Tables 3-3 and 3-4).</li>
</ol>
<p>F. Patient Education (Box 3-1)</p>
<ol>
<li>Prepatch testing</li>
</ol>
<p>a. Explain procedure, timing of visits, and need for testing.
b. Describe the testing materials.
c. Explain the requirements of testing.
d. Inform the patient about patch testing safety.</p>
<ol start="2">
<li>After patch testing</li>
</ol>
<p>a. Counsel for negative results.
b. Counsel for positive results. The last and most important step is to determine if there is clinical relevance to a positive reaction. Clinical correlation with appropriate exposure history needs to be determined.</p>
<ol>
<li>Discuss avoidance of allergens and available alternatives.</li>
<li>Distribute written information regarding allergens to be avoided.</li>
<li>Be available for phone follow-up.</li>
</ol>
<p>c. Inform the patients that they may not have been tested to an allergen, which could have yielded a positive results due to allergen not being selected or available.</p>
<p><img src="assets/images/image-20251225-c776155d.jpeg" alt="img-31.jpeg">
A</p>
<p><img src="assets/images/image-20251225-456343a9.jpeg" alt="img-32.jpeg">
B</p>
<p><img src="assets/images/image-20251225-d0f6e24f.jpeg" alt="img-33.jpeg">
Figure 3-7. A: Finn chamber technique using filter paper disc for liquid allergen with petrolatum vehicle beside the liquid one. B: Finn chamber allergen preparation shows ointment and liquid with disc allergen. C: Finn chamber application to upper back—rolling up from bottom to top. (Courtesy of Noreen Heer Nicol and Anne Marie Ruskowski Lord.)</p>
<p><img src="assets/images/image-20251225-3bec6586.jpeg" alt="img-34.jpeg">
Figure 3-8. T.R.U.E TEST panel application and marking. (Courtesy of Noreen Heer Nicol and Anne Marie Ruskowski Lord.)</p>
<p>TABLE 3-1 Standard Allergen Tests Available in the United States</p>
<table><thead><tr><th>Panel</th><th>T.R.U.E TEST Allergen Panel Series</th></tr></thead><tbody><tr><td>1.2</td><td>Nickel sulfate</td></tr><tr><td>Wool alcohols</td><td></td></tr><tr><td>Neomycin sulfate</td><td></td></tr><tr><td>Potassium dichromate</td><td></td></tr><tr><td>Caine mix</td><td></td></tr><tr><td>Fragrance mix</td><td></td></tr><tr><td>Colophony</td><td></td></tr><tr><td>Paraben mix</td><td></td></tr><tr><td>Negative control</td><td></td></tr><tr><td>Balsam of Peru</td><td></td></tr><tr><td>Ethylenediamine dihydrochloride</td><td></td></tr><tr><td>Cobalt dichloride</td><td></td></tr><tr><td>2.2</td><td>p-tert-Butylphenol formaldehyde resin</td></tr><tr><td>Epoxy resin</td><td></td></tr><tr><td>Carba mix</td><td></td></tr><tr><td>Black Rubber mix</td><td></td></tr><tr><td>Cl+ Me–isothiazolinone (MCI/MI)</td><td></td></tr><tr><td>Quaternium-15</td><td></td></tr><tr><td>Methyldibromo glutaronitrile</td><td></td></tr><tr><td>p-Phenylenediamine</td><td></td></tr><tr><td>Formaldehyde</td><td></td></tr><tr><td>Mercapto mix</td><td></td></tr><tr><td>Thimerosal</td><td></td></tr><tr><td>Thiuram mix</td><td></td></tr><tr><td>3.2</td><td>Diazolidinyl urea</td></tr><tr><td>Quinoline mix</td><td></td></tr><tr><td>Tixocortol-21-pivalate</td><td></td></tr><tr><td>Gold sodium thiosulfate</td><td></td></tr><tr><td>Imidazolidinyl urea</td><td></td></tr><tr><td>Budesonide</td><td></td></tr><tr><td>Hydrocortizone-17-butyrate</td><td></td></tr><tr><td>Mercaptobenzothiazole</td><td></td></tr><tr><td>Bacitracin</td><td></td></tr><tr><td>Parthenolide</td><td></td></tr><tr><td>Disperse blue 106</td><td></td></tr><tr><td>2-Bromo-2-nitropropane-1,3-diol (Bronopol)</td><td></td></tr></tbody></table>
<p><img src="assets/images/image-20251225-c291b724.jpeg" alt="img-35.jpeg">
Figure 3-9. Finn chambers individually marked for interpretation. (Courtesy of Noreen Heer Nicol and Anne Marie Ruskowski Lord.)</p>
<p>TABLE 3-2 Characteristics of Positive Patch Test Reactions</p>
<table><thead><tr><th>Allergic Reaction</th><th>Irritant Reaction</th></tr></thead><tbody><tr><td>Persists and/or worsens after patch removal or appears later</td><td>Fades rapidly after patch test removal</td></tr><tr><td>Spreading erythema</td><td>Glazed, scaled</td></tr><tr><td>Edema</td><td>Follicular</td></tr><tr><td>Vesicles</td><td>Pustular</td></tr><tr><td></td><td>Bullous</td></tr></tbody></table>
<p>TABLE 3-3 Morphology Codes for Patch Test Interpretation  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{}^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<table><thead><tr><th>Code</th><th>Reaction</th></tr></thead><tbody><tr><td>1 or +</td><td>Weak reaction: nonvesicular, but with erythema, infiltration, possibly papules</td></tr><tr><td>2 or ++</td><td>Strong reaction: edematous and vesicular, with erythema, edema, papules, and vesicles</td></tr><tr><td>3 or +++</td><td>Extreme reaction: spreading, bullous, ulcerative</td></tr><tr><td>4 or +/?</td><td>Doubtful reaction: macular erythema only</td></tr><tr><td>5</td><td>Irritant reaction</td></tr><tr><td>6 or -</td><td>Negative reaction</td></tr><tr><td>7</td><td>Excited skin</td></tr><tr><td>8</td><td>Not tested</td></tr></tbody></table>
<p>Adapted From Ruszkowski, A. M., Nicol, N. H., &amp; Moore, J. A. (1995, February). Patch testing basics: Patient selection, application techniques, and guidelines for interpretation. Dermatology Nursing (Suppl.), 18.</p>
<p>TABLE 3-4 Description of Patch Test Reactions</p>
<p><img src="assets/images/image-20251225-d0b66d32.jpeg" alt="img-36.jpeg"></p>
<p>Weak Positive Reaction [+] Erythema and edema; some papules; no vesicles</p>
<p><img src="assets/images/image-20251225-9c1de246.jpeg" alt="img-37.jpeg"></p>
<p>Strong Positive Reaction [++] Erythema and edema; papules; vesicles covering  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>  or less of the test site</p>
<p><img src="assets/images/image-20251225-46f36c47.jpeg" alt="img-38.jpeg"></p>
<p>Extreme Positive Reaction [+++] Coalescing vesicles covering more than  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>  of the test site</p>
<p>Images courtesy of Anne Marie Ruskowski Lord.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-3-1-patch-testing-do-s-and-don-ts-for-patients">Box 3-1. Patch Testing Do's and Don'ts for Patients<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-3-1-patch-testing-do-s-and-don-ts-for-patients" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Do not have recently taken oral steroids, had recent intramuscular injection of corticosteroid, used medium to high potency topical corticosteroids to planned testing areas, or had intense sun exposure or phototherapy to testing areas. If you have used any of these treatments in recent weeks, discuss with your health care provider as there needs to be individual determination of appropriateness for testing. There may be a high potential for false negative patch testing response in the presence of these interventions.</p>
</li>
<li>
<p>Do not apply creams or oils to preferred testing area 1 to 2 days before initial patch application.</p>
</li>
<li>
<p>Do keep the patch test area dry for the entire testing period.</p>
</li>
<li>
<p>Do commit to keeping all three appointments for this patch testing procedure.</p>
</li>
</ul>
<p>Appointment 1: Patch application
Appointment 2: Patch removal and initial interpretation—48 hours after application
Appointment 3: Patch interpretation—72 hours to 1 week after application</p>
<ul>
<li>Do take a bath or shower on the morning of testing as you will not be able to shower or bathe again until the testing period is over. You may sponge bathe all areas except the patch test site.</li>
<li>Do keep the patch test area dry for the entire testing period.</li>
<li>Do not engage in any strenuous activity while the test is in progress. Any activity in which considerable sweating occurs should be avoided, as sweating will cause loosening of the tape.</li>
<li>Do wear loose clothing throughout the day. Wear a tight-fitting T-shirt to bed to avoid catching the edges of the tape on the bedsheets.</li>
<li>Do call the patch testing office immediately if any of the patches appear loose; also reinforce the loose patch with Scanpor tape, noting the date and time they have been loose.</li>
<li>Do contact the office immediately if a patch has severe itching or burning. You will be given instructions in removing the patch.</li>
</ul>
<p>Adapted from Nicol, N. H., Ruszkowski, A. M., &amp; Moore, J. A. (1995, February). Update on patch testing: A round table discussion. Dermatology Nursing (Suppl.), 23.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adelman, D. C., Casale, T. B., &amp; Corren, J. (2012). Manual of allergy and immunology (5th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.
Arndt, K. A. &amp; Hsu, J. T. S. (2007). Manual of dermatologic therapeutics (7th ed.. Philadelphia, PA: Lippincott Williams &amp; Wilkins.
Adkinson, N. F., Bocher, B. S., Burks, A., Busse, W. W., Holgate, S. T., Lemanske, R. F., &amp; O'Hehir, R. E. (2014). Middleton's allergy: Principles and practice (8th ed.). Philadelphia, PA: Saunders-Elsevier.
Callen, J. P., Jorizzo, J. L., Zone, J. J., &amp; Piette, W. W. (2009). Dermatological signs of internal disease (4th ed.). Philadelphia, PA: Saunders-Elsevier.
Craven, R., Hirnle, C., &amp; Jensen, S. (2013). Fundamentals of nursing: Human health and function. (7th ed.). Philadelphia, PA.: Lippincott Williams &amp; Wilkins.
Fisher, A. A. (1986). Contact dermatitis. Philadelphia, PA: Lea &amp; Febiger.
Fonacier, L. (2015). A practical guide to patch testing. The Journal of Allergy and Clinical Immunology: In Practice, S2213-2198(15), 244-245. doi: 10.1016/j.jaip.2015.05.001.
Fonacier, L., Bernstein, D. I., Pacheco, K., Holness, L., Blessing-Moore, J., Khan, D., ..., Wallace, D. (2015). Contact dermatitis: a practice parameter-update 2015. The Journal of Allergy and Clinical Immunology: In Practice, 3(3S), S1-S39.
Goldsmith, L. A., Katz, S. I., Gilchrest, B. A., Paller, A. S., Leffell, D. J., &amp; Wolff, K. (2012). Fitzpatrick's dermatology in general medicine (8th ed.). New York, NY: McGraw-Hill.
Hunter-Yates, J. (2007) Diagnostic and therapeutic techniques. In K. A. Arndt &amp; J.T.S. Hsu (Eds.), Manual of dermatologic therapeutics, (7th ed., pp. 255-264). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Jarell, A. &amp; Schalock, P. C. (2011). Procedures in dermatologic diagnosis and therapy. In P. C. Schalock, J. T. S. Hsu, &amp; K. A. Arndt (Eds.), Lippincott's primary care dermatology (pp. 20–27). Philadelphia, PA: Lippincott Williams &amp; Wilkins.
Marks, J. G., Elsner, P., &amp; DeLeo, V. A. (2002). Contact &amp; occupational dermatology. St. Louis, MO: Mosby-Year Book, Inc..
Marks, J. G. &amp; Miller, J. J. (2006) Lookingbill and Marks' principles of dermatology (4th ed.). Philadelphia, PA: Saunders-Elsevier.
McCann, S. E. &amp; Huether, S. E. (2014). Structure, function, and disorders of the integument. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Pathophysiology—the biologic basis for disease in adults and children (7th ed., pp. 1616–1652). St. Louis, MO: Mosby-Elsevier.
Nicol, N. H. (2009). Assessment of the integumentary system. In J. M. Black &amp; J. H. Hawks (Eds.), Medical-surgical nursing: Clinical management for positive outcomes (8th ed., pp. 1186–1198). Philadelphia, PA: WB Saunders Company.
Nicol, N. H., &amp; Huether, S. E. (2014). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Pathophysiology—The biologic basics for disease in adults and children (7th ed., pp. 1653–1667). St. Louis, MO: Mosby-Elsevier.
Nicol, N. H., &amp; Huether, S. E. (2012a). Structure, function, and disorders of the integument. In S. E. Huether, K.L. McCance, V.L. Brasher, &amp; N.S. Rote (Eds.), Understanding pathophysiology (6th ed., pp. 1038–1069). St. Louis, MO: Mosby-Elsevier.
Nicol, N. H., &amp; Huether, S. E. (2012b). Alterations of the integument in children. In S. E. Huether, K. L. McCance, V. L. Brasher, &amp; N. S. Rote (Eds.), Understanding pathophysiology (6th ed., pp. 1070–1082). St. Louis, MO: Mosby-Elsevier.
Nicol, N. H., Ruszkowski, A. M., &amp; Moore, J. A. (1995, February). Update on patch testing: Around table discussion. Dermatology Nursing (Suppl.), 1–30.
Penzer, R., &amp; pages 1-30 Ersser, S. J. (2010). Principles of skin care. Oxford, UK: Wiley-Blackwell.
Perry, A. G., &amp; Potter, P. A. (2002). Documenting nurses' progress notes. In A.G. Perry &amp; P.A. Potter (Eds.), Clinical nursing skills &amp; techniques (5th ed., p. 53). St. Louis, MO: Mosby, Inc.
Warshaw, E. M., Belsito, D. V., Taylor, J. S., Sasseville, D., DeKoven, J. G., Zirwas M. J., ..., Maibach H. I. (2013). North American Contact Dermatitis Group patch test results: 2009 to 2010. Dermatitis, 24(2):50–59. doi: 10.1097/DER.0b013e3182819c51.
Warshaw, E. M., Maibach, H. I., Taylor, J. S., Sasseville, D., DeKoven, J. G., Zirwas, M. J., ..., Belsito, D. V. (2015). North American contact dermatitis group patch test results: 2011–2012. Dermatitis, 26(1):49–59. doi: 10.1097/DER.000000000000097.
Weinberg, S., Prose, N. S., &amp; Kristal, L. (2008). Color atlas of pediatric dermatology, (4th ed.). New York, NY: McGraw-Hill.
Wolff, K., Johnson, R. A., Saavedra, A. P. (2013). Fitzpatrick's color atlas and synopsis of clinical dermatology (7th ed.). New York, NY: McGraw-Hill.
Zug, K. A., Pham, A. K., Belsito, D. V., DeKoven, J. G., DeLeo, V. A., Fowler, J. F. Jr., ..., Zirwas, M. J. (2014). Patch testing in children from 2005 to 2012: results from the North American contact dermatitis group. Dermatitis, 25(6):345–55. doi:10.1097/DER.000000000000083.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>What of the following tools is used to aid in the diagnosis of bullous and vesicular disorders?</li>
</ol>
<p>a. Bacterial culture
b. Wood lamp
c. Tzanck smear
d. None of the above</p>
<ol start="2">
<li>KOH (potassium hydroxide) preparation test is used to aid in the diagnosis of:</li>
</ol>
<p>a. Scabies
b. Fungal disorders
c. Herpes zoster
d. Connective tissue disorders</p>
<ol start="3">
<li>
<p>Which of the following biopsy techniques may require the use of suturing?
a. Shave
b. Punch
c. Elliptical/wedge
d. B and C
e. All of the above</p>
</li>
<li>
<p>Cryosurgery is frequently used to treat:
a. Keratoses
b. Warts
c. Melanoma
d. A and B.
e. All of the above</p>
</li>
<li>
<p>Patch testing should be recommended for patients presenting with:
a. Atopic dermatitis
b. Dyshidrotic eczema
c. Vitiligo
d. A and B
e. All of the above</p>
</li>
<li>
<p>Mr. Lyons is scheduled for patch testing. The nurse explains to him that the patches will be placed on his upper back for:
a. 24 hours
b. 48 hours
c. 72 hours
d. 96 hours</p>
</li>
<li>
<p>Mr. Lyons is instructed that during patch testing, he should:
a. Keep patch area dry
b. Avoid strenuous activity
c. Wear loose clothing while patches being worn
d. All of the above</p>
</li>
<li>
<p>Which one of the following statements is false?</p>
</li>
</ol>
<p>a. Patches should be applied to clean skin that is free of dermatitis.
b. Patches should not be applied to the midline of the back.
c. Patients may apply strong topical corticosteroid cream to the testing area during patch testing.
d. Patches should not be applied on hairy areas.</p>
<ol start="9">
<li>
<p>The presentation of an extreme reaction (+3) can be characterized by:
a. Macular erythema, only
b. Nonvesicular reaction with erythema
c. Spreading and bullous
d. Edema and papules</p>
</li>
<li>
<p>Patients can be patch tested to unknown substances.
a. True
b. False</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>1.c
2.b
3.d
4.d
5.d
6.b
7.d
8.c
9.c
10.b</p>
<p>CHAPTER 4</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-treatment-modalities">Therapeutic/Treatment Modalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Beth Haney</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Identify appropriate treatment modalities for skin diseases and conditions.</li>
<li>Recognize risks and benefits of local, topical, and systemic treatments and medications.</li>
<li>Describe types and potencies of steroid treatments and their applications.</li>
<li>Define the systemic antibiotics related to clinical use, absorption, metabolism, adverse reaction, and dosage.</li>
<li>Identify the pros and cons of vitamin A therapy.</li>
<li>List the steps to applying an Unna’s boot correctly.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Knowledge of current and available therapeutic skin treatments is an important aspect of clinical nursing.</li>
<li>Percutaneous absorption in intact skin may be unpredictable, but increased when the skin barrier is broken or compromised.</li>
<li>Patient education regarding importance of compliance to treatment regimen, benefits, and risks is paramount to successful treatment.</li>
<li>Topical modalities should be used with caution on open wounds; choice of topical medication should consider rate of absorption, healing, presence of infection, and possible sensitivities.</li>
<li>The proper application of venous compression therapy such as Unna’s boot is important to positive outcomes.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The skin is the largest organ of the body; it averages 20 square feet and weighs about 9 pounds.</p>
<p>The skin regulates body temperature, protects underlying skin cells from environmental toxins and harmful ultraviolet radiation, and acts as a barrier to prevent water loss, invasion of foreign substances, as well as immune defense. The outermost layer of the epidermis, the stratum corneum, provides these functions through a barrier that consists of fatty acids, cholesterol, and ceramides that reside between cornified cells. When the skin is intact, it also regulates percutaneous absorption. Any insult that removes lipids, water, or protein from the epidermis can severely compromise this protective function. The goal of topical and systemic preparations is to maintain and restore the functions of the skin barrier. For example, alkaline soaps affect the stratum corneum by changing the normal acidity of the skin (normal skin pH is 5.4 to 5.9). Alteration of the acid mantle can decrease bacterial resistance. Absorption rates of medications vary depending on the anatomic site, that is, eyelids, mucous membranes, palms, or soles of the feet.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-topical-agents">II. TOPICAL AGENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-topical-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-vehicles">A. Vehicles<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-vehicles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Choice of the appropriate vehicle is paramount to successful treatment and determines the rate of the absorption of the active ingredient into the skin. Fat-soluble vehicles, especially natural emollients, are more rapidly absorbed than water-soluble vehicles.</p>
<ol>
<li>
<p>Ointment: Consists primarily of greases such as petroleum jelly with little or no water and desirable for dryer lesions/conditions
a. Increases lubrication
b. Translucent
c. Greater penetration of medicine than creams, which increases percutaneous absorption, thus enhancing potency of medications
d. Usually are preservative-free
e. Should not be used in extremely eczematous inflammation or in intertriginous areas, such as the groin due to occlusive properties
f. May cause folliculitis when used in hairy areas</p>
</li>
<li>
<p>Creams: Mixture of organic chemicals (oil) and water emulsion and usually contains preservatives
a. Used for lubrication and easily applied
b. Highly versatile due to ability to use on almost any area of the body and therefore are the most prescribed
c. Do not increase percutaneous absorption
d. Are more cosmetically acceptable
e. Some may cause dryness with extended use, therefore best for acute exudative inflammation
f. White color and can be greasy in texture
g. Can cause side effects such as burning, stinging, and/or allergy depending on components</p>
</li>
<li>
<p>Solutions and lotions: Powder suspended in liquid (may contain water and alcohol as well as other chemicals) and delivers medication as uniform film</p>
</li>
</ol>
<p>a. Suitable for hairy areas, frequently used for scalp due to ease of penetration, and leaves no residue
b. Have greater content of alcohol and water
c. May over dry the skin and wear off easily
d. Absorb moisture, promoting drying
e. May cause stinging and drying in intertriginous areas, such as the groin</p>
<ol start="4">
<li>
<p>Gel: Greaseless mixture of propylene glycol and water, and some contain alcohol
a. Easily applied
b. Drying and cooling and good for acute exudative inflammation and pruritic eruptions like poison ivy
c. Aggravates dry, cracked lesions if it contains alcohol
d. May cause burning on eroded skin</p>
</li>
<li>
<p>Powder: Finely ground solid particles
a. Absorptive and promotes drying
b. Decreases skin friction
c. Good vehicle to deliver medication to intertriginous areas</p>
</li>
<li>
<p>Aerosols: Medications suspended in a base and delivered under pressure
a. Similar to a lotion but more drying
b. Useful for applying medication to hairy areas
c. Useful on wet lesions</p>
</li>
<li>
<p>Paste: Powder in ointment and 50% or greater powder content
a. Provides protection
b. Decreases rate of percutaneous absorption
c. Messy</p>
</li>
<li>
<p>Foam
a. Useful for scalp dermatoses and spread between strands of hair until reaches the scalp where the medication is then delivered
b. Good for acute exudative inflammation
c. May cause stinging shortly after application</p>
</li>
</ol>
<p>B. Application of topical agents (Tables 4-1 and 4-2): The objective of topical treatment is to lubricate or medicate, or both. Proper application technique should always be used. Hydrating the skin before application will increase percutaneous absorption. Frequency of application and amount will be dictated by severity of dermatosis and the medication chosen.</p>
<ol>
<li>
<p>Remove any "caked" topical before applying additional topical
a. Remove creams with water.
b. Mineral or cottonseed oil may be used to remove ointments or pastes.
c. Always use gentle motions when removing topical medications.</p>
</li>
<li>
<p>Applying creams and ointments
a. The amount of cream or ointment used depends on the area to be treated.
b. Amount can be calculated as 1 g of cream covers 100 cm² of skin. One fingertip unit (FTU) is the amount of ointment expressed from a 5-mm nozzle applied from the distal crease of the index finger to the tip and weighs approximately 0.5 g.</p>
</li>
</ol>
<p>c. Apply in long downward (direction of hair growth) strokes using the palm of the hand.
d. Only a thin film of medication is necessary.</p>
<ol start="3">
<li>
<p>Applying pastes
a. Use tongue depressor if available.
b. May warm container of medication in warm water to soften, thus facilitating application.</p>
</li>
<li>
<p>Applying lotions/solutions
a. Shake well.
b. Pour small amount in the palm of the hand.
c. Pat onto the skin.
d. A brush or gauze may be used for application; avoid use of cotton; it filters out medication and may stick to the skin.</p>
</li>
<li>
<p>Applying sprays and aerosols
a. Shake well.
b. Direct spray to affected area (distance as determined by package insert).
c. Use short bursts when applying.</p>
</li>
<li>
<p>Applying powders
a. Dry affected area thoroughly.
b. "Dust" affected area leaving only a thin layer of powder.
c. Gauze or powder puff facilitates application.
d. Use caution around patients with tracheostomies or respiratory problems.</p>
</li>
<li>
<p>Applying gels
a. Cleanse affected areas.
b. If acne medication, wait a minimum of 30 minutes after cleansing before application to reduce incidence of irritation.</p>
</li>
</ol>
<p>C. Occlusion: This produces a barrier usually by the use of plastic film (Figure 4-1). It enhances absorption by preventing medication evaporation and increasing hydration of stratum corneum by moisture retention. Topical medications penetrate 10 to 100 times more effectively when the stratum corneum is moist.</p>
<ol>
<li>Cleanse skin of debris and other medications with soap and water.</li>
<li>Apply prescribed topical thinly while skin is damp.</li>
<li>Snugly fit plastic wrap, compress air out, and seal borders with paper tape; airtight dressing is unnecessary.</li>
<li>Leave dressing intact for prescribed time, best results are obtained if the dressing is left on for at least 2 hours, and many patients leave dressing on for 8 hours while sleeping. A reasonable schedule is twice daily occlusion for 2 hours or once daily overnight for 8 hours with simple application once or twice daily.</li>
<li>Remove gently and cleanse skin.</li>
<li>Problems associated with occlusion.
a. Sweat retention
b. Maceration
c. Folliculitis
d. Atrophy</li>
</ol>
<p>e. Striae</p>
<p>f. May increase risk for bacterial/fungal overgrowth</p>
<ol start="7">
<li>Long-term occlusion with even a low-potency topical steroid may result in temporary suppression of the hypothalamic-pituitary-adrenal (HPA) axis; this function returns after occlusion is discontinued.</li>
</ol>
<p>TABLE 4-1 Quantity of Topical Cream to Apply and Dispense for Single or Multiple Application(s)</p>
<table><thead><tr><th>Area Treated</th><th>One Application (g)</th><th>BID for 10 day (g)b</th><th>BID for 2 Weeks (g)b</th><th>BID for 1 Month (g)b</th></tr></thead><tbody><tr><td>Face and neck</td><td>2.5 FTUa(1.25 g)</td><td>30 g(1.07 oz.)</td><td>40 g(1.25 oz.)</td><td>75 g(2.7 oz.)</td></tr><tr><td>Trunk (front or back)</td><td>7 FTU (3.5 g)</td><td>75 g(2.7 oz.)</td><td>120 g(4.3 oz.)</td><td>210 g(7.5 oz.)</td></tr><tr><td>One arm</td><td>3 FTU (1.5 g)</td><td>30 g(1.07 oz.)</td><td>60 g(2.1 oz.)</td><td>90 g(3.2 oz.)</td></tr><tr><td>One hand (both sides)</td><td>1 FTU (0.5 g)</td><td>15 g(0.5 oz.)</td><td>15 g(0.5 oz.)</td><td>30 g(1.07 oz.)</td></tr><tr><td>One leg</td><td>6 FTU (3 g)</td><td>60 g(2.1 oz.)</td><td>90 g(3.2 oz.)</td><td>180 g(6.4 oz.)</td></tr><tr><td>One foot</td><td>2 FTU (1 g)</td><td>20 g(0.7 oz.)</td><td>30 g(1.07 oz.)</td><td>60 g(2.1 oz.)</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{}^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span>  FTU,fingertip unit. The amount of cream/ointment expressed from tube applied to the fingertip. FTU weighs about  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mtext>  </mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">{0.5}\mathrm{\;g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord">0.5</span></span><span class="mord"><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span>  .
bWeight is based on application frequency and available tube sizing. In some cases, the tube will have more than the prescribed amount. Adapted from Habif, et al. (2011). Skin disease and treatment (3rd ed.). St. Louis, MO: Mosby.</p>
<p>TABLE 4-2 Guidelines for Patient Education Regarding Application of Topical Medications</p>
<table><thead><tr><th>Successful topical therapy greatly depends on the patient's under-standing of how to apply the topical agent as well as what product they have been prescribed. Knowledge of the drug and product and educating patients using the following guidelines will aid in achieving successful outcomes.</th></tr></thead><tbody><tr><td>Review with the patient any preapplication instructions, including:</td></tr><tr><td>Where to apply</td></tr><tr><td>How much to apply How often to apply</td></tr><tr><td>The sequence of application for multiple products</td></tr><tr><td>Assess the patient's ability to comply and request at-home assistance if necessary.</td></tr><tr><td>Review the importance of proper application and desired outcome.</td></tr><tr><td>The expected results</td></tr><tr><td>Who and when to call with questions</td></tr></tbody></table>
<p>Adapted from Nicol, N. H. (2005). Use of moisturizers in dermatologic disease: The role of healthcare providers in optimizing treatment outcomes. Cutis, 76, 32-33.</p>
<p><img src="assets/images/image-20251225-455c6343.jpeg" alt="img-39.jpeg">
FIGURE 4-1. Occlusive dressing. (From Carter, P. J. (2011). Lippincott textbook for nursing assistants. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-topical-medications">III. TOPICAL MEDICATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-topical-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Numerous topical medications are available for treating skin disorders—corticosteroids, antifungals, antibacterials, antivirals, scabicides and pediculicides, keratolytics and caustics, and antineoplastics.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-topical-steroids">A. Topical steroids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-topical-steroids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Used extensively in treating skin disorders</li>
<li>Reduce inflammation through their ability to induce vasoconstriction</li>
<li>Relieve pruritus</li>
<li>Induce remission of many cutaneous disorders</li>
<li>Potency ranking—groups from 1 to 7 with 1 being the most potent; most dermatoses may be managed with low to moderately potent topical steroids (Table 4-3).</li>
<li>Possible side effects</li>
</ol>
<p>TABLE 4-3 Potency Ranking of Some Commonly Used Topical Steroids</p>
<table><thead><tr><th>Group</th><th>Generic Name</th><th>Brand Name</th></tr></thead><tbody><tr><td>I</td><td>Clobetasol propionate</td><td>Cormax 0.05%, Olux 0.05%</td></tr><tr><td></td><td>Halobetasol propionate</td><td>Ultravate 0.05%</td></tr><tr><td></td><td>Betamethasone dipropionate (optimized vehicle)</td><td>Diprolene 0.05%</td></tr><tr><td></td><td>Diflorasone diacetate</td><td>Psorcon 0.05%</td></tr><tr><td>II</td><td>Amcinonide</td><td>Cyclocort 0.1%</td></tr><tr><td></td><td>Betamethasone dipropionate</td><td>Diprosone 0.05%,</td></tr><tr><td></td><td>Halcinonide</td><td>Elocon 0.1%</td></tr><tr><td></td><td>Fluocinonide</td><td>Halog 0.1%</td></tr><tr><td></td><td>Desoximetasone</td><td>Lidex 0.05%</td></tr><tr><td>III</td><td>Fluticasone propionate</td><td>Topicort 0.025%</td></tr><tr><td></td><td>Betamethasone valerate</td><td>Cutivate 0.005%</td></tr><tr><td>IV</td><td>Triamcinolone acetonide</td><td>Betatrex 0.1%</td></tr><tr><td></td><td>Fluocinolone acetonide</td><td>Kenalog 0.1%</td></tr><tr><td>V</td><td>Hydrocortisone butyrate</td><td>Synalar 0.025%</td></tr><tr><td></td><td>Hydrocortisone valerate</td><td>Locoid 0.1%</td></tr><tr><td>VI</td><td>Alclometasone dipropionate</td><td>Westcort 0.2%</td></tr><tr><td></td><td>Desonide</td><td>Aclovate 0.05%</td></tr><tr><td>VII</td><td>Hydrocortisone</td><td>DesOwen 0.05%</td></tr><tr><td></td><td></td><td>Hytone 2.5%</td></tr><tr><td></td><td></td><td>Hytone 1.0%</td></tr></tbody></table>
<p>Adapted from Habif, T. P. (2016). Clinical dermatology: A color guide to diagnosis and therapy (back inside cover). Philadelphia, PA: Elsevier</p>
<p>a. Atrophy—older skin, inguinal, genital, and perianal areas most predisposed to atrophy</p>
<p>and may be irreversible depending on the potency of steroid used</p>
<p>b. Striae—irreversible
c. Telangiectasia—often persists after discontinuation of steroid
d. Acneiform eruptions—develop after months of use and reversible
e. Interfere with epithelialization and collagen synthesis in wound healing
f. Burning, itching, irritation, and/or dryness—usually due to the vehicle
g. Hypo-/hyperpigmentation—reversible on discontinuation of steroid
h. Bruising—reversible
i. HPA axis suppression—results from application of potent (fluorinated) steroids in excess of 50 to 100 g/week in adults and 10 to 20 g in children, for 2 or more weeks, and reversible
j. Steroid rosacea and perioral dermatitis—results from progression from weaker steroids to more potent concentrations. Strong steroids must be discontinued. Erythema and pustules eventually subside, but atrophy and telangiectasias may be permanent.
k. Ocular hypertension, glaucoma, and cataracts when topical steroids are used around the eyes
l. Folliculitis and milia caused from occlusive plastic dressings
m. Hypertrichosis of the face</p>
<ol start="7">
<li>Nursing considerations
a. Assess efficacy of medication regularly.
b. Assess the patient for development of side effects; length of therapy increases the risk of developing side effects.
c. Assess for tachyphylaxis, which is the tolerance to the vasoconstriction properties of topical steroids.
d. Assess for signs of superimposed infections.
e. Assess response related to vehicle—ointment-based preparations are generally more potent than chemically equivalent cream-based agents.
f. Avoid use of topical steroids on the face, perineal area, or axillae unless otherwise indicated; if required, monitor closely.
g. Hydration increases percutaneous absorption; application after soaking the skin in lukewarm water will increase absorption; in steroid-responsive generalized dermatoses, application following a bath or shower is most efficacious.
h. Compromised skin has increased percutaneous absorption.
i. Frequency of application depends on steroid potency and severity of dermatoses.</li>
</ol>
<p>B. Topical calcineurin inhibitors (TCI): Tacrolimus 0.03% to 0.1% (Protopic) and pimecrolimus (Elidel)</p>
<ol>
<li>
<p>Used for treating intermittent flares of atopic dermatitis (AD) and chronic treatment of AD as alternative to topical steroids</p>
</li>
<li>
<p>These drugs can be used as first line therapy or following treatment with topical steroids.</p>
</li>
<li>
<p>Neither causes certain side effects, such as thinning of the skin (atrophy), or stretch marks (striae), spider veins or discoloration of the skins making them desirable when AD is on face.</p>
</li>
<li>
<p>Side effects</p>
</li>
</ol>
<p>a. Burning and stinging with initial use
b. Possible increased risk of secondary infection from bacterial, viral, and fungal infections</p>
<ol start="5">
<li>Despite a number of epidemiological and clinical studies, no clear link between TCI use and lymphoma risk has been established.</li>
</ol>
<p>C. Topical antifungals (antimycotic agents)</p>
<ol>
<li>Used to treat fungal or dermatophyte infections (superficial infections of the skin, hair, and nails) and also called tinea</li>
</ol>
<p>a. Tinea pedis (Figure 4-2)</p>
<p><img src="assets/images/image-20251225-f92735d5.jpeg" alt="img-40.jpeg">
FIGURE 4-2. Tinea pedis. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p>b. Tinea cruris (Figure 4-3)</p>
<p><img src="assets/images/image-20251225-ccefe17b.jpeg" alt="img-41.jpeg">
FIGURE 4-3. Tinea cruris. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p>c. Tinea corporis (Figure 4-4)</p>
<p><img src="assets/images/image-20251225-34610782.jpeg" alt="img-42.jpeg">
FIGURE 4-4. Tinea corporis. (From Werner, R. (2012). Massage therapist's guide to pathology. Philadelphia, PA: Wolters Kluwer.)</p>
<p>d. Tinea versicolor (Figure 4-5)</p>
<p><img src="assets/images/image-20251225-b5e89dfb.jpeg" alt="img-43.jpeg">
FIGURE 4-5. Tinea versicolor; note the hypopigmented areas. (From Fleisher, G. R., Ludwig, S., &amp; Baskin, M. N. (2004). Atlas of pediatric emergency medicine. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p>e. Tinea rubrum (Figure 4-6)</p>
<p><img src="assets/images/image-20251225-1c906b83.jpeg" alt="img-44.jpeg">
FIGURE 4-6. Tinea rubrum; chronic tinea of the sole caused by Trichophyton rubrum. (From Centers for Disease Control and Prevention Public Health Image Library.)</p>
<p>f. Tinea manuum (Figure 4-7)</p>
<p><img src="assets/images/image-20251225-9b33cd8f.jpeg" alt="img-45.jpeg">
FIGURE 4-7. Tinea manuum. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<ol start="2">
<li>Antifungal-corticosteroid combinations</li>
</ol>
<p>a. Used to alleviate the symptoms of inflammation and pruritus secondary to certain types of fungal infection but may lead to worsening symptoms if specific type is not correctly diagnosed
b. Produce more rapid response/alleviation of symptoms
c. May mask superimposed bacterial infections
d. Use in chronic dermatophyte-induced infections may make evaluation of response or titration of therapy difficult secondary to the topical steroid.
e. Combination medications are more expensive.</p>
<ol start="3">
<li>Antifungal chosen based on the following:</li>
</ol>
<p>a. Species of dermatophyte
b. Body site involved
c. Severity of infection
d. Duration of infection (days, weeks, years, recurrent)
e. Patient's age and/or pregnancy status
f. Concurrent medical conditions/drug therapy</p>
<ol start="4">
<li>Possible side effects</li>
</ol>
<p>a. Skin irritation
b. Overgrowth of fungus when occlusion is used</p>
<p>c. Blistering
d. Stinging
e. Peeling
f. Pruritus</p>
<ol start="5">
<li>Nursing considerations
a. Assess the patient's history for pre-existing condition that might preclude use of topical antifungal.
b. Assess for any evidence of skin irritation secondary to medication.
c. Assess patient/family/significant other’s knowledge of medication and appropriate application.
d. Moist areas of the body (intertriginous and perineal areas) are particularly prone to fungal infections.
e. Ointment-based antifungal products are not desirable due to their occlusive properties.</li>
</ol>
<p>D. Topical antipruritics</p>
<ol>
<li>Usually contain camphor, menthol, phenol, or a topical anesthetic; have anesthetic and counterirritant properties that induce cooling; and indicated for the temporary relief of pruritus.</li>
<li>Examples
a. PrameGel
b. Sarna lotion and cream
c. Calamine lotion
d. Aveeno anti-itch lotion/cream
e. Pramosone
f. Benadryl cream</li>
<li>Nursing considerations
a. May be applied liberally 3 to 4 times/day
b. Underlining etiology of pruritus must be pursued and corrected.
c. Monitor for skin irritation especially with topical antipruritics.</li>
</ol>
<p>E. Topical antibacterials</p>
<ol>
<li>May be used in combination with other topical modalities</li>
<li>Suitable in treating inflammatory acne vulgaris</li>
<li>Suitable for use in open wounds and may facilitate granulation</li>
<li>Preparations chosen based on organism cultured and skin problem</li>
<li>Examples
a. Bacitracin—used for gram-positive infections and prophylaxis in minor cuts, burns, and abrasions
b. Garamycin—used for aerobic gram-negative and some gram-positive infections
c. Meclocycline sulfosalicylate—used for acne vulgaris
d. Mupirocin—greatest activity against gram-positive organisms such as S. aureus and streptococci. Effective treatment for impetigo and nasal colonization of methicillin-resistant staph aureus carrier state
e. Neomycin sulfate—used for aerobic gram-negative and some aerobic gram-positive infections, although can cause contact dermatitis for sensitive individuals</li>
</ol>
<p>f. Nitrofurazone—used as adjunct therapy in second- and third-degree burns and in skin grafts/donor sites to prevent rejection due to bacterial contamination
g. Silver sulfadiazine—used for gram-negative and gram-positive infections
h. Erythromycin—indicated for acne vulgaris, rosacea, and folliculitis
i. Chloramphenicol—used for prophylaxis and treating superficial bacterial infections
j. Tetracycline hydrochloride—used for prophylaxis and treatment of superficial infections
k. Clindamycin—skin and soft tissue infections, impetigo, abscesses, and cellulitis</p>
<ol start="6">
<li>Nursing considerations
a. Use contraindicated in patients with a history of prior sensitization
b. Unless otherwise indicated, cleanse affected area with antibacterial soap and water before application.
c. Observe for any signs of allergic reaction—burning, swelling, redness, or worsening of condition.
d. With prolonged use, monitor for superinfections and overgrowth of nonsusceptible organisms, especially fungus.
e. Alcohol-based antibacterial solutions may cause burning upon application.
f. Nasal application of mupirocin may cause headache, cough, itching, and alterations in taste.</li>
</ol>
<p>F. Topical antivirals</p>
<ol>
<li>Acyclovir and penciclovir (Denavir)—used to prevent or treat herpetic viral infections and reduce viral shedding; mode of action is interference with viral replication but is less effective than systemic therapy (Figures 4-8 and 4-9).</li>
</ol>
<p><img src="assets/images/image-20251225-8bf23c31.jpeg" alt="img-46.jpeg">
FIGURE 4-8. Herpes labialis. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-ca59c0d4.jpeg" alt="img-47.jpeg">
FIGURE 4-9. Herpes zoster; drying hemorrhagic crusts appear in a “zosteriform” distribution. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<ol start="2">
<li>n-docosanol (Abreva) cream—OTC and may shorten episode by hours or 1 day</li>
<li>Contraindicated with hypersensitivity to any components</li>
<li>Use cautiously during lactation, renal impairment.</li>
<li>Possible side effects: burning/stinging, pruritus, or rash</li>
<li>Nursing considerations</li>
</ol>
<p>a. Ointment must thoroughly cover all lesions.
b. Initiate treatment as soon as possible after onset of symptoms, within 24 hours if possible.
c. Monitor for side effects and process.</p>
<p>G. Scabicides and pediculicides</p>
<p>(See Chapter 16 for further detail on infestations and the treatments indicated.)</p>
<p>H. Keratolytics/caustics</p>
<ol>
<li>Keratolytics dissolve and separate the stratum corneum in diseases where hyperkeratosis</li>
</ol>
<p>is a manifestation; caustics have an antimitotic action.</p>
<ol start="2">
<li>
<p>Examples
a. Coal tar (cream, shampoo, ointment, gel, lotion, soap, bath solution)
b. Salicylic acid (cream, gel, ointment, patch, shampoo, solution)
c. Anthralin
d. Cantharidin
e. Podophyllum resin
f. Resorcinol
g. Silver nitrate
h. Sulfur
i. Trichloroacetic or bichloroacetic acid</p>
</li>
<li>
<p>Possible side effects
a. Irritation
b. Burning
c. Pain
d. Inflammation
e. Increased dryness
f. Erosions
g. Blistering
h. Hyperpigmentation
i. Hearing loss, tinnitus, dizziness, confusion, headache, and hyperventilation with salicylic acid if salicylism develops
j. Bleeding, dizziness, hematuria, and vomiting may be seen as side effects of podophyllum resin.</p>
</li>
<li>
<p>Nursing considerations
a. Use with caution in pregnant or lactating women.
b. Do not apply to face, groin, axillae, mucous membranes, and broken or inflamed skin.
c. Do not apply caustics to intertriginous areas.
d. Do not use occlusion with caustics.
e. Salicylic acid is contraindicated for use in children under 2 years of age, diabetics, or individuals with impaired circulation.
f. Do not apply salicylic acid to moles, birthmarks, unusual warts with hair, genital warts, or warts on mucous membranes.
g. Prolonged use of salicylic acid can lead to salicylate toxicity.
h. When applying caustics, protect uninvolved skin by applying petrolatum.
i. Apply caustics only to affected areas.</p>
</li>
</ol>
<p>I. Antineoplastics</p>
<ol>
<li>
<p>Used for treating reactive and proliferative cutaneous malignancies</p>
</li>
<li>
<p>Exert action through different mechanisms.
a. Cycle specific are more effective against proliferating cells.
b. Phase specific are more effective against a specific phase of the cell cycle.
c. Interfere with the synthesis of deoxyribonucleic acid (DNA) through different mechanisms</p>
</li>
<li>
<p>Categories of antineoplastics.
a. Alkylating agents—nitrogen mustard (mechlorethamine) and BiCNU (carmustine)
b. Disrupt the structure of DNA through nonspecific cell cycle manner
c. Interfere with normal cell division in rapidly proliferating tissue</p>
</li>
<li>
<p>Used in treating T-cell lymphoma (mycosis fungoides)
a. Antimetabolites—5-fluorouracil
b. Interfere with the synthesis of nucleic acids and proteins
c. Phase specific and inhibits RNA and DNA synthesis</p>
</li>
<li>
<p>Used in treating superficial basal cell carcinomas, multiple actinic leukoplakia, or solar keratosis
a. Retinoid X receptors bexarotene gel (Targretin) 1% for the topical treatment of resistant T-cell lymphoma
b. Bexarotene gel inhibits the growth of some tumor cell lines of hematopoietic and squamous cell origin.
c. The exact mechanism of action in the treatment of T-cell lymphoma is unknown.
d. Affects cellular differentiation and proliferation and also downregulates CCR4 and E-selectin expression, affecting malignant T-cell trafficking to the skin</p>
</li>
<li>
<p>Possible side effects
a. Pain
b. Pruritus
c. Hyperpigmentation
d. Irritation
e. Inflammation
f. Burning
g. Scarring
h. Swelling
i. Alopecia
j. Photosensitivity
k. Scaling
l. Contact dermatitis</p>
</li>
<li>
<p>Nursing considerations
a. Apply with care near eyes, nose, and mouth.
b. Always wear gloves when applying.
c. Can cause photosensitivity.
d. Avoid occlusion.
e. Erythema, scaling, blistering, burning, and pruritus are expected results of topical treatment with 5-fluorouracil.
f. Nitrogen mustard is applied total body with exception of the groin.
g. Nitrogen mustard may be applied in liquid form or compounded in a petrolatum base.
h. Inspect skin before and during treatment.</p>
</li>
</ol>
<p>J. Vitamin A/retinoids</p>
<ol>
<li>Used in treating noninflammatory acne, photoaging, hyperpigmentation, flat warts, molluscum contagiosum, senile comedones, and actinic keratosis and to enhance</li>
</ol>
<p>percutaneous absorption of other topical agents; metabolized in the skin (Figures 4-10 through 4-12).</p>
<p><img src="assets/images/image-20251225-1211393f.jpeg" alt="img-48.jpeg">
FIGURE 4-10. Acne of the face. (Image provided by Stedman's.)</p>
<p><img src="assets/images/image-20251225-85bf4e01.jpeg" alt="img-49.jpeg">
FIGURE 4-11. Actinic keratosis; keratotic papule characteristic of a hypertrophic actinic keratosis. (From Goroll, A. H., &amp; Mulley, A. G. (2009). Primary care medicine. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-e8fc50a6.jpeg" alt="img-50.jpeg">
FIGURE 4-12. Molluscum contagiosum. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<ol start="2">
<li>Mechanism of action</li>
</ol>
<p>a. Initiates increased cell turnover in both normal follicles and comedones
b. Reduces cohesion between keratinized cells
c. Causes skin peeling and extrusion of comedones; new comedone formation is prevented with continued use
d. Improves skin turgor and reduces fine wrinkling
e. Improves circulation, which improves skin color</p>
<ol start="3">
<li>Possible side effects</li>
</ol>
<p>a. Erythema
b. Peeling
c. Thinning of stratum corneum increasing risk of sunburn/sun damage
d. Increased susceptibility to irritation from wind/cold
e. Dryness
f. Edema
g. Blisters
h. Stinging</p>
<ol start="4">
<li>Nursing considerations</li>
</ol>
<p>a. Use with caution in pregnant or lactating women.</p>
<p>b. Avoid applying around eyes, mouth, angles of the nose, and mucous membranes.
c. Increases risk of sunburn.
d. Astringents, alcohol-based lotions, and acne soaps may not be tolerated while using retinoids.</p>
<p><img src="assets/images/image-20251225-e11dcc9c.jpeg" alt="img-51.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="topical-medications">Topical Medications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#topical-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Understand preapplication instructions.</li>
<li>Use specified and appropriate technique for application; when multiple products are to be applied, understand the order of application.</li>
<li>Use the medication at specified times only.</li>
<li>The medication is only to be applied to areas for which it is prescribed.</li>
<li>Do not overuse or misuse medications as that can result in serious cutaneous and systemic complications.</li>
<li>Monitor results of therapy.</li>
<li>Do not borrow or lend medications to friends or family members.</li>
<li>Use medications as directed.</li>
<li>Follow up with your health care provider if any problems occur.</li>
</ul>
<p><img src="assets/images/image-20251225-e490c692.jpeg" alt="img-52.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="topical-antifungals">Topical Antifungals<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#topical-antifungals" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Review any preapplication instructions; some products may stain fabric, skin, or hair.</li>
<li>Use appropriate technique for application.</li>
<li>Review frequency of applications.</li>
<li>Medication is only to be used on areas for which it is prescribed; self-medication can have disastrous results.</li>
<li>Need to use full course of medication unless side effects occur.</li>
<li>Review expected results from therapy.</li>
<li>Do not lend medication to friends/relatives.</li>
<li>Keep affected areas dry; use nonocclusive, well-ventilated footwear; wash affected</li>
</ul>
<p>areas thoroughly; and change shoes and socks at least once a day.</p>
<p><img src="assets/images/image-20251225-22763255.jpeg" alt="img-53.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="topical-antipruritics">Topical Antipruritics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#topical-antipruritics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Antipruritic agents provide relief from itching.</li>
<li>May be applied liberally 3 to 4 times a day.</li>
<li>If no improvement, call health care provider.</li>
<li>Avoid sun exposure to prevent photosensitivity reactions.</li>
<li>Do not ingest.</li>
</ul>
<p><img src="assets/images/image-20251225-2bb52e34.jpeg" alt="img-54.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="topical-antibacterials">Topical Antibacterials<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#topical-antibacterials" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Understand treatment objectives and if unclear, ask questions.</li>
<li>Use correct application techniques, including preapplication process.</li>
<li>Need to use full course of medication.</li>
<li>Use medication only on affected areas.</li>
<li>Call health care provider if side effects develop.</li>
<li>Consult with health care provider if no improvement in 3 to 5 days.</li>
</ul>
<p><img src="assets/images/image-20251225-db7e90f7.jpeg" alt="img-55.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="topical-antivirals">Topical Antivirals<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#topical-antivirals" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>
<p>Understand treatment objectives and if unclear, ask questions.</p>
</li>
<li>
<p>Use appropriate application of topical medications.</p>
</li>
<li>
<p>Important to complete therapy</p>
</li>
<li>
<p>Understand possible side effects and what to do should they occur.</p>
</li>
<li>
<p>The use of other creams or ointments may delay healing and may cause spreading of lesions.</p>
</li>
<li>
<p>Contact health care provider if symptoms not relieved by 7 days.</p>
</li>
</ul>
<p><img src="assets/images/image-20251225-2bb52e34.jpeg" alt="img-56.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="keratolytics">Keratolytics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#keratolytics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Understand treatment objectives and if unclear, ask questions.</li>
<li>Use correct application of topical medications.</li>
<li>Be aware of possible side effects of treatment.</li>
<li>Important to complete therapy.</li>
<li>Apply topicals only to affected areas and avoid surrounding skin.</li>
<li>Topical is not to be applied to broken skin, wounds, or cuts.</li>
<li>Do not use occlusion unless directed to do so.</li>
</ul>
<p><img src="assets/images/image-20251225-4a6b7db9.jpeg" alt="img-57.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antineoplastics">Antineoplastics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antineoplastics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Understand the treatment objectives; if unclear, ask questions.</p>
</li>
<li>
<p>Important to complete therapy.</p>
</li>
<li>
<p>Use correct application of topical and wash hands thoroughly after application.</p>
</li>
<li>
<p>Be aware of possible side effects of treatment.</p>
</li>
<li>
<p>Possibility of increased photosensitivity; avoid sun exposure and/or use a sunscreen of at least SPF 30 daily.</p>
</li>
<li>
<p>If using 5-fluorouracil, there are various stages of inflammation that will occur, including redness, scaling, blistering, burning, and itching, which are expected; therapy is discontinued when ulceration and erosion begin and occurs in 2 to 12 weeks depending on diagnosis.</p>
</li>
<li>
<p>This is a potent prescription medication, which should not be shared with others or used for other skin conditions than the one that it has been prescribed to treat.</p>
</li>
</ul>
<p><img src="assets/images/image-20251225-0c8aab31.jpeg" alt="img-58.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="retinoids">Retinoids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#retinoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Understand treatment objectives, and if unclear, ask questions.</li>
<li>Use correct application technique as described by your health care provider.</li>
<li>Avoid using keratolytics, alcohol-based products, abrasive cleansers, astringents, and topical products containing spice or lime.</li>
<li>Topical moisturizer can be used if skin becomes too dry.</li>
<li>Apply topical medication after thoroughly cleaning and drying the skin.</li>
<li>Possibility of increased sensitivity to sun; use a sunscreen of at least SPF 30.</li>
<li>Important to adhere to prescribed regimen.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-intralesional-therapy">IV. INTRALESIONAL THERAPY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-intralesional-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Intralesional steroids</p>
<ol>
<li>Injected directly into or just beneath the lesion</li>
<li>Provides a reservoir of medication that lasts for several weeks to months</li>
<li>Used to supplement other treatment modalities</li>
<li>Conditions treated</li>
</ol>
<p>a. Psoriasis
b. Alopecia areata
c. Cystic acne
d. Hypertrophic scars/keloids
e. Chronic eczematous inflammation and lichen simplex chronicus
f. Discoid lupus (use lidocaine/steroid solution as for herpes zoster)</p>
<ol start="5">
<li>Most commonly used mixture: 2.5 to 10 mg/mL suspension of triamcinolone acetonide</li>
<li>Other mixtures</li>
</ol>
<p>a. 10 mg/mL—effective for chronic eczematous inflammation, acne, and hypertrophic scars/keloids
b. 10 mg/mL diluted with 1% Xylocaine or physiologic saline—effective for acne and discoid lupus
c. 2.5 to 5.0 mg/mL—effective in suppressing inflammation</p>
<ol start="7">
<li>
<p>Possible side effects
a. Prolonged, continuous use may lead to adrenal suppression.
b. Atrophy may result after multiple injections in same site.</p>
</li>
<li>
<p>Nursing considerations
a. Injections may be painful.
b. Atrophy can result from multiple treatments.
c. Multiple treatments may be necessary in some conditions such as keloids.
d. Vial of steroid solution must be shaken thoroughly before drawing up solution.
e. If syringe of medication is not used immediately, syringe should be shaken immediately prior to injection.</p>
</li>
</ol>
<p>B. Intralesional antineoplastic agents.</p>
<ol>
<li>
<p>Bleomycin sulfate
a. Useful in treating recalcitrant periungual or plantar warts and Kaposi sarcoma
b. Solution: 1 unit/mL in physiologic saline (dissolve 15 unit vial of bleomycin in 15 mL of sterile physiologic saline)
c. Inject 0.1 to 1.0 mL until wart blanches.</p>
</li>
<li>
<p>Vinblastine
a. Useful in treating Kaposi sarcoma
b. Solution: 0.1 to 0.5 mg/mL q4wk
c. Maximum total dose to be used is 2 mg.</p>
</li>
<li>
<p>Interferon alfa-2b, recombinant, and interferon alfa-n3
a. Treatment indications
i. Genital warts that are unresponsive to all forms of conventional treatment, imposing significant social or physical limitations
ii. Kaposi sarcoma
iii. Basal/squamous cell cancers
b. Possible side effects
i. Injection site reactions—redness, pain, swelling, and discoloration
ii. Flu-like symptoms</p>
</li>
<li>
<p>Nursing considerations
a. A thorough history to determine presence of underlying medical problems (cardiac, liver, or renal)
b. Medication must be refrigerated.
c. Initial treatment for warts will be 3 times/week for 3 weeks.
d. Flu-like symptoms can be managed with acetaminophen.</p>
</li>
</ol>
<p>PATIENT EDUCATION
Antineoplastic Agents</p>
<ul>
<li>Understand treatment objective, and if unclear, ask questions.</li>
<li>Understand possible side effects and how to handle.</li>
<li>Important to adhere to prescribed treatment regimen.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-systemic-medications">V. SYSTEMIC MEDICATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-systemic-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Antibiotics: Act to prevent or treat infection from pathogenic microorganisms</p>
<ol>
<li>Macrolides: Azithromycin and erythromycin—highly effective; one of the safest antibiotics; topical erythromycin is the drug of choice in treating acne and folliculitis.</li>
</ol>
<p>a. Members of macrolide group
b. Bacteriostatic—inhibits protein synthesis
c. Bactericidal in high concentrations
d. Pharmacokinetics</p>
<p>i. Inactivated rapidly by gastric acid
ii. Dissolves poorly in water
iii. Distributed well to most tissues with the exception of cerebrospinal fluid (CSF)
iv. Transported across the placenta and excreted in breast milk
v. Metabolized in the liver and excreted in the bile and small amount excreted in urine
vi. Peak serum concentration level occurs 1 to 4 hours after a single 250-mg dose of erythromycin in a fasting patient and 2.5 to 3.2 after dose of azithromycin</p>
<p>e. Pharmacotherapeutics</p>
<p>i. Broad spectrum of antimicrobial activity, effective against the following:</p>
<p>(a) Pneumococci
(b) Group A Streptococci
(c) Staphylococci aureus (not effective against methicillin-resistant S. aureus)
(d) Gram-negative and gram-positive bacteria
(e) May be used in patients with penicillin allergy who have group A beta hemolytic streptococci or S. pneumoniae infection</p>
<p>ii. Dosage/indications</p>
<p>(a) Erythromycin—Adults: 250 mg PO qid × 10 days, 333 mg PO q8h, or 500 mg PO q12h (base or stearate), 400 mg PO q6h or 800 mg PO q12h (ethylsuccinate); pediatric dose (base and ethylsuccinate): children greater than 1 month: 30 to 50 mg/kg/d PO in divided doses q6–8h (max. 2 g/d as base or 3.2 g/d as ethylsuccinate); 30 to 50 mg/kg/d PO divided q6h (max. 2 g/d as stearate).
(b) Azithromycin—Adults: 500 mg PO qd on first day, then 250 mg/d PO for 4 additional days (total dose 1.5 mg): children 6 month and older: 10 mg/kg PO (not greater than 500 mg/dose) on first day, then 5 mg/kg PO (not greater than 250 mg) for four additional days.
(c) Skin and soft tissue infections</p>
<p>(i) Chlamydia trachomatis urethritis
(ii) Erythrasma
(iii) Gonorrhea</p>
<p>(d) Strep. pyogenes infections
(i) Lymphangitis
(ii) Impetigo
(iii) Ecthyma</p>
<p>(e) S. aureus infections
(i) Folliculitis
(ii) Furunculosis
(iii) Infected dermatitis</p>
<p>iii. Adverse reactions
(a) Commonly causes nausea and vomiting when taken on an empty stomach
(b) Diarrhea
(c) Cholestatic hepatitis with fever, abdominal pain, nausea, vomiting, eosinophilia, and elevated serum bilirubin
(d) Stevens-Johnson syndrome and toxic epidermal necrolysis (azithromycin)</p>
<p>iv. Drug interactions
(a) Theophylline
(b) Cyclosporine
(c) Carbamazepine
(d) Warfarin
(e) Digitalis
(f) Ergotamine
(g) Methylprednisolone
(h) Pimozide
(i) Diltiazem
(j) Ketoconazole
(k) Verapamil</p>
<ol start="2">
<li>Penicillins</li>
</ol>
<p>a. Derived from strains of Penicillium notatum and Penicillium chrysogenum, which are common molds seen on bread or fruit.</p>
<p>b. First generation
i. Penicillin G and penicillin V
ii. Newer semisynthetic penicillinase—resistant
(a) Oxacillin
(b) Cloxacillin
(c) Dicloxacillin</p>
<p>c. Second generation
i. Amoxicillin and clavulanate (Augmentin)
ii. Ampicillin
iii. Amoxicillin
iv. Ampicillin/sulbactam (Unasyn)</p>
<p>d. Third generation</p>
<p>i. Ticarcillin (Ticar)
ii. Ticarcillin/potassium clavulanate (Timentin)</p>
<p>e. Fourth generation</p>
<p>i. Piperacillin (Pipracil)
ii. Piperacillin sodium and tazobactam sodium (Zosyn)</p>
<p>f. Pharmacokinetics</p>
<p>i. Kills bacteria by destroying the cell walls, bactericidal
ii. Natural penicillins (penicillin G and V) effective against the following:</p>
<p>(a) Gram-positive organisms
(b) Gram-negative organisms
(c) Anaerobic organisms</p>
<p>iii. Penicillinase-resistant penicillins (cloxacillin, dicloxacillin, nafcillin, oxacillin)</p>
<p>(a) S. aureus
(b) S. epidermidis
(c) Some streptococci infections</p>
<p>iv. Absorption</p>
<p>(a) Oral absorption varies and limited by gastric acidity and binding with food. All should be taken on an empty stomach with the exception of amoxicillin.
(b) Completely and rapidly absorbed throughout the body after parental administration.
(c) Distributed widely in fluids/tissue including liver, kidneys, bones, muscle, and placenta and enters breast milk
(d) Does not readily enter CSF
(e) Minimally metabolized in the liver
(f) Excreted unchanged and primarily through the kidneys</p>
<p>v. Peak serum concentrations vary from one-half hour to 24 hours depending on route of administration.</p>
<p>g. Pharmacotherapeutics</p>
<p>i. Broad spectrum of antimicrobial activity</p>
<p>(a) Procaine penicillin used for susceptible strains of gonorrhea
(b) Benzathine penicillin G preferred for syphilis
(c) Dicloxacillin: Treatment of osteomyelitis, suspected or proven staphylococcal infections, and most streptococci and S. aureus infections
(d) Aminopenicillins (ampicillin and amoxicillin): Broad spectrum, active against gram-negative bacteria, and better absorbed with less GI distress</p>
<p>ii. Dosage/indications</p>
<p>(a) Dependent on type of penicillin and route of administration
(b) Used to treat common infections, syphilis, and staph infections</p>
<p>iii. Adverse reactions</p>
<p>(a) Hypersensitivity reactions (anaphylaxis, the major adverse reaction)
(b) Neurotoxicity
(c) Nephrotoxicity</p>
<p>(d) Electrolyte imbalances
(e) Hematologic reactions
(f) Cardiovascular reactions</p>
<p>iv. Drug interactions
(a) Probenecid
(b) Methotrexate
(c) Tetracyclines
(d) Chloramphenicol
(e) Aminoglycosides (penicillin G, azlocillin, carbenicillin, mezlocillin, piperacillin, ticarcillin)
(f) Neomycin (penicillin V)
(g) Allopurinol</p>
<ol start="3">
<li>Cephalosporins</li>
</ol>
<p>a. Pharmacokinetics
i. Properties and mechanisms of action resemble penicillins.
ii. Semisynthetic derivation of cephalosporin C (produced by fungus <em>Acremonium chrysogenum</em>); classified by generation, which is determined by spectra of activity. As progression is made from the first generation to the fourth generation, the activity against gram-negative bacteria increases, the ability to penetrate CSF increases, and there is greater resistance to beta lactamases.
iii. Rapidly absorbed by the GI tract
iv. May take with or without food
v. Distributed widely through soft tissue and bodily fluids except CSF
vi. Excreted essentially unchanged by the kidneys except for cefoperazone, which is excreted in bile, and ceftriaxone, which is partly metabolized and partly excreted in urine, and are excreted in the feces
vii. Oral cephalosporins reach a peak serum concentration level within 1 to 6 hours after administration; IV administration levels achieved within 30 minutes; IM administration in 15 minutes to 3 hours</p>
<p>b. First generation
i. Parenteral
(a) Cefazolin
ii. Oral
(a) Cephalexin
(b) Cefadroxil
iii. Treatment of gram-positive and gram-negative organisms (most staphylococci, groups A and B hemolytic streptococci, most streptococci)</p>
<p>c. Second generation
i. Parenteral
(a) Cefoxitin
(b) Cefotetan
(c) Cefuroxime
ii. Oral</p>
<p>(a) Cefaclor
(b) Cefprozil
(c) Cefuroxime</p>
<p>iii. Treatment of gram-negative, gram-positive, and anaerobic organisms (same as first generation as well as Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Enterobacter, Citrobacter, Clostridium, Bacteroides)</p>
<p>d. Third generation</p>
<p>i. Parenteral</p>
<p>(a) Cefotaxime
(b) Ceftriaxone
(c) Ceftazidime
(d) Cefoperazone</p>
<p>ii. Oral</p>
<p>(a) Cefixime
(b) Cefdinir
(c) Cefditoren
(d) Cefpodoxime
(e) Ceftibuten</p>
<p>iii. Treatment of gram-negative, gram-positive, and anaerobic organisms (same as first and second generation as well as Pseudomonas aeruginosa, Enterobacter)</p>
<p>e. Fourth generation</p>
<p>i. Parenteral
(a) Cefepime
ii. Treatment of gram-negative, gram-positive, and anaerobic organisms (same as third generation but also effective against P. aeruginosa)</p>
<p>f. Fifth generation</p>
<p>i. Parenteral
(a) Ceftaroline
ii. Treatment of gram-negative, gram-positive, and anaerobic organisms (same as third generation but also effective against P. aeruginosa and with improved gram-positive activity, in particular MRSA)</p>
<p>g. Pharmacotherapeutics—ineffective against enterococci (Streptococcus faecalis), methicillin-resistant staphylococci, and beta hemolytic streptococci</p>
<p>h. Dosage/indications</p>
<p>i. Based on drug and condition being treated and route of administration
ii. Treatment of skin infections due to S. aureus and group A and B beta hemolytic strep
iii. Cellulitis due to H. influenzae</p>
<p>i. Adverse reactions (considered to be very safe)</p>
<p>i. Hypersensitivity reactions (most common)
ii. Cross-reactivity in patients who are sensitive to penicillins
iii. Pain, induration, and tenderness at site of injection
iv. In patients with impaired renal function, confusion, and seizures</p>
<p>v. In orally administered drug: nausea, vomiting, and diarrhea
vi. Cephalosporins may produce nephrotoxicity.
vii. Possibility of superinfection</p>
<p>j. Drug interactions
i. Disulfiram-like reaction with cefoperazone and cefotetan
(a) Headache
(b) Flushing
(c) Dizziness
(d) Nausea, vomiting, and abdominal cramping
ii. Concomitant use of cephalosporins and imipenem/cilastatin
(a) Antagonizes antibacterial activity of beta lactam cephalosporins</p>
<ol start="4">
<li>Tetracyclines
a. Pharmacokinetics
i. Absorbed from the duodenum
ii. Distributed widely into the body tissues, fluids with some penetration into CSF, placenta, and breast milk
iii. Excreted primarily unchanged by the kidneys (except for doxycycline and minocycline; bile and feces)
iv. Onset, peak, and duration of action vary among tetracyclines; ranges from 30 minutes to 4 hours.</li>
</ol>
<p>b. Pharmacotherapeutics
i. Provide broad-spectrum coverage against gram-positive, gram-negative, aerobic, and anaerobic bacteria, spirochetes, mycoplasmas, rickettsiae, chlamydiae, and some protozoa
ii. Doxycycline and minocycline provide more action against various organisms.</p>
<p>c. Dosage/indications
i. Minocycline hydrochloride (Minocin)
(a) Treatment of severe acne: 50 mg qid or 100 mg bid
(b) Not recommended in children under 8 years old
ii. Tetracycline hydrochloride
(a) Treatment of acne, Lyme disease, and syphilis in penicillin-allergic patients
(i) 250 to 500 mg PO q6h for gram-positive and gram-negative organisms
(ii) 500 mg PO qid for 10 to 30 days for Lyme disease
(iii) 250 to 500 PO mg qid for acne
(b) Pediatric dose (&gt;8 years old): 25 to 50 mg/kg/d PO in divided doses every 6 hours
iii. Doxycycline (Vibramycin, Doryx)
(a) Treatment of acne, anthrax, malaria prophylaxis, as well as other infections treated with tetracyclines
(i) Most infections: 100 mg PO q12h
(ii) Malaria prophylaxis: 100 mg PO qd
(iii) Lyme disease: 100 mg PO q12h
(iv) Anthrax: 100 mg PO q12h × 60 days</p>
<p>(b) Pediatric dose (&gt;8 years old): Oral: 25 to 50 mg/kg/d in divided doses every 6 hours</p>
<p>d. Adverse reactions</p>
<p>i. GI disturbances—nausea, vomiting, and diarrhea (Tetracycline must be taken on an empty stomach with either juice or water for proper absorption.)</p>
<p>ii. Risk of superinfection</p>
<p>iii. Significantly affects tooth enamel, therefore not recommended in children under age of 8 or pregnant patients</p>
<p>iv. Photosensitivity reactions</p>
<p>v. Nephrotoxicity in patients with renal failure</p>
<p>vi. Hepatotoxic reactions in patients with an excessive serum concentration due to renal failure</p>
<p>vii. Light-headedness, loss of balance, dizziness, and tinnitus (most common with minocycline)</p>
<p>viii. Yeast infections</p>
<p>ix. Hypersensitivity reactions, though uncommon</p>
<p>e. Drug interactions</p>
<p>i. Antacids with calcium, aluminum, and magnesium—chlortetracycline, doxycycline, minocycline, and tetracycline</p>
<p>ii. Iron salts, bismuth, subsalicylate, and zinc sulfate—tetracycline and doxycycline</p>
<p>iii. Barbiturates, carbamazepine, and phenytoin—decrease effects of doxycycline</p>
<p>iv. Decreases effect of penicillin—all tetracyclines</p>
<p>v. Decreases effect of warfarin—all tetracyclines</p>
<p>B. Antifungals (antimycotics): Used to treat superficial (topical) and systemic infections</p>
<ol>
<li>Nystatin</li>
</ol>
<p>a. Pharmacokinetics</p>
<p>i. Little or no absorption, distribution, or metabolism</p>
<p>ii. Excretion negligible with local application</p>
<p>b. Pharmacotherapeutics</p>
<p>i. Primarily treat superficial skin infections</p>
<p>ii. Effective against Candida albicans, Candida guilliermondii, and other Candida species</p>
<p>iii. Oral nystatin is used to prevent fungal infection in neutropenic patients</p>
<p>c. Dosage</p>
<p>i. For oral candidiasis: 400,000 to 600,000 units swish and swallow (retain in the mouth as long as possible) qid, or 500,000 to 1,000,000 units oral tablets dissolved in the mouth q8h</p>
<p>d. Adverse reactions</p>
<p>i. Hypersensitivity reactions (uncommon)</p>
<p>ii. Bitter taste</p>
<p>iii. High doses may cause diarrhea, nausea, vomiting, and abdominal pain</p>
<p>e. Drug interactions</p>
<p>i. None</p>
<ol start="2">
<li>Amphotericin B intravenous (IV)</li>
</ol>
<p>a. Pharmacokinetics
i. Distributed throughout the body tissues and fluids and poor CSF penetration
ii. Very prolonged and excreted by the kidneys</p>
<p>b. Pharmacotherapeutics
i. Indicated for treating severe, potentially fatal systemic fungal infections
ii. Extremely toxic; therefore, risk/benefit must be weighed carefully
iii. Used to treat aspergillosis, coccidiomycosis, cryptococcus, candidiasis, and phycomycosis infections</p>
<p>c. Dosage
i. Test dose: 1 mg in 250 mL of dextrose 5% over 20 to 30 minutes
ii. Systemic fungal infections: 0.25 mg to 1.5 mg/kg/d based on organism present and patient's tolerance and infused over 4 to 6 hours
iii. Pediatric dosage: Infants and children: 0.1 mg/kg/dose to a maximum of 1 mg; infuse over 30 to 60 minutes. Maintenance dose: 0.25 to 1 mg/kg/d given once daily; infuse over 2 to 6 hours. Once therapy has been established, amphotericin B can be administered on an every-other-day basis at 1 to 1.5 mg/kg/dose; cumulative dose: 1.5 to 2 g over 6 to 10 weeks</p>
<p>d. Adverse reactions
i. Nephrotoxicity
ii. Hypokalemia
iii. Chills and fever
iv. Nausea, vomiting, and anorexia
v. Muscle and joint pain
vi. Headache and chest pain
vii. Abdominal pain
viii. Normochromic or normocytic anemia
ix. Phlebitis/thrombophlebitis
x. Hypotension/hypertension
xi. Flushing
xii. Hypersensitivity reactions, chills, and fever
xiii. Leukocytosis</p>
<p>e. Drug interactions
i. Aminoglycosides
ii. Cyclosporine
iii. Azole antifungals
iv. Corticosteroids
v. Extended-spectrum penicillins
vi. Pancuronium bromide
vii. Electrolyte solutions</p>
<ol start="3">
<li>Fluconazole (Diflucan)</li>
</ol>
<p>a. Pharmacokinetics
i. Synthetic, broad-spectrum agent</p>
<p>ii. Well absorbed after oral administration
iii. Distributed in all body fluids, including CSF and breast milk
iv. Excreted unchanged in the urine
v. Peak plasma concentration 2 to 4 hours after administration</p>
<p>b. Pharmacotherapeutics: Indicated for treating candidal and cryptococcal infections and used in neonates and children</p>
<p>c. Dosage
i. Oropharyngeal candidiasis: 200 mg PO first day, then 100 mg PO daily for 2 weeks
d. Adverse reactions: All reactions are more common in HIV patients.
i. Transient elevations in serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) alkaline phosphatase, and bilirubin, hepatotoxicity
ii. Dizziness
iii. Nausea, vomiting, diarrhea, and abdominal pain
iv. Skin rash, Stevens-Johnson syndrome, and anaphylaxis
v. Headache</p>
<p>e. Drug interactions
i. Warfarin
ii. Levels of phenytoin, theophylline, tacrolimus, and cyclosporine may increase with fluconazole.
iii. Patients taking rifampin, rifabutin, and isoniazid may require higher doses of fluconazole to get therapeutic results.</p>
<ol start="4">
<li>Terbinafine (Lamisil)
a. Pharmacokinetics
i. Disrupts the cell wall of fungal hyphae (fungicidal). Metabolized in the liver and excreted in the feces
b. Pharmacotherapeutics
i. Indicated for treating widespread tinea infections of the skin and onychomycosis
c. Dosage: 250 mg PO qd × 1 to 2 weeks for tinea corporis, 2 weeks for tinea pedis, 6 weeks for fingernail involvement, and 12 weeks for toenails
d. Adverse reactions
i. Elevated liver enzymes (rare)
ii. Leukocytopenia (rare)
iii. Stevens-Johnson-type reaction (rare)
iv. Taste disruption
v. Indigestion, anorexia, diarrhea, nausea, and vomiting
vi. Headache</li>
</ol>
<p>e. Drug interactions
i. Rifampin
ii. Cyclosporine
iii. Tagamet (oral antacid may decrease absorption)</p>
<ol start="5">
<li>Ketoconazole (Nizoral). Oral ketoconazole is less often prescribed now than in the past years because newer azole drugs such as itraconazole and fluconazole are less likely to</li>
</ol>
<p>cause liver dysfunction.</p>
<p>a. Pharmacokinetics
i. Varied absorption and distribution and pH dependent
ii. Metabolized in the liver and excreted through bile and feces
iii. Peak plasma concentration reached in 1 to 4 hours.</p>
<p>b. Pharmacotherapeutics
i. Treatment of superficial and systemic infections with susceptible fungal organisms
(a) Active against certain dermatophytes (tinea corporis, tinea cruris, tinea versicolor)
(b) Yeasts such as candida and malassezia
ii. Response to treatment
(a) Mucosal infections—respond in days
(b) Skin infections—respond in weeks
(c) Nail infections—respond in months</p>
<p>c. Dosage
i. 200 mg PO daily; may increase to 400 mg if unresponsive
ii. Duration varies with organism/site.
(a) 2 weeks for oral candidiasis
(b) 2 to 6 weeks for dermatophyte infections
(c) 6 to 12 months for chronic mucocutaneous candidiasis and tinea unguium</p>
<p>d. Adverse reactions
i. Nausea/vomiting and diarrhea
ii. Pruritus, skin rash, dermatitis, and urticaria
iii. Headache
iv. Insomnia and lethargy
v. Dizziness
vi. Interference with adrenal and corticosteroid synthesis leading to decreased circulatory testosterone
vii. Disulfiram-like reaction if alcohol is ingested</p>
<p>e. Drug interactions
i. Warfarin
ii. Methylprednisolone
iii. Cyclosporine
iv. Some hypoglycemic medications
v. Quinidine
vi. Corticosteroids</p>
<ol start="6">
<li>Itraconazole (Sporanox)
a. Pharmacokinetics
i. Bioavailability maximal when taken with food
ii. Metabolized in the liver and excreted in feces
b. Pharmacotherapeutics: Indicated in treating onychomycosis of the nails and deep fungal infections (blastomycosis, aspergillosis, and histoplasmosis)
c. Dosage</li>
</ol>
<p>i. Toenails with or without fingernail involvement: 200 mg qd for 12 consecutive weeks
ii. Fingernails only: 200 mg bid for 1 week; 3-week period without therapy, then 200 mg bid for an additional week to 6 months</p>
<p>d. Adverse reactions
i. Elevated liver enzymes
ii. GI disorders
iii. Rash/pruritus
iv. Hypertension/orthostatic hypotension
v. Headache
vi. Malaise
vii. Myalgia
viii. Nausea
ix. Vertigo</p>
<p>e. Drug interactions
i. Warfarin
ii. Antihistamines
iii. Ritonavir and indinavir
iv. Benzodiazepines: Midazolam, triazolam, and diazepam
v. Calcium channel blockers
vi. Cyclosporine
vii. Methylprednisolone
viii. Digoxin and quinidine
ix. Phenobarbital, carbamazepine, and phenytoin
x. Isoniazid, rifampin, and rifabutin</p>
<p>Note: Sporanox increases plasma concentrations of drugs from 1 through 8 and decreases plasma concentrations of drugs from 9 through 10.</p>
<ol start="7">
<li>Griseofulvin
a. Pharmacokinetics: Disrupts mitosis of fungal cells
i. Metabolized by the liver and excreted through urine, feces, and perspiration
b. Pharmacotherapeutics
i. Indicated for treating fungal infections of the skin except tinea versicolor and not effective for nails
ii. Duration of therapy varies with site of infection.
c. Dosage
i. Gris-PEG: 125 to 250 mg PO in single or divided doses for 2 to 8 weeks
ii. Grifulvin V: 500 to 1,000 mg in single or divided doses for 2 to 8 weeks
iii. Pediatric: Gris-PEG and grifulvin V 125 mg/5 cc suspension; 10 to 25 mg/kg/d
d. Adverse reactions
i. Nausea, vomiting, and diarrhea
ii. Fatigue
iii. Confusion
iv. Headaches</li>
</ol>
<p>v. Rare: Proteinuria, urticaria, rash, serum sickness, photosensitivity, hearing loss, paresthesia, dizziness, insomnia, leukopenia, and oral candidiasis</p>
<p>e. Drug interactions</p>
<p>i. Alcohol
ii. Barbiturates
iii. Warfarin</p>
<p>C. Antivirals</p>
<ol>
<li>Acyclovir, famciclovir, and valacyclovir—used in the management of herpes simplex viruses.</li>
</ol>
<p>a. Pharmacokinetics</p>
<p>i. Absorbed in the GI tract
ii. Distributed throughout the body
iii. Crosses the placenta and enters breast milk
iv. Metabolized in the liver
v. Excreted in the urine
vi. Peak concentration levels reached within 1.5 to 2.5 hours after oral administration; immediately after IV administration.</p>
<p>b. Pharmacotherapeutics</p>
<p>i. Effectiveness limited to herpes viruses (HSV 1 and 2; varicella-zoster virus)
ii. Initial and recurrent genital herpes treated with oral acyclovir, valacyclovir, or famciclovir; all are effective for suppressive therapy
iii. Recurrences may be reduced with long-term use
iv. Severe initial and recurrent mucocutaneous HSV infections and varicella-zoster, particularly in immunocompromised patients, require parenteral administration
v. Decreases severity, pain, and viral shedding
vi. Decreases duration of lesions</p>
<p>c. Dosage depends on disease and type of episode (must be adjusted in patients with renal dysfunction).</p>
<p>i. Acyclovir: 200 to 800 mg 5/day for 7 to 10 days
ii. Famvir: 125 to 1,000 mg bid to tid for 1 to 10 days
iii. Valacyclovir: 500 to 1,000 mg 1 to 2 times a day for 3 to 10 days
iv. Medication must be started within 72 hours for optimal reduction in shedding.
v. All three medications are indicated to help prevent postherpetic neuralgia.</p>
<p>d. Adverse reactions</p>
<p>i. Headache and dizziness
ii. Nausea, vomiting, and diarrhea
iii. Pruritus
iv. Fatigue
v. Insomnia
vi. Irritability
vii. Depression
viii. Hypotension
ix. Rare: Thrombocytosis, thrombocytopenia, transient lymphopenia, transient</p>
<p>leukopenia, and bone marrow hypoplasia</p>
<p>e. Drug interactions
i. Probenecid (and other drugs that inhibit tubular secretion or absorption)
ii. Cimetidine
iii. Phenytoin
iv. Theophylline</p>
<p>D. Antineoplastics</p>
<ol>
<li>
<p>Methotrexate
a. Pharmacokinetics
i. Well absorbed and distributed throughout the body
ii. Undergoes minimal metabolism and mostly excreted by the kidneys
iii. Peak plasma concentration reached 1 hour after oral dosing
iv. Crosses placenta and enters breast milk and very little concentration in CSF
b. Pharmacotherapeutics
i. Used for treating recalcitrant, severe psoriasis, mycosis fungoides, and psoriatic/rheumatoid arthritis
ii. May be used as steroid-sparing drug in immunobullous diseases
(a) A folic acid antagonist and inhibits cell division
(b) Has some activity as an immunosuppressive agent
c. Dosage: Varies from 10 mg to 30 mg/week
d. Adverse reactions
i. Hepatic fibrosis and cirrhosis with long-term use
(a) Liver function may be abnormal despite frequently normal blood tests.
(b) Liver biopsy should be done periodically with long-term use.
ii. Bone marrow suppression is usually dose dependent; white blood cell (WBC) must be monitored carefully.
iii. Nausea
iv. Malaise
v. Headaches
vi. Teratogenic in females, harmful to male sperm, and birth control indicated during course of medication
e. Drug interactions
i. Probenecid
ii. Salicylates and non-steroidal anti-inflammatory drugs (NSAIDS)
iii. Alcohol
iv. Cholestyramine
v. Live vaccines
vi. Penicillins
vii. Oral hypoglycemic agents</p>
</li>
<li>
<p>Cyclophosphamide (Cytoxan)
a. Pharmacokinetics
i. Synthesized derivation of nitrogen mustard
ii. Alkylating agent—disrupt the structure of DNA</p>
</li>
</ol>
<p>iii. Absorbed well
iv. Peak plasma concentration reached 1 hour after oral dosing.
v. Hepatic metabolism
vi. Excreted in the urine</p>
<p>b. Pharmacotherapeutics
i. Used for steroid-sparing therapy of immunobullous diseases and leukocytoclastic vasculitis
ii. Used in advanced mycosis fungoides and in connective tissue diseases
iii. Activity and effectiveness depend on type of cancer, the extent of disease, and patient's overall condition.</p>
<p>c. Dosage
i. 1 to 5 mg/kg up to 100 mg/kg PO
ii. Dosage must be adjusted in patient with impaired liver or renal function</p>
<p>d. Adverse reactions
i. Bone marrow suppression
ii. Late lymphoreticular malignancies
iii. Hemorrhagic cystitis
iv. Anorexia, nausea, and vomiting
v. Secondary neoplasms
vi. Pulmonary fibrosis</p>
<p>e. Drug interactions
i. Succinylcholine
ii. Allopurinol
iii. Warfarin
iv. Live virus vaccines (decreases antibody response)</p>
<p>E. Retinoid (vitamin A)</p>
<ol>
<li>Isotretinoin (Accutane)
a. Pharmacokinetics
i. Isomer of retinoic acid, a metabolite of vitamin A
ii. Inhibits sebaceous gland function
iii. Prevents abnormal keratinization
iv. Peak plasma concentrations reached 3 to 5 hours after dosing
v. Metabolized in the liver and excreted in urine and feces</li>
</ol>
<p>b. Pharmacotherapeutics
i. Indicated in treating recalcitrant cystic and nodular acne
ii. May be used in ichthyosis, pityriasis rubra pilaris, and Darier disease
iii. May affect basal cell carcinoma (BCC), squamous cell carcinoma (SCC), cutaneous T-cell lymphoma (CTCL), keratoacanthoma, verruca vulgaris, discoid lupus erythematosus (DLE), and pustular/erythrodermic psoriasis
iv. Females must have a negative pregnancy test before initiation of treatment and must use birth control for the duration of treatment. Women should continue contraception for one month and be reassured they may safely become pregnant one month after stopping isotretinoin treatment</p>
<p>v. iPLEDGE program: Computer-based risk management program designed to eliminate fetal exposure to isotretinoin. All prescribers, pharmacists, men, and women must be registered with the iPLEDGE program</p>
<p>c. Dosage
i. 0.5 to 2 mg/kg PO daily in two divided doses for 15 to 20 weeks
ii. Contraindicated if patient is sensitive to any ingredients or sensitivity to parabens, glycerin, or soybean oil
iii. Use with caution in diabetics and patients with hepatic disease and hypertriglyceridemia</p>
<p>d. Adverse reactions
i. Cheilitis
ii. Conjunctivitis
iii. Skin fragility
iv. Dry skin and mucous membranes
v. Epistaxis
vi. Dry nose and mouth
vii. Corneal opacities
viii. Inflammatory bowel disease
ix. Hypertriglyceridemia
x. Arthralgia
xi. Hepatotoxicity
xii. Photosensitivity
xiii. Pseudotumor cerebri</p>
<p>e. Drug interactions
i. Vitamin A or vitamin A supplements, may result in hypervitaminosis
ii. Minocycline
iii. Tetracycline
iv. Drugs with anticholinergic properties
v. Alcohol-containing acne preparations or cosmetics
vi. Alcohol</p>
<ol start="2">
<li>Acitretin (Soriatane)
a. Pharmacokinetics—binds to and activates retinoid X receptors; results in anti-inflammatory, antiproliferative, and normalization of keratinocyte differentiation
b. Pharmacotherapeutics
i. Treatment of ichthyosis, pityriasis rubra pilaris, and pustular and erythrodermic psoriasis; monotherapy is less effective for plaque psoriasis (Figure 4-13)
ii. Contraindicated in pregnant patients or women who may become pregnant within 3 years
iii. Complete blood count (CBC), baseline liver function, pregnancy test, lipid profile, and renal function tests must be checked before beginning treatment and 1- to 2-week intervals for the first 2 months decreasing to 1 to 3 months if values are within normal limits
iv. Pregnancy tests monthly during treatment and every 3 months for 3 years after</li>
</ol>
<p>treatment</p>
<p>c. Dosage
i. 10 to 50 mg/d qd. Doses of about 25 mg/d decrease side effects.
ii. Maintenance dose: 25 to 50 mg/d</p>
<p>d. Adverse reactions
i. Cheilitis (&gt;75%)
ii. Pseudotumor cerebri
iii. Headache
iv. Dizziness
v. Alopecia (50% to 75%)
vi. Dryness of skin and mucous membranes
vii. Elevated liver enzymes
viii. Hypo- or hyperkalemia and hyperlipidemia
ix. Bone pain
x. Photosensitivity
xi. Xerostomia</p>
<p>e. Drug interactions
i. Alcohol
ii. Hepatotoxic medications
iii. Vitamins/minerals with A, D, E, K, folate, and iron
iv. Tetracyclines
v. Vitamin A/vitamin A supplements</p>
<p>F. Corticosteroids</p>
<ol>
<li>
<p>Pharmacokinetics
a. Absorbed well through the gastrointestinal (GI) tract and intra muscular (IM) absorption slower
b. Metabolized in the liver
c. Excreted by the kidneys
d. Cross the placenta and are distributed in breast milk
e. Rapid onset of action, usually within 1 hour after oral dosing</p>
</li>
<li>
<p>Pharmacotherapeutics
a. Anti-inflammatory
b. Immunosuppressive
c. Indicated for a wide variety of conditions and diseases including recalcitrant cases of acne, dermatomyositis, and cutaneous lichen planus</p>
</li>
<li>
<p>Dosage: Based on disease process and severity</p>
</li>
<li>
<p>Adverse reactions: Usually seen with long-term treatment
a. Adrenocortical insufficiency
b. Muscle wasting
c. Cataracts
d. Cushingoid signs and symptoms
e. Skin atrophy, striae, and hirsutism
f. Petechiae and ecchymoses</p>
</li>
</ol>
<p>g. Polycythemia and enhanced coagulability
h. Fluid/electrolyte imbalance
i. Weight gain
j. Immunosuppression
k. Mood changes
l. Psychosis, depression, and euphoria
m. Osteoporosis
n. Hypertension</p>
<ol start="5">
<li>Drug interactions
a. Barbiturates
b. Phenytoin
c. Rifampin
d. Amphotericin B
e. Furosemide
f. Thiazide diuretics
g. Erythromycin
h. Salicylates
i. NSAIDs
j. Vaccines and toxoids
k. Estrogen, oral contraceptives that contain estrogen
l. Hypoglycemic agents
m. Isoniazid
n. Fluoroquinolones</li>
</ol>
<p>G. Psoralens (methoxsalen, oxsoralen, oxsoralen ultra, methoxypsoralen (8-MOP))</p>
<ol>
<li>
<p>Pharmacokinetics
a. Increase melanization of the epidermis and thickening of the stratum corneum
b. Photosensitizer
c. Bonds with cellular DNA and causes cell damage when exposed to ultraviolet A (UVA) light, decreasing cell turnover rate
d. 95% absorbed from the GI tract
e. Peak serum concentration increased when taken with food
i. Oxsoralen-Ultra reaches peak serum concentration 30 minutes to 1 hour after ingestion
ii. Oxsoralen reaches peak level in 1.5 to 6 hours after ingestion, with half-life being 2 hours
f. Metabolized in the liver and excreted in urine</p>
</li>
<li>
<p>Pharmacotherapeutics
a. Used in treating psoriasis, CTCL, and vitiligo
b. Contraindicated if patient has increased risk for developing melanoma and SCC
c. Contraindicated if patient is aphakic, has disorder associated with photosensitivity, is an albino, or has documented cataracts</p>
</li>
<li>
<p>Dosage
a. Psoriasis: Individualized according to weight</p>
</li>
</ol>
<p>b. Vitiligo: 20 mg with food or milk 2 to 4 hours prior to treatment
c. CTCL: Individualized according to stage, overall prognosis, and quality of life</p>
<ol start="4">
<li>
<p>Adverse reactions
a. Severe burns (must avoid sun exposure for 24-hour postingestion)
b. Rash and pruritus
c. Erythema and peeling
d. Nausea
e. Nervousness
f. Insomnia
g. Dizziness
h. Headache
i. Depression
j. Malaise
k. Cataract
l. Infection</p>
</li>
<li>
<p>Drug interactions
a. Photosensitizing drugs
i. Phenothiazines
ii. Thiazides
iii. Sulfonamides
iv. Tetracyclines
v. Griseofulvin
vi. Coal tar derivatives
vii. Nalidixic acid
viii. Halogenated salicylamides</p>
</li>
</ol>
<p>H. Immunosuppressants</p>
<ol>
<li>Cyclosporine (Neoral)
a. Pharmacokinetics
i. Distributed widely throughout the body; skin shows high concentrations.
ii. Crosses the placenta and enters breast milk
iii. Metabolized in the liver
iv. Excreted primarily in bile
v. Peak serum concentration reached within 2 to 6 hours after oral dosing.
vi. Variable absorption through GI tract
b. Pharmacotherapeutics
i. Prevention of graft rejection without destruction of bone marrow
ii. Used for treating psoriasis, alopecia areata, pyoderma gangrenosum, Behcet disease, AD, and lichen planus
iii. Limited to treating moderately severe to severe recalcitrant psoriasis
iv. Contraindicated in patients with renal impairment, severe hepatic impairment, uncontrolled hypertension, other infections, prone to infection or malignancy, and vaccination with live viruses
c. Dosage</li>
</ol>
<p>i. Determined on body weight
ii. Psoriasis: 2.5 to 5 mg/kg/d in one or two divided doses
iii. Initial dosing may be at maximum level (5 mg/kg/d) for rapid response with adjustment of 0.5 to 1 mg/kg/d each week as needed</p>
<p>d. Adverse reactions
i. Tremor
ii. Hypertension
iii. Hepatotoxicity
iv. Diarrhea, nausea, vomiting, and anorexia
v. Nephrotoxicity
vi. Hirsutism and acne</p>
<p>e. Drug interactions
i. Many drugs in many classes including antibiotics, antifungals, retinoids, antiepileptics, NSAIDs, and antihypertensives</p>
<ol start="2">
<li>Azathioprine (Imuran)
a. Pharmacokinetics—see cyclosporine
b. Pharmacotherapeutics
i. Immunosuppressive effect and steroid sparing
ii. Used in immunobullous diseases, leukoplastic vasculitis, and connective tissue disease
c. Dosage
i. 1 to 3 mg/kg/d PO, based on severity of disease
ii. If no response after 6 to 8 weeks, dose may be increased by 0.5 mg/kg/d.
d. Adverse reactions
i. Leukopenia, anemia, pancytopenia, and thrombocytopenia
ii. Bone marrow suppression
iii. Nausea, vomiting, and anorexia
iv. Pancreatitis
v. Malaise
vi. Hepatotoxicity
vii. Rash
viii. Alopecia
ix. Increased risk of SCC and infections
e. Drug interactions
i. Allopurinol
ii. Nondepolarizing neuromuscular blocking agents
iii. Antineoplastics, cyclosporine, live virus vaccines, Echinacea, and melatonin</li>
</ol>
<p>I. Antihistamines</p>
<ol>
<li>Nonsedating (Claritin, Zyrtec, Allegra)
a. Pharmacokinetics
i. Peak plasma levels reached in 2 to 12 hours.
ii. Metabolized in the liver and excreted in feces
iii. H1-receptor antagonist</li>
</ol>
<p>b. Pharmacotherapeutics
i. Relief of allergic rhinitis
ii. Chronic idiopathic urticaria</p>
<p>c. Dosage
i. Loratadine (Claritin): one 10-mg tablet daily
ii. Cetirizine HCL (Zyrtec): Adults and children over 6 years old 5 mg to 10 mg PO qd
iii. Fexofenadine (Allegra): Adults and children 12 or older 60 mg PO bid or 180 mg qd</p>
<p>d. Adverse reactions
i. Confusion
ii. Blurred vision
iii. Pharyngitis
iv. Increased appetite
v. Nausea
vi. Nervousness
vii. Dry mouth
viii. Fatigue
ix. Photosensitivity
x. Rash</p>
<p>e. Drug interactions
i. Central nervous system (CNS) depressants and alcohol
ii. Grapefruit, apple, and orange juice.
iii. Tricyclic antidepressants
iv. Monoamine oxidase (MAO) inhibitors
v. Phenothiazines
vi. Norepinephrine/phenylephrine
vii. Amiodarone</p>
<ol start="2">
<li>Benadryl, Atarax, Tavist, and Periactin: H1 antagonists have the same pharmacokinetics/pharmacotherapeutics as the nonsedating drugs except they cause drowsiness.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="scales">Scales<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#scales" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="assets/images/image-20251225-95797c48.jpeg" alt="img-59.jpeg">
FIGURE 4-13. Plaque psoriasis showing erythematous plaques with secondary scaling.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vi-local-anesthetics">VI. LOCAL ANESTHETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-local-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Local anesthetics are drugs that slow or stop nerve conduction when applied close to nerve tissue. Local anesthetics block the flow of sodium ions, thereby preventing transmission of the impulse. Both temporary sensory and motor nerve paralyses occur in the affected nerve</p>
<p>distribution with complete recovery in the normal course of events.</p>
<p>B. Injectable anesthetics</p>
<ol>
<li>
<p>Ester linked—cocaine, procaine (Novocain), and tetracaine (Pontocaine)
a. Metabolized in plasma or local tissue by the enzyme pseudocholinesterase
b. Metabolized to para-aminobenzoic acid (PABA) among other metabolites to which patients may already have been sensitized and may lead to severe allergic reactions
c. Metabolized by the liver and excreted through the kidneys</p>
</li>
<li>
<p>Amide linked
a. Metabolized in the liver and excreted by the kidneys.
b. Allergies to the amide group of anesthetics are rare.
c. Common amide anesthetics include the following:
i. Lidocaine (Xylocaine)—rapid onset, low toxicity and allergic potential, water soluble, and compatible with vasoconstrictors and tissue fluid. Intermediate acting and duration of 30 to 60 minutes
ii. Mepivacaine (Carbocaine)—less toxic than lidocaine or procaine but slower onset of action. Intermediate acting and duration of 45 to 90 minutes
iii. Bupivacaine (Marcaine)—more potent and toxic than lidocaine and mepivacaine. Longer duration of action, onset of action delayed. Long acting and duration of 2 to 4 hours
iv. Etidocaine (Duranest)—four times more potent than lidocaine and lasts two times longer; useful for nerve blocks. Long acting and duration of 5 to 10 hours</p>
</li>
<li>
<p>Other agents
a. Antihistamines (Benadryl)
i. May be combined with epinephrine
ii. Benadryl produces sedative effect if over 50 mg given. One suggested formula: 2 mL Benadryl (25 mg/mL), 8 mL normal saline, and 0.1 mL epinephrine (1:1,000)
iii. Normal saline (to be effective must be injected to produce wheal; is inadequate for large procedures)</p>
</li>
</ol>
<p>C. Vasoconstrictors (epinephrine premixed 1:100,000 to 1:200,000)</p>
<ol>
<li>Shortens time of onset, prolongs durations, and increases the depth of anesthesia</li>
<li>Reduces systemic absorption and toxicity by reducing rate of clearance, gaining more effective anesthesia with less drug volume</li>
<li>Reduces bleeding during procedure (plain lidocaine is a vasodilator)</li>
<li>Useful with shorter-acting anesthetics and of little benefit with Marcaine or Duranest, although may provide hemostatic benefit</li>
</ol>
<p>D. Untoward effects of systemic absorption of epinephrine</p>
<ol>
<li>Normal reaction to epinephrine includes restlessness, increased heart rate, palpitations, pounding in the head, and chest pain. These symptoms alert the provider of pending CNS toxicity with further absorption.</li>
<li>Avoid vasoconstrictors.
a. Digits with compromised digital circulation
b. Patients with catecholamine sensitivity and patients taking ergot alkaloids or lurasidone</li>
</ol>
<p>c. For patients with normal circulation, it is safe to use epinephrine in areas including tip of the nose, fingers, toes, ears, and penis although not recommended for field or ring blocks in these areas.</p>
<ol start="3">
<li>Dilute concentration of epinephrine.</li>
</ol>
<p>a. Hypertensive patients or those with cardiovascular disease
b. Anxious or nervous patients
c. When patient is taking phenothiazines, MAO inhibitors, beta blockers, and tricyclic antidepressants (raises blood pressure)</p>
<p>E. Adverse reactions to local anesthesia</p>
<ol>
<li>Usually related to vasoconstrictors and may result in anxiety, tremor, tachycardia, and diaphoresis when absorbed.</li>
<li>Vasovagal reactions include hyperventilation, apprehension, and syncope.</li>
<li>Local reactions such as delayed swelling, erythema, and blistering.</li>
<li>True allergic reaction includes pruritus, hypotension, hives, urticaria, and angioedema with bronchospasm manifested by wheezing and coughing.</li>
</ol>
<p>F. Systemic toxicity depends on concentration of local anesthesia in blood.</p>
<ol>
<li>Maximum safe doses:</li>
</ol>
<p>a. Adult: Repeated doses at 2-hour intervals</p>
<p>i. 1% lidocaine with epinephrine 50 mL
ii. 1% lidocaine without epinephrine 30 mL
iii. Suggest 0.5% lidocaine when large amounts required.
iv. Mepivacaine without epinephrine 30 mL
v. Mepivacaine with epinephrine 50 mL
vi. Bupivacaine 0.25% with epinephrine 90 mL
vii. Bupivacaine 0.25% without epinephrine 70 mL
viii. Etidocaine 0.5% with epinephrine 400 mg
ix. Etidocaine 0.5% without epinephrine 300 mg</p>
<p>b. Children less than 8 years old: 80% of the maximum allowable dose</p>
<ol start="2">
<li>Plasma concentration is the result of a balance between the rate of absorption and its rate of elimination dependent upon the following:</li>
</ol>
<p>a. Inadvertent intravascular injection (into an artery or vein)</p>
<p>i. May occur with nerve blocks
ii. Inadvertent injection into scalp artery may more easily reach cerebral circulation and produce CNS response
b. Total dosage (see above)
c. Speed of injection
d. Vascularity of injection site
e. Presence of vasoconstrictors in solution
f. Physiologic characteristics of local anesthetics
g. Decreased metabolism of local anesthesia
h. Health status of patient (be cautious in elderly, sick, and patient with renal or hepatic disease)</p>
<p>G. Systemic toxicity mainly involves CNS and cardiovascular system.</p>
<ol>
<li>Toxic blood levels of 1% lidocaine</li>
</ol>
<p>a. Concentrations of 1% lidocaine—10 mg/mL
b. Depending on site, peak blood level of between 0.5 and 2.0 µg/mL is reached for every 100 mg lidocaine given; therapeutic range—1.5 to 5 µg/mL.
c. 50 mg IV results in blood level of about 1 µg/mL.
d. Avoid in patients with Wolf–Parkinson–White syndrome</p>
<ol start="2">
<li>CNS toxicity (mirrors blood concentration of local anesthetic)</li>
</ol>
<p>a. 1 to 5 µg/mL</p>
<p>i. Ringing in ears
ii. Perioral numbness and tingling
iii. Metallic taste in mouth
iv. Light-headedness and talkativeness
v. Nausea and vomiting
vi. Double vision</p>
<p>b. 5 to 7.5 µg/mL may precede seizure activity.</p>
<p>i. Nystagmus
ii. Slurred speech
iii. Hallucinations
iv. Localized muscle twitching
v. Fine tremors of face and hands</p>
<p>c. 7.5 to 10 µg/mL: Focal seizure activity may increase to culminate in grand mal seizures (may be life threatening).</p>
<p>i. Seizure is usually self-limiting.</p>
<p>(a) Protect from injury and lie patient flat and maintain open airway
(b) Oxygen delivery with mask
(c) IV diazepam if necessary</p>
<p>d. 20 to 25 µg/mL: Cardiac toxicity, hypertension, arrhythmias, CNS depression, CV collapse, bronchospasm, and coma</p>
<ol start="3">
<li>Cardiovascular effects (heart and peripheral arteries)</li>
</ol>
<p>a. All anesthetics except cocaine are vasodilators and can result in hypotension; patient may become pale, nauseated, with cold sweating.
b. Inject with patient lying flat.
c. Trendelenburg position if reactions appear. Apply cool wet washcloth to forehead, monitor vital signs, and physician may order oxygen.</p>
<p>H. Preventing CNS and cardiovascular reactions</p>
<ol>
<li>Use minimum effective dose, especially on head and neck.</li>
<li>Aspirate before injection.</li>
<li>Use nerve block whenever possible.</li>
<li>Allow sufficient time for anesthesia before reinjecting.</li>
<li>Avoid injection of inflamed tissue, which results in unsatisfactory anesthesia due to lower tissue pH.</li>
<li>Use vasoconstrictors when indicated.</li>
<li>Some providers consider preoperative diazepam when large amounts of local anesthetics</li>
</ol>
<p>must be used; this raises seizure threshold but may induce respiratory depression.</p>
<ol start="8">
<li>Consider pre-existing renal, hepatic, and cardiac failure that may decrease clearance and increase risk of toxic dose.</li>
<li>Reduce dose in elderly, pts. weighing less than 50 kg, and children.</li>
</ol>
<p>I. Allergy</p>
<ol>
<li>More common in patients with underlying atopic or immunologic problems and multiple drug allergies (especially procaine penicillin)</li>
<li>Ester groups primarily responsible for allergic reactions and less incidence (rare) in amide groups</li>
<li>Topical sensitization to lidocaine has been substantiated leading to anaphylaxis</li>
<li>Allergy symptoms
a. Skin: Pruritus, urticaria, erythema, and facial swelling
b. GI: Nausea, vomiting, abdominal cramps, and diarrhea
c. Respiratory: Bronchospasm and hypoxia</li>
<li>Treatment of allergy to local anesthetic
a. SQ epinephrine (may need IV epinephrine)
b. Maintain airway
c. Oxygen and IV fluids
d. Transport to acute care facility (needs observation for 6 hours)</li>
</ol>
<p>J. Effects on fetus/newborns</p>
<ol>
<li>Avoid during first trimester while organogenesis has begun.</li>
<li>Postpone large procedures if possible until after delivery (hepatic system of fetus is immature).</li>
<li>Small procedures require minimal anesthetic and may be performed if necessary. Dilute epinephrine 1:300,000; fetal heart monitoring is recommended.</li>
<li>All local anesthetics are excreted into breast milk, and toxicity to infant is possible.</li>
</ol>
<p>K. Topical anesthetics: The epidermis offers an effective barrier to diffusion of anesthetic agents while absorption through mucous membranes occurs quickly.</p>
<ol>
<li>Cocaine (4% solution): A vasoconstrictor useful for anesthesia of nasal mucosa
a. Maximum safe dose: 5 mL (200 mg) in adult
b. Soak cotton ball in solution and apply topically to nasal mucosa with forceps.
c. Peak effect is 2 to 5 minutes lasting 30 to 40 minutes.
d. Absorption in mucosa is slow; increased cocaine blood level may occur 4 to 6 hours after nasal application.
e. Renders superficial (not deep) anesthesia only.</li>
<li>Benzocaine available as 20% gel or aerosol, gel 7.5% to 20%, 20% solution, 2% to 20% ointment, or liquid 10% to 20%
a. Useful in oral mucosa
b. Associated with increased risk of contact allergy
c. Cetacaine, used by otolaryngologists, is:
i. 14% benzocaine
ii. 2% tetracaine
iii. 2% butamben</li>
</ol>
<p>iv. Spray of 1 second with 0.1 cc solution produces 30 seconds mucosal anesthesia.</p>
<ol start="3">
<li>
<p>2% lidocaine jelly
a. Contains parabens
b. Maximum dose: 30 mL (600 mg) in 12-hour period</p>
</li>
<li>
<p>EMLA, cream (lidocaine 2.5% and prilocaine 2.5%), is an emulsion in which the oil phase is an eutectic mixture of lidocaine and prilocaine in a ratio of 1:1 by weight.
a. Applied to intact skin under occlusive dressing at least 1 to 2 hours before procedure
b. May cause a transient local blanching followed by temporary local erythema
c. Application of EMLA cream to larger areas or for longer times than those recommended could result in overabsorption of anesthetic resulting in serious side effects</p>
</li>
<li>
<p>0.5% proparacaine (Alcaine, Parcaine)—1 to 2 gtts on conjunctival surface prior to administering local anesthesia will prevent sting of lidocaine in eye and help eliminate blink reflex.</p>
</li>
<li>
<p>Viscous lidocaine for oral mucosa.</p>
</li>
<li>
<p>Oraqix gel is used orally.</p>
</li>
</ol>
<p>L. Injection technique: Patient comfort and safety</p>
<ol>
<li>
<p>Discuss procedure, goals, and expectations with patient.</p>
</li>
<li>
<p>Consider need for preoperative sedation.</p>
</li>
<li>
<p>Comfort measures
a. Positioning, distraction (conversation, music), and ice prior to injection
b. Eliminate preservatives that are acidic and contribute to the "sting" of local anesthesia infiltration by:
i. Mix fresh solution of 0.1 mL epinephrine (1:1,000) to each 10-mL plain lidocaine. pH 6.5 to 6.8. Tissue fluid pH is 7.3 to 7.4.
ii. Buffer stock lidocaine with epinephrine 1:100,000 with 1 cc sodium bicarb (8.4% solution) to every 10-mL lidocaine. Results in pH of 7.0 to 7.3.
(a) Decreased duration may be due to more rapid absorption of less-charged buffered agents.
(b) Epinephrine concentration reduced to 1:200,000.
(c) Do not buffer bupivacaine (Marcaine) with epinephrine—may result in prolonged numbness of injection site.
(d) Some providers keep buffered solution up to 1 week. Loss of 25% epinephrine effect occurs by that time.</p>
</li>
<li>
<p>Infiltration of anesthesia
a. Equipment includes gloves, goggles, 18- to 20-gauge needle for drawing up solutions, 30 gauge 1" needles for injection, Luer-Lock syringes, alcohol prep, preloaded syringes may save time.
b. Pain is caused by inevitable expansion of tissue on injection and the speed with which it occurs.
i. SQ injection is less painful since tissue is more distensible but onset is delayed (and duration of reaction is longer).
ii. Intradermal injection produces immediate anesthesia with prolonged effect due to</p>
</li>
</ol>
<p>placement but is more painful.</p>
<p>iii. Whenever dermis is bound tightly to underlying tissue and there is little fat (e.g., nose), there is more resistance to instillation of local anesthetic and increased pain.
iv. Use careful approach to bone.</p>
<p>c. Proper technique includes the following:
i. Rapid needle penetration into tense skin
ii. SLOW INJECTION to lessen burning sensation
iii. Limit number of punctures by trailing the needle; inject proximal to distal. Injecting from within the laceration or wound is less painful than into intact skin
iv. Proper placement of anesthesia (not too deep)
v. Allow time for vasoconstrictors to take effect, at least 10 to 15 minutes
vi. Carefully test injected areas by "light" touch with needle—not dart-like jabs. Make sure patients are well anesthetized prior to procedure</p>
<p>M. Field block: Circumferential injections in superficial and deep planes</p>
<ol>
<li>Avoids distortion of surgical field</li>
<li>Prevents possible implantation of cancer cells beyond surgical margins</li>
<li>Limits amount of anesthesia required to anesthetize area</li>
<li>Paralysis due to anesthesia of motor nerves; prepare patient in advance</li>
</ol>
<p>N. Nerve block</p>
<ol>
<li>Requires less anesthetic volume and higher concentration such as 2% lidocaine useful
a. Duration of action may be prolonged with use of long-acting agent such as Duranest.
b. Use of vasoconstrictors in blocks does not decrease bleeding at operative site, but does increase duration of anesthetic.</li>
<li>Requires greater skill and knowledge of anatomy</li>
<li>Allow time for block to take effect—10 minutes minimum</li>
<li>Complications of nerve blocks
a. Laceration of nerve—long-term or permanent anesthesia in area supplied by nerve.
b. Intravascular injection may lead to acute toxicity.
c. Nurse should maintain observation of patient following nerve blocks.
d. Hematoma formation—apply firm pressure for 5 minutes to injection site to avoid hematoma formation resulting from vessel laceration.
e. Needle breakage usually resulting from attempt to change needle position while in contact with bone.
f. Infection or abscess—nerve blocks are considered an invasive procedure, maintain sterile technique.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vii-topical-treatments">VII. TOPICAL TREATMENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vii-topical-treatments" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Balneotherapy</p>
<ol>
<li>Objectives
a. Cleansing
b. Hydration</li>
</ol>
<p>c. Enhance delivery of medication
d. Pain relief</p>
<ol start="2">
<li>
<p>Types of baths
a. Antibacterial: Potassium permanganate (1:32,000; 1:64,000)
i. Used for infected eczema, dirty ulcerations, and furunculosis
ii. Lowers bacterial load
b. Colloidal: Starch/baking soda and Aveeno colloidal or oilated colloidal
i. Used for red, pruritic, or oozing conditions
ii. Soothing; helps relieve pruritus
c. Emollient: Bath oils
i. Dry skin conditions
ii. Cleanse and hydrate
d. Tar: Oils with tar and coal tar concentrate (liquor carbonis detergens)
i. Scaly dermatoses (psoriasis)
ii. Relieve pruritus
iii. Loosen scale
iv. Potentiate UVB/UVA
e. Paraffin dips
i. Wax is melted.
ii. Usually used for hands, arms, and feet</p>
</li>
<li>
<p>Nursing considerations
a. Average home tub holds 150 to 200 L of water.
b. Hot water and soap are drying, increasing pruritus; use tepid water and limit soap use.
c. Pat dry leaving some moisture on the skin.
d. Apply medication or emollient immediately after patting skin dry.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-ee8ecdd0.jpeg" alt="img-60.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="balneotherapy">Balneotherapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#balneotherapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Use appropriate bath preparation.</li>
<li>Hot water increases drying and itching; use tepid water to decrease pruritus.</li>
<li>Bath additives can cause slippery conditions; use rubber mats.</li>
</ul>
<p>A. Soaks</p>
<ol>
<li>Objectives
a. Loosen eschar/crusts
b. Decrease/prevent infection</li>
</ol>
<p>c. Relieve pruritus
d. Promote drying in moist dermatoses
e. Enhance re-epithelialization
f. Decrease pain</p>
<ol start="2">
<li>
<p>Types of soaks (see Table 4-4 for wet dressings)
a. Tap water
i. Cooling
ii. Relieve pruritus
iii. Loosen eschar/crust
b. Aluminum acetate (Domeboro, Aluwets, Burow solution); one tablet in one quart of water
i. Cooling
ii. Relieve pruritus
iii. Loosen eschar/crust
iv. Promote drying in moist dermatoses
v. Provides mild antiseptic effect (mix 1 tablet with 1 pint water)
c. Potassium permanganate (KMnO₄): 0.25% to 0.5%
i. Cooling
ii. Relieve pruritus
iii. Loosen eschar/crust
iv. Provide astringent effect
v. Provide antimicrobial effect (especially <em>P. aeruginosa</em>)
d. Normal saline: 0.9%
i. Cooling
ii. Relieve pruritus
iii. Loosen eschar/crust
e. Silver nitrate (AgNO₃): 0.5% to 50% solution
i. Astringent
ii. Antibacterial</p>
</li>
<li>
<p>Nursing considerations
a. Soaks must be kept wet.
b. Gauze pads with fillers should not be used for soaks (retain too much solution/fibers may be left in wounds).</p>
</li>
</ol>
<p>TABLE 4-4 Examples of Wet Dressings</p>
<table><thead><tr><th>Agent</th><th>Strength</th><th>Preparation</th><th>Germicidal Activity</th><th>Astringent Activity</th><th>Comments</th></tr></thead><tbody><tr><td>Normal saline</td><td>0.9%</td><td>1 tsp to a pint of water</td><td>-</td><td>-</td><td>Inexpensive, easy to prepare</td></tr><tr><td>Burow solution (aluminum acetate) Domeboro packets/tablets</td><td>5%</td><td>Dilute to 1:10–1:40 One packet/table to a pint of water yields a 1:40 solution; two yields a 1:20 solution.</td><td>Mild Mild</td><td>+ +</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>-</td><td></td></tr><tr><td>Silver nitrate</td><td>0.1%–0.5%</td><td>1 tsp or a 50% stock solution to 1,000 cc yields a 0.25% solution.</td><td>Good</td><td>+</td><td>Stains, can cause pain</td></tr><tr><td>Acetic acid (vinegar is 5% acetic acid)</td><td>1%–2.5%</td><td>Dilute 1:5 with standard 5% household vinegar</td><td>Good</td><td>+</td><td>Odiferous, can be irritating</td></tr></tbody></table>
<p>Adapted from Habif, T. P. (2010). Clinical dermatology: A color guide to diagnosis and therapy (back inside cover). St. Louis, MO: Mosby.</p>
<p><img src="assets/images/image-20251225-8a7eddc8.jpeg" alt="img-61.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="soaks">Soaks<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#soaks" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Understand objective of soak, and if unclear, ask questions.</li>
<li>Demonstrate mixing of solution (if applicable) and appropriate application technique.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-therapeutic-shampoos">I. Therapeutic shampoos<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-therapeutic-shampoos" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Objective
a. Cleansing
b. Remove accumulated scales, crusts, or medications
c. Deliver medication</p>
</li>
<li>
<p>Types of shampoos
a. Salicylic acid/sulfur
b. Zinc pyrithione (Denorex, Head and Shoulders)
c. Surfactants
d. Tar
e. Selenium sulfide
f. Nizoral</p>
</li>
<li>
<p>Nursing considerations
a. Avoid scrubbing scalp with fingernails to remove scale.
b. Allow shampoo to stay on scalp to enhance penetration.
c. Dryers may increase scaling and pruritus.
d. Rinsing with a solution of two tablespoons of white vinegar in one gallon of water will help prevent hair from becoming dry.</p>
</li>
</ol>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-shampoos">Therapeutic Shampoos<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-shampoos" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Understand the objective of therapy, and if unclear, ask questions.</li>
<li>Use appropriate technique for therapeutic shampoo.</li>
<li>Tar shampoos may cause discoloration.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="viii-laser">VIII. LASER<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#viii-laser" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: Laser is an acronym for light amplification by stimulated emission of radiation. The energy from the laser is directed at the skin, and the majority will be absorbed by chromophores. Lasers produce measurable, repeatable, consistent zones of tissue damage. They can cut, coagulate, and vaporize tissue to some degree.</p>
<p>B. Types: See Tables 4-5,4-6 through 4-7 for types and indications for use.</p>
<p>C. Nursing considerations</p>
<ol>
<li>Must have thorough knowledge of laser safety for both patient and health care providers</li>
<li>Written policy and procedures addressing laser safety must be in place, and a laser safety course is highly recommended.</li>
<li>Pre- and posttreatment education is essential.</li>
<li>Photosensitivity may occur after photodynamic therapy, lasting 4 to 6 weeks.</li>
<li>Laser light is damaging to structures of the eye; therefore, safety glasses or goggles that protect against the specific wavelengths used must be worn by both operator and patient.</li>
</ol>
<p>TABLE 4-5 Lasers Used to Treat Cutaneous Lesions</p>
<table><thead><tr><th>Laser Type</th><th>Wavelength (nm)</th><th>Mode of Output</th><th>Clinical Use</th></tr></thead><tbody><tr><td>Argon (blue-green)</td><td>488; 514</td><td>Continuous</td><td>Vascular and pigmented lesions</td></tr><tr><td>Argon-pumped tunable dye (green-yellow-red)</td><td>504-690</td><td>Continuous</td><td>Vascular and pigmented lesions; photodynamic therapy</td></tr><tr><td>Flashlamp-pumped pigmented lesion dye (green)</td><td>510</td><td>Short pulsed</td><td>Pigmented lesions; tattoos—epidermal</td></tr><tr><td>Copper vapor/bromide (green)</td><td>511</td><td>Pseudocontinuous</td><td>Pigmented lesions—epidermal</td></tr><tr><td>Krypton (green)</td><td>521; 531</td><td>Continuous</td><td>Pigmented lesions—epidermal</td></tr><tr><td>KTP-potassium titanyl phosphate (green)</td><td>532</td><td>Pseudocontinuous</td><td>Vascular and pigmented lesions</td></tr><tr><td>KTP-potassium titanyl phosphate (green)</td><td>532</td><td>Long pulsed</td><td>Vascular and pigmented lesions</td></tr><tr><td>Frequency-doubled Q-switched Nd:YAG (green)</td><td>532</td><td>Pulsed</td><td>Vascular and pigmented lesions; tattoos</td></tr><tr><td>Krypton (yellow)</td><td>568</td><td>Continuous</td><td>Vascular lesions</td></tr><tr><td>Copper vapor/bromide (yellow)</td><td>578</td><td>Pseudocontinuous</td><td>Vascular lesions</td></tr><tr><td>Flashlamp-pumped dye (yellow)</td><td>585-600</td><td>Long pulsed</td><td>Vascular lesions, warts, hypertrophic scars, striae</td></tr><tr><td>Q-switched ruby (red)</td><td>694</td><td>Pulsed</td><td>Pigmented lesions; tattoos</td></tr><tr><td>Q-switched ruby (red)</td><td>694</td><td>Long pulsed</td><td>Hair reduction, pigmented lesions—dermal</td></tr><tr><td>Q-switched alexandrite (infrared)</td><td>755</td><td>Pulsed</td><td>Pigmented lesions—epidermal and dermal; tattoos</td></tr><tr><td>Alexandrite (infrared)</td><td>755</td><td>Long</td><td>Hair reduction</td></tr><tr><td>Diode (infrared)</td><td>810</td><td>Long pulsed</td><td>Hair reduction</td></tr><tr><td>Q-switched Nd:YAG (infrared)</td><td>1,064</td><td>Pulsed</td><td>Pigmented lesions—dermal; tattoos</td></tr><tr><td>Nd:YAG (infrared)</td><td>1,064</td><td>Continuous</td><td>Deep coagulation of tissue</td></tr><tr><td>Nd:YAG (infrared)</td><td>1,064</td><td>Long pulsed</td><td>Hair reduction</td></tr><tr><td>Nd:YAG (infrared)</td><td>1,320</td><td>Pulsed</td><td>Nonablative skin resurfacing</td></tr><tr><td>Er:YAG (infrared)</td><td>2,940</td><td>Pulsed</td><td>Skin resurfacing</td></tr><tr><td>Carbon dioxide (infrared)</td><td>10,600</td><td>Continuous/pulsed</td><td>Tissue cutting; coagulation; vaporization/skin resurfacing</td></tr></tbody></table>
<p>Adapted from Habif, T. P. (2010). Clinical dermatology: A color guide to diagnosis and therapy (back inside cover). St. Louis, MO: Mosby.</p>
<p>TABLE 4-6 Vascular Lesions Treated with Lasers</p>
<table><thead><tr><th>Laser Type</th><th>Clinical Use</th><th>Other Considerations</th></tr></thead><tbody><tr><td>KTP</td><td>Telangiectases; thick PWS in adults</td><td>Increased risk of scarring</td></tr><tr><td>Frequency-doubled Q-switched Nd:YAG</td><td>Telangiectases, cherry angioma, capillary hemangioma</td><td>Temporary unsightly purpura</td></tr><tr><td>Krypton</td><td>Telangiectases; thick PWS in adults</td><td>Better for large-caliber vascular lesions; increased risk of scarring</td></tr><tr><td>Copper vapor</td><td>Telangiectases; thick PWS in adults</td><td>Better for large-caliber vascular lesions; increased risk of scarring</td></tr><tr><td>Flashlamp-pumped dye</td><td>Flat PWS and PWS in children; telangiectases</td><td>Least risk of scarring; temporary unsightly purpura</td></tr><tr><td>Nd:YAG</td><td>Deep coagulation of tissue; cavernous hemangioma</td><td>Better for deep, large-caliber vascular lesions; increased risk of scarring</td></tr><tr><td></td><td>PWS</td><td>Angiokeratoma</td></tr><tr><td></td><td>Capillary (cutaneous) hemangioma</td><td>Adenoma sebaceum</td></tr><tr><td></td><td>Cavernous (subcutaneous) hemangioma</td><td>Angiolymphoid hyperplasia</td></tr><tr><td></td><td>Cherry angioma</td><td>Rosacea</td></tr><tr><td></td><td>Nevus araneus (spider nevi)</td><td>Poikiloderma of Civatte</td></tr><tr><td></td><td>Venous lake</td><td>Telangiectases</td></tr><tr><td></td><td>Glomus tumor</td><td>Verrucae</td></tr><tr><td></td><td>Kaposi sarcoma</td><td>Hypertrophic scars</td></tr><tr><td></td><td>Pyogenic granuloma</td><td>Striae Some scars</td></tr></tbody></table>
<p>PWS, port-wine stain.
Adapted from Habif, T. P. (2010). Clinical dermatology: A color guide to diagnosis and therapy (back inside cover). St. Louis, MO: Mosby.</p>
<p>TABLE 4-7 Pigmented Lesions Treated with Lasers</p>
<table><thead><tr><th>Laser Type</th><th>Clinical Use</th><th></th><th>Other Considerations</th></tr></thead><tbody><tr><td>Argon</td><td>Epidermal pigmented lesions</td><td></td><td>Scarring</td></tr><tr><td>Argon</td><td>Epidermal pigmented lesions</td><td></td><td>Scarring</td></tr><tr><td>Flashlamp-pumped pigmented lesion dye</td><td>Epidermal pigmented lesions; tattoos (red, orange, purple, yellow, tan)</td><td></td><td></td></tr><tr><td>Copper vapor</td><td>Epidermal pigmented lesions</td><td></td><td></td></tr><tr><td>Krypton</td><td>Epidermal pigmented lesions</td><td></td><td></td></tr><tr><td>KTP</td><td>Epidermal pigmented lesions</td><td></td><td></td></tr><tr><td>Frequency-doubled Q-switched Nd:YAG</td><td>Epidermal pigmented lesions; tattoos (red, orange, purple, tan)</td><td></td><td></td></tr><tr><td>Q-switched ruby</td><td>Dermal and epidermal pigmented lesions; tattoos (black, blue, green)</td><td></td><td></td></tr><tr><td>Q-switched alexandrite</td><td>Dermal and epidermal pigmented lesions; tattoos (black, blue, green)</td><td></td><td></td></tr><tr><td>Q-switched Nd:YAG</td><td>Dermal pigmented lesions; tattoos (black, blue)</td><td></td><td></td></tr><tr><td>Nd:YAG</td><td>Dermal pigmented lesions; tattoos (black, blue)</td><td></td><td></td></tr><tr><td></td><td>Tattoos</td><td></td><td></td></tr><tr><td></td><td>Dermal pigmented lesions</td><td>Nevus of Ota, Becker nevus, Melasma</td><td></td></tr><tr><td></td><td>Epidermal pigmented lesions</td><td>Solar lentigo, ephilides, epidermal nevus, Café au lait</td><td></td></tr></tbody></table>
<p>Cafe au lait, melasma, and Becker's nevi have variable responses to laser treatment. Adapted from Habif, T.P. (2016). Clinical dermatology: A color guide to diagnosis and treatment (6th ed.). Philadelphia, PA. Elsevier. Adapted from Marcus, J., &amp; Goldberg, D. J. (1996). Lasers in dermatology: A nursing perspective. Dermatology Nursing, 8(3), 181-195.</p>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="laser-treatment">Laser Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laser-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Understand objective of treatment, risks, side effects, and benefits.</li>
<li>Understand pre- and posttreatment interventions.</li>
<li>There is an increased vulnerability of skin; need to avoid environmental stresses including UV radiation.</li>
<li>Possible need for multiple treatments when indicated.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ix-dermatologic-surgery">IX. DERMATOLOGIC SURGERY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ix-dermatologic-surgery" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Shave biopsy: See Diagnostic Options, Chapter 3.
B. Punch biopsy: See Diagnostic Options, Chapter 3.
C. Excisional biopsy: See Diagnostic Options, Chapter 3.
D. Wedge biopsy: See Diagnostic Options, Chapter 3.
E. Mohs: See Chapter 3.</p>
<p>F. Dermabrasion</p>
<ol>
<li>Definition: The process of planning the superficial layer of epidermis and dermis. The area to be treated may be anesthetized by injecting local anesthesia or freezing the area with fluoroethyl spray.</li>
<li>Indications
a. Removal of superficial scars, that is, acne scarring
b. Removal of hyperplastic tissue
c. Tattoo removal
d. Rhinophyma
e. Sun-damaged skin</li>
<li>Nursing considerations
a. Patient expectations may be unrealistic; be clear and direct when informing patient of outcome.
b. Results are seen slowly.
c. Discomfort may increase as lesions dry and heal.
d. Risk of infection due to loss of protective barrier.
e. Photosensitivity postprocedure.
f. Edema is common postprocedure; keep head elevated at least 45 degrees during first 24 to 48 hours.
g. Analgesics may be indicated for postprocedure discomfort.</li>
</ol>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dermabrasion">Dermabrasion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermabrasion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Understand procedure process.</li>
<li>A thorough understanding of the treatment effects will be paramount to satisfaction; understand the need for follow-up treatments or therapies.</li>
<li>May use petrolatum to relieve tightness after treatment.</li>
<li>Keep head elevated for 24 to 48 hours postprocedure to reduce edema.</li>
<li>Use saline solution for wound cleansing to help reduce edema.</li>
<li>Monitor for signs of infection, that is, increasing pain, pus, and unusual swelling.</li>
<li>Use sun protection at all times when outside.</li>
<li>Take analgesics as directed for discomfort.</li>
<li>Expect oozing for at least 24 hours.</li>
<li>Crust will form and will last approximately 1 week.</li>
<li>Skin may remain red for approximately 2 to 3 months.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="x-unna-s-boot">X. UNNA'S BOOT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#x-unna-s-boot" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: A dressing for venous ulcers consisting of 3- to 4-inch bandage impregnated with calamine-gelatin-zinc oxide paste. It is applied to the leg and produces a semirigid boot.</p>
<p>B. Indications</p>
<ol>
<li>To reduce edema</li>
<li>Decrease healing time in stasis ulcers</li>
<li>Give support to surgical wounds</li>
<li>Protect lesions from manipulation</li>
<li>Excellent alternative to elastic wraps particularly for patients who are not self-sufficient</li>
<li>Reduction of pain</li>
<li>Soothing and antipruritic</li>
<li>Acute and chronic tendonitis</li>
<li>Ankle sprain, with or without fracture</li>
</ol>
<p>C. Application</p>
<ol>
<li>
<p>Can be applied to legs before arising in the morning to prevent edema.</p>
</li>
<li>
<p>Applied with graduated pressure with greatest pressure at ankle and gradually lessening as wrapped up the leg.</p>
</li>
<li>
<p>Use Unna paste boot gauze.</p>
</li>
<li>
<p>Wash leg with warm water and dry thoroughly.</p>
</li>
<li>
<p>Apply a thin layer of topical medication, when indicated (bacitracin zinc/polymyxin B sulfate ointment).</p>
</li>
<li>
<p>Apply hydrocolloid or hydrogel dressing over ulcer.</p>
</li>
<li>
<p>Begin wrap behind first metatarsal prominence.</p>
</li>
<li>
<p>Wrap, enclosing the heel and being certain there are no wrinkles to cause discomfort, and keep ankle at a right angle.</p>
</li>
<li>
<p>Use only one layer of Kling or Kerlix as an underlayer if desired.</p>
</li>
<li>
<p>When passing over the ulcer, do not allow edge of gauze to lie directly on ulcer; this will cause pain.</p>
</li>
<li>
<p>Continue wrapping proximally, with a  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>  overlap with each wrap (Figure 4-14).</p>
</li>
<li>
<p>Be sure that pressure of wrap is greater at ankle, decreasing to knee.</p>
</li>
<li>
<p>Wrap the leg with three layers and stop wrap just below popliteal space.</p>
</li>
<li>
<p>Gently mold the wrap by gently rubbing.</p>
</li>
<li>
<p>Place about 2.5 yards of tube gauze, Kling, Coban, or a stockinette over the form.</p>
</li>
<li>
<p>Have patient secure the gauze at the knee and then begin stretching while rotating the tube gauze form.</p>
</li>
<li>
<p>Relax tension when at the foot, rotating the form once.</p>
</li>
<li>
<p>Push back over the foot rotating toward the knee.</p>
</li>
<li>
<p>Pull tension on loose ends of tube gauze and secure with 2-inch Elastoplast (see Figure 4-15).</p>
</li>
<li>
<p>Fold down and trim loose edges and secure with tape.</p>
</li>
<li>
<p>Unna's boot should remain comfortably in place for 3 to 11 days.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-eaf1bba9.jpeg" alt="img-62.jpeg">
FIGURE 4-14. Unna's boot application. Begin behind first metatarsal prominence and</p>
<p>continue wrapping proximally, with a  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>  overlap. Be sure that pressure of wrap is greater at ankle, decreasing to knee. Wrap the leg with three layers and stop wrap just below popliteal space. (From Lippincott's Nursing Procedures and Skills, 2007.)</p>
<p><img src="assets/images/image-20251225-bb236206.jpeg" alt="img-63.jpeg">
FIGURE 4-15. Completed Unna's boot. (From Lippincott's Nursing Procedures and Skills, 2007.)</p>
<p>Note: It may be helpful to apply a bland emollient to the unaffected areas of the legs to decrease dryness and pruritus during time boot is in place.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="xi-photopheresis">XI. PHOTOPHERESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#xi-photopheresis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Indications</p>
<p>Photopheresis is indicated for the palliative treatment of the skin manifestations of CTCL (Figure 4-16).</p>
<p>B. Overview</p>
<ol>
<li>Photopheresis, or extracorporeal photochemotherapy (ECP), is an FDA-approved therapy for CTCL (see Chapter 6). CTCL is a malignancy of human T lymphocytes (helper T cells). These malignant lymphocytes often target the skin and spend part of their life cycle residing there. This infiltration of malignant cells into the skin can be seen in several variations and ranges. Manifesting various lesions including patch-plaque-type disease, fissures and ulcerations, tumors, and/or a universal erythrodermic scaly version that may cover the entire skin surface.</li>
<li>Treatment is determined primarily by the extent of disease, quality of life, age, and comorbidities.</li>
</ol>
<p>a. The photopheresis UVAR XTS instrument integrates three main subsystems designed to collect and separate a portion of the patient's blood and to photoactivate the</p>
<p>collected WBCs.</p>
<p>b. In photopheresis, the injectable drug, methoxsalen (UVADEX), is given directly into the reservoir collection bag (collected WBCs) just prior to the photoactivation phase.</p>
<p>c. Using a 16- to 17-gauge butterfly needle inserted in the antecubital vein, a portion of blood is removed (300 to 400 mL) and then processed through a centrifuge where the individual components of the blood are separated. Some of the plasma and as many of the white blood cells as can be collected are stored in a reservoir bag.</p>
<p>d. The red blood cells are returned to the patient immediately. The plasma and the white blood cells are then circulated through an ultraviolet light field where the UV light activates the methoxsalen that is now attached to the lymphocytes.</p>
<ol start="3">
<li>
<p>How the UVA-activated methoxsalen affects the white blood cells and primarily the malignant T cells found in CTCL is still not completely understood. We do know that the UVA light activates the methoxsalen inside the cell. This leads to cross-linking of the DNA and the death of the cell.</p>
</li>
<li>
<p>Ongoing research also suggests that the methoxsalen combined with UVA may somehow affect the presentation of endogenous antigens on the cell surface. When these treated white blood cells are returned to the patient, it appears that they are now capable of stimulating the patient's previously unresponsive immune system, thereby fighting the disease. The total understanding of how these processes take place is unknown.</p>
</li>
</ol>
<p>C. Pretreatment Workup</p>
<ol>
<li>Prior to the patient being referred for treatment, a complete physical examination, body surface area (BSA) measurement, modified severity-weighted assessment tool (mSWAT), skin biopsy, lymph node biopsy, flow cytometry, or monoclonal antibody test must be performed to confirm the diagnosis. In addition, results from the following tests should be evaluated prior to starting photopheresis.</li>
</ol>
<p>a. CBC with differential
b. Chemistry panel
c. Hepatitis and HIV screening
d. Chest x-ray and electrocardiogram
e. Lactate dehydrogenase
f. PET or CT scan</p>
<ol start="2">
<li>
<p>It is important that the patient is screened for any underlying renal, hepatic, cardiovascular, or infectious disease prior to starting the photopheresis procedure. The removal of close to a unit of blood during the procedure can put the patient at risk for a hypotensive/hypovolemic episode. Therefore, the above tests should be performed and the results evaluated very carefully by the medical staff to ensure that the patient can tolerate the procedure.</p>
</li>
<li>
<p>The patient's disease should be staged by an experienced practitioner, usually a specialized dermatologist or hematologist-oncologist.</p>
</li>
</ol>
<p>D. Orientation to Therapy</p>
<ol>
<li>
<p>Prior to starting the actual treatment, the patient should be introduced to the photopheresis nursing staff and undergo an orientation to the unit and its procedures. One of the nurses' most important roles is to be an advocate for the patient.</p>
</li>
<li>
<p>Any interested relatives should be invited to participate with the patient to establish as much support as possible. The Cutaneous Lymphoma Foundation (CLF) was formed in 1998 and is dedicated to supporting people with cutaneous lymphomas. The website is <a href="http://www.clfoundation.org" target="_blank" rel="noopener noreferrer">www.clfoundation.org</a></p>
</li>
<li>
<p>Written material regarding the disease and the procedure should be offered to the patient and copies given to relatives.</p>
</li>
<li>
<p>Additional written instructions regarding policies and unit procedures should be provided for the patient.</p>
</li>
<li>
<p>Written information regarding the ultraviolet light should be presented; precautions should be discussed and provided.</p>
</li>
<li>
<p>The patient should be instructed in how to contact the medical/nursing staff in case of potential emergency situations (fever, pain, bleeding, or other acute symptoms).</p>
</li>
<li>
<p>The primary nurse in charge should also arrange for the patient to meet with the office staff to review health insurance coverage for the procedure.</p>
</li>
</ol>
<p>E. Procedure Information</p>
<ol>
<li>
<p>After a thorough explanation by a member of the medical staff, a consent form is obtained by the physician in charge.</p>
</li>
<li>
<p>The patient is given an appointment for the procedure.</p>
</li>
<li>
<p>The patient is reminded about the most common precautions that must be taken (use sunscreen, UV-protective glasses). These instructions should be provided to the patient in writing.</p>
</li>
<li>
<p>A follow-up telephone call prior to starting therapy to review all instructions and to evaluate the patient's level of understanding is beneficial.</p>
</li>
<li>
<p>Prior to the actual procedure, the patient is examined by the medical staff and an assessment is performed by the primary nurse. This assessment includes the following:</p>
</li>
</ol>
<p>a. Recent medical history
b. Review of allergies
c. Review of medications currently being used
d. Vital signs
e. Physical exam
f. A brief review of the recent social history</p>
<ol start="6">
<li>If the patient is cleared, the procedure is performed. After the procedure, the patient may be discharged if:</li>
</ol>
<p>a. Vital signs are normal
b. He/she has no new complaints
c. He/she has a secured pressure dressing on the needle site
d. He/she uses appropriate sun protection
e. He/she is cleared for discharge by the medical staff</p>
<ol start="7">
<li>The photopheresis procedure in most institutions is a 3- to 4-hour outpatient procedure.</li>
</ol>
<p>a. After the patient has been cleared for treatment, venous access is obtained using a 16- to 17-gauge intravenous needle.
b. The preferred access site is one of the large antecubital veins.
c. In some patients, it can be very difficult to obtain a sufficient access. It might be</p>
<p>necessary to insert some type of a central line, similar to those used for chemotherapy or hyperalimentation. This increases the risk for infections in this high-risk group of patients and should be avoided if possible.</p>
<p>d. The photopheresis UVAR XTS system automatically sets the photoactivation time (light exposure time) based upon the total treatment volume, hematocrit of the treatment volume, and remaining UVA lamp life.</p>
<p>e. During the procedure, the patient will also receive between 500 to 650 mL of 0.9% saline, some mixed with heparin to prevent the blood from clotting as it goes through the instrument. It is also given to maintain the patient's blood volume and to prevent any hypovolemia. Patients who are susceptible to fluid shifts may experience an exacerbation of congestive heart failure symptoms if they cannot tolerate this fluid during treatment.</p>
<p>F. Post-treatment Precautions</p>
<ol>
<li>Prior to leaving, the patient is instructed as to the following precautions:</li>
</ol>
<p>a. Bleeding tendency</p>
<p>i. Due to the use of heparin as an anticoagulant during the procedure, the patient should be instructed to watch for bleeding immediately after the treatment primarily from the needle site. The amount of heparin used during the treatment is fairly low (between 6,000 and 10,000 units of heparin) and will rarely cause such complications.</p>
<p>ii. The pressure dressing that is applied to the needle insertion site should remain in place for at least 4 hours. When it is removed, the patient may place an adhesive bandage over the site.</p>
<p>iii. If any bleeding occurs from the needle site, the patient should be instructed to apply pressure to the site. If the bleeding does not stop within a reasonable period of time, the patient should be instructed to either seek help from his/her local health care provider and emergency room or call 9-1-1 and request help.</p>
<p>b. Methoxsalen</p>
<p>i. When using methoxsalen, a drug that causes sensitivity when activated by ultraviolet light, the patient should be instructed in specific precautions (as recommended by the manufacturer).</p>
<p>a. Sun exposure should be avoided for 24 hours after treatment, and sunscreen should be applied to the skin areas that may be exposed to sunlight.</p>
<p>b. Protective UV wraparound sunglasses should be worn during daylight for the next 24 hours.</p>
<p>c. It is recommended by the drug manufacturer that all patients should have an annual eye exam to monitor the effects of the methoxsalen (cataracts).</p>
<p>c. Additional information</p>
<p>i. Patient should be instructed that a small fever spike may occur 4 to 6 hours after the treatment. This is a common reaction and there is no cause for alarm. This usually will subside without any need for treatment. If it does persist for longer than 24 hours, patient should notify their provider.</p>
<p>ii. Patient should be instructed how to avoid potential light-sensitive medications that</p>
<p>might interfere with the photopheresis treatment. A list of light-sensitive drugs should be provided and reviewed with the patient and/or significant other.</p>
<p>iii. Patient and significant others should be informed how to contact the unit staff and/or provider for any emergencies or concerns.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="g-scheduling">G. Scheduling<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#g-scheduling" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>The photopheresis treatments are always given on 2 consecutive days every 2 to 4 weeks for 6 months. The physician in charge determines the actual treatment schedule depending on the severity of the patient's condition. As the patient's condition improves, the interval between the treatments may be extended.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="h-adjunctive-therapy">H. Adjunctive Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#h-adjunctive-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Patients with a partial response to photopheresis can often gain additional improvement if an adjunctive therapy is selected. The physician, together with the patient, will determine when and if any additional therapy is needed. Some of the adjunctive therapies used are the following:</li>
</ol>
<p>a. Total skin electron beam therapy (TSEBT) is given to selected skin areas or to the total skin surface and is best used for patients with extensive skin involvement.
b. Chemotherapeutic agents such as methotrexate, nitrogen mustard, and carmustine
c. The different interferons can also be used.
d. Psoralen and ultraviolet A radiation (PUVA) PUVA
e. Bexarotene (Targretin) (oral or topical)
f. Noncytotoxic and biologic agents: Corticosteroids (oral or topical), denileukin diftitox, alemtuzumab, and histone deacetylase inhibitors
g. Allogeneic stem cell transplantation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-complications">I. Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Photopheresis has been used worldwide since 1987 and was FDA approved in 1988. Presently, no major side effects have been identified. The photopheresis treatment does not appear to suppress the immune system or expose the patient to an increased risk of opportunistic infections or other malignant diseases.</li>
</ol>
<p>a. Minor side effects that can occasionally occur:</p>
<p>i. Hematoma and bleeding from needle site that can be easily treated with pressure dressings and ice packs
ii. Slight fever spike 4 to 8 hours after reinfusion of the treated cells that usually does not require treatment
iii. Increased erythema and itching immediately after the treatment. This will most often respond to oral antihistamines
iv. Hypovolemia/hypotension caused by volume shifts during treatment. In most situations, this can be corrected by infusion of intravenous fluids and positioning the patient in a Trendelenburg position
v. Nausea from ingestion of 8-MOP
vi. Catheter-related infection, headache, and chills</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="j-response">J. Response<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#j-response" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>During the initial clinical trials that led to the FDA approval of photopheresis (1984 to 1987), the data showed that approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of patients treated with photopheresis</li>
</ol>
<p>had an excellent response to the therapy. Thirty percent had some response but might benefit from adjunctive treatments, and 30% showed no response. Recent clinical publications have reported 33% to 88% response rates.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="k-nursing-considerations">K. Nursing Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#k-nursing-considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-evaluation-and-teaching">1. Evaluation and teaching<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-evaluation-and-teaching" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>a. It is very important that the patient receives a general medical evaluation prior to starting therapy to exclude any significant medical problems that might be a contraindication to photopheresis (cardiac, renal, hepatic disease, or any infectious disease).</p>
<p>b. Both the patient and significant others should receive a detailed orientation to the procedure, the unit, and its policies.</p>
<p>i. The unit coordinator or the primary nurse should meet with the patient and significant others and provide additional verbal information as needed. Make sure that the patient has plenty of opportunities to ask questions.</p>
<p>ii. If possible, have the patient observe an actual treatment and meet other patients who are receiving therapy.</p>
<p>c. Allow the patient time to absorb the information given. Do not start treatment on the same day patient is being oriented to the procedure.</p>
<p>d. Give the patient detailed instructions regarding possible side effects, expectations, and information regarding other forms of therapy that may be needed.</p>
<p>e. Communicate all test data and results to the patient directly, if the patient has requested this information.</p>
<p>f. Provide a multidisciplinary approach using all disciplines within the system (medicine, nursing, social work, psychiatry, dietary, and other resources from within the institution as they are needed).</p>
<p><img src="assets/images/image-20251225-ee6e9ce1.jpeg" alt="img-64.jpeg">
A</p>
<p><img src="assets/images/image-20251225-da4bc61f.jpeg" alt="img-65.jpeg">
C</p>
<p><img src="assets/images/image-20251225-532c9e4e.jpeg" alt="img-66.jpeg">
D,E
FIGURE 4-16. The cutaneous phases of mycosis fungoides.</p>
<p>A:Early patch-stage lesions in a sun-protected region.</p>
<p>B:Hyperpigmented diffuse patches on the back of a dark-skinned patient.
C: Scattered thin and thick plaques on the back.
D:Early keratoderma of the sole.
E:Ulcerated tumor within a plaque on the posterior leg.</p>
<p>F: Coalescing nodules and tumors with dermal thickening forming “leonine facies” in this patient with transformed cutaneous T-cell lymphoma (CTCL). (From Greer, J. P., et al. (2013). Wintrobe’s clinical hematology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-9f040679.jpeg" alt="img-67.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="photopheresis">Photopheresis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#photopheresis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Understand the objectives, outcomes, and side effects of treatment, and if unclear, ask questions.</li>
<li>Expect a fever for a couple of hours after treatment; this is common and usually does not require treatment.</li>
<li>If you experience increased redness or itching post-treatment, antihistamines help relieve these symptoms.</li>
<li>Contact your health care provider if you have any vision changes or other unexpected side effects.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Beckmann, C. R. B., Ling, F. W., Herbert, W. N. P., Laube, D. W., Smith, R. P., Casanova, R., ..., Weiss, P. M. (2014). Obstetrics and gynecology (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Calderwood, S. B. (2014). Cephalosporins. UptoDate. Retrieved from <a href="http://www.uptodate.com/contents/cephalosporins?source=preview&amp;amp;language=en-US&amp;amp;anchor=H12&amp;amp;selectedTitle=1~150#H2999961" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/cephalosporins?source=preview&amp;amp;language=en-US&amp;amp;anchor=H12&amp;amp;selectedTitle=1~150#H2999961</a></p>
<p>De Lima, E. L., Salome, G. M., De Brito Rocha, M. J. A., &amp; Ferreira, L. M. (2013). The impact of compression therapy with Unna’s boot on the functional status of VLU patients. Journal of Wound Care, 22(10), 558–561.</p>
<p>Domino, F. J., Baldor, R. A., Golding, J., Grimes, J. A., &amp; Scott-Taylor, J. (Eds.) (2013). The 5-minute clinical consult 2013 (21st ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Edmunds, M. W., &amp; Mayhew, M. S. (2009). Pharmacology for the primary care provider (3rd ed.). St. Louis, MO: Mosby.</p>
<p>Ersser, S. J., Maguire, S., Nicol, N., Penzer, R., &amp; Peters, J. (2009). Best practice in emollient therapy: A statement for health care professionals (2nd ed.). Dermatological Nursing (Supplement), 8(3), 1–22.</p>
<p>Frye, R., Myers, M., Axelrod, K. C., Ness, E. A., Piekarz, R. L., Bates, S. E., &amp; Booher, S. (2012). Romidepsin: A new drug for the treatment of cutaneous T-cell lymphoma. Clinical Journal of Oncology Nursing, 16(2), 195–204.</p>
<p>Goldstein, A. O., &amp; Goldstein, B. G. (2014a). Cutaneous warts. Retrieved from: <a href="http://www.uptodate.com/contents/cutaneous-warts?source=search_result&amp;amp;search=warts&amp;amp;selectedTitle=1%7E21" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/cutaneous-warts?source=search_result&amp;amp;search=warts&amp;amp;selectedTitle=1%7E21</a></p>
<p>Goldstein, A. O., &amp; Goldstein, B. G. (2014b). Dermatophyte (tinea) infections. UptoDate. Retrieved from: <a href="http://www.uptodate.com/contents/dermatophyte-tinea-infections?source=search_result&amp;amp;search=tinea&amp;amp;selectedTitle=1%7E109#H1" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/dermatophyte-tinea-infections?source=search_result&amp;amp;search=tinea&amp;amp;selectedTitle=1%7E109#H1</a></p>
<p>Habif, T. P. (2010). Clinical dermatology: A color guide to diagnosis and therapy. St. Louis, MO: Mosby</p>
<p>Habif, T. P. (2016). Clinical dermatology: a Color guide to diagnosis and therapy (6th ed.). Philadelphia, PA: Elsevier</p>
<p>Habif, T. P., Campbell, J. L., Chapman, M. S., Dinulos, J. G., &amp; Zug, K. A. (2011). Skin disease and treatment (3rd ed.). St. Louis, MO: Mosby.</p>
<p>Herbert-Ashton, M., &amp; Clarkson, N. (2008). Quick look nursing: Pharmacology (2nd ed.). Burlington, MA: Jones and Bartlett.</p>
<p>Hsu, D. C. (2014). Infiltration of local anesthetics. UptoDate. Retrieved from: <a href="http://www.uptodate.com/contents/infiltration-of-local-anesthetics?source=search_result&amp;amp;search=anesthetics&amp;amp;selectedTitle=4%7E150#H2694370" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/infiltration-of-local-anesthetics?source=search_result&amp;amp;search=anesthetics&amp;amp;selectedTitle=4%7E150#H2694370</a>
Jablonski, N. (2006). Skin: A natural history. Los Angeles, CA: UC Press.
Jawed, S. I., Mykowski, P. L., Horowitz, S., Moskowitz, A., &amp; Querfeld, C. (2014a). Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): Part I. Clinical and histopathologic features and new molecular and biologic markers. Journal of the American Academy of Dermatology, 70(2), 205-e1-205-e16.
Jawed, S. I., Mykowski, P. L., Horowitz, S., Moskowitz, A., &amp; Querfeld, C. (2014b). Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): Part II. Prognosis, management, and future directions. Journal of the American Academy of Dermatology, 70(2), 223-e1-223-e17.
Katsambas, A., &amp; Dessinioti, C. D. (2014). Pityriasis rubra pilaris. Retrieved from: <a href="http://www.uptodate.com/contents/pityriasis-rubra-pilaris" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/pityriasis-rubra-pilaris</a>? source=search_result&amp;search=retinoids&amp;selectedTitle=13%7E150#H427352231
Klein, M. J. (2013). Superficial heat and cold. <em>Medscape</em>. Retrieved from: <a href="http://emedicine.medscape.com/article/1833084-overview#a01" target="_blank" rel="noopener noreferrer">http://emedicine.medscape.com/article/1833084-overview#a01</a>
Kolarsick, P. A., Kolarsick, M. A., &amp; Goodwin, C. (2011). Anatomy and physiology of the skin. Journal of the Dermatology Nurses Association, 3(4), 203-213.
Lapolla, W., Yentzer, B.a., Bagel, J., Halvorson, C. R., &amp; Feldman, S., R. (2011). A review of phototherapy protocols for psoriasis treatment. Journal of the American academy of dermatology, vol. 64(5), 936-949.
Lansigan, F., &amp; Foss, F. (2010). Current and emerging treatment strategies for cutaneous T-cell lymphoma. <em>Drugs</em>, 70(3), 273-286.
Lee, M., &amp; Kalb, R. E. (2008). Systemic therapy for psoriasis. Dermatology Nursing, 20(2), 105-111.
Macksey, L. F. (2011). Surgical procedures and anesthetic implications: A handbook for nurse anesthesia practice. Burlington, MA: Jones and Bartlett.
Malamed, S. F. (2013). Handbook of local anesthesia (6th ed.). Missouri, MO: Mosby.
McCann, S. A. (2007). Cutaneous T-cell lymphoma: Overview and nursing perspectives. Nursing Clinics of North America, 42, 421-455.
Medscape (no author, 2014). Coal tar shampoo. Retrieved from: <a href="http://reference.medscape.com/drug/neutrogena-t-geloriginal-dhs-tar-coal-tar-shampoo-999365#4" target="_blank" rel="noopener noreferrer">http://reference.medscape.com/drug/neutrogena-t-geloriginal-dhs-tar-coal-tar-shampoo-999365#4</a>
Menter, A.,...Bhushan, R. (2010) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section five. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American academy of dermatology, vol 62(1), 114-135.
Nicol, N. H. (2005). Use of moisturizers in dermatologic disease: The role of healthcare providers in optimizing treatment outcomes. Cutis, 76, 32-33.
Nicol, N. H. (2011). Efficacy and safety considerations in topical treatments for atopic dermatitis. Pediatric Nursing, 37(6), 295-302.
Phenninger, J. L., &amp; Fowler, G. C. (2011). Procedures for primary care (3rd ed.). St. Louis, MO: Elsevier.
Richards, E.G. &amp; Morison, W. (2014). Psoralen plus ultraviolet A (PUVA) photochemotherapy. Retrieved from: <a href="http://www.uptodate.com/contents/psoralen-plus-ultraviolet-a-puva-photochemotherapy" target="_blank" rel="noopener noreferrer">www.uptodate.com/contents/psoralen-plus-ultraviolet-a-puva-photochemotherapy</a>
Schreml, S., Szeimies, R. M., Karrer, S., Heinlin, J., Landthaler, M., &amp; Babilos, P. (2010). The impact of the pH value on skin integrity and cutaneous wound healing. Journal of the European Academy of Dermatology and Venereology, 24(4), 373-378.
Talpur, R., Demierre, M. F., Geskin, L., Baron, E., Pugliese, S., Eubank, K., ..., Duvic, M. (2011). Multicenter photopheresis intervention trial in early stage mycosis fungoides. Clinical Lymphoma, Myeloma, &amp; Leukemia, 11(2), 219-227.
Travers, N. (2013). Overview of laser therapy for common vascular lesion. Journal of Dermatology Nurses' Association, 5(5), 280-285.
Ustine, R. P., &amp; Pfenniger, J. L. (2012). Dermatologic and cosmetic procedures in office practice. Philadelphia, PA: Saunders.
Vallerand, A. H., Sanoski, C. A., &amp; Deglin, J. H. (2013). Davis's drug guide for nurses (13th ed.). Philadelphia, PA: F.A. Davis.
Wheeler, T. (2010). Psoriasis: Impact and management of moderate to severe disease. British Journal of Nursing, 19(1), 10-17.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Intralesional steroids can be appropriate for patients with:</li>
</ol>
<p>a. Psoriasis.
b. Alopecia areata.
c. Cystic acne.
d. Hypertrophic scars.
e. All of the above.</p>
<ol start="2">
<li>
<p>There is a higher risk of burning and blistering with systemic psoralen than with topical application.
a. True
b. False</p>
</li>
<li>
<p>Properties of antimetabolites (e.g., 5-fluorouracil) include all of the following except:
a. Interferes with the synthesis of nucleic acids and proteins.
b. Phase specific; inhibits RNA and DNA synthesis.
c. Used in treating superficial basal cell carcinomas, multiple actinic leukoplakia, or solar keratosis.
d. Affects cellular differentiation and proliferation and also down-regulates CCR4 and E-selectin expression, affecting malignant T-cell trafficking to the skin.</p>
</li>
<li>
<p>Side effects of retinoid therapy include:
a. Erythema and dryness of skin.
b. Blisters and stinging.
c. Peeling and edema.
d. All of the above.</p>
</li>
<li>
<p>Side effects of steroid therapy include all of the following except:
a. Mood changes.
b. Muscle wasting.
c. Hypopigmentation/hyperpigmentation.
d. Alopecia.</p>
</li>
<li>
<p>Local anesthetics block the flow of sodium ions, thereby preventing transmission of the impulse.
a. True
b. False</p>
</li>
<li>
<p>Epinephrine has all of the following properties except:
a. Shortens time of onset, prolongs durations, and increases the depth of anesthesia.
b. Reduces systemic absorption and toxicity by reducing rate of clearance, gaining more effective anesthesia with less drug volume.</p>
</li>
</ol>
<p>c. Useful with longer-acting anesthetics.
d. Reduces bleeding during procedure (plain lidocaine is a vasodilator).</p>
<ol start="8">
<li>
<p>CNS and cardiovascular reactions with local anesthetics can be managed by injecting quickly to avoid prolonged burning at the injection site.
a. True
b. False</p>
</li>
<li>
<p>Cryosurgery is indicated for which of the following conditions?
a. Thickened seborrheic keratosis.
b. Molluscum contagiosum.
c. Psoriasis.
d. Cutaneous melanoma.</p>
</li>
<li>
<p>Salicylic acid should not be applied to any of the following except:
a. Warts.
b. Moles.
c. Birthmarks.
d. Mucous membranes.</p>
</li>
<li>
<p>Possible side effects of antifungals include:
a. Overgrowth of fungus when occlusion is used.
b. Blistering.
c. Skin irritation.
d. Overgrowth of fungus when occlusion is used.
e. All of the above.</p>
</li>
<li>
<p>Antimicrobial activity of the macrolide class of antibiotics includes all of the following except:
a. Pneumococci.
b. Group A Streptococci.
c. Staphylococci aureus (not methicillin-resistant S. aureus).
d. Gram-positive bacteria only.</p>
</li>
<li>
<p>Isotretinoin is an effective drug for cystic acne, but the following must be considered:
a. May impair ability to drive.
b. Must be prescribed and used by providers and patients who have successfully registered in the iPLEDGE program.
c. Should be taken with caution because it inhibits adrenal gland function.
d. Patients should increase their intake of vitamin A supplements.</p>
</li>
<li>
<p>Properties of cephalosporins include all of the following except:</p>
</li>
</ol>
<p>a. Rapidly absorbed by the GI tract.
b. Must be taken with food.
c. Distributed widely through soft tissue and bodily fluids except CSF.
d. Oral cephalosporins reach a peak serum concentration level within 1 to 6 hours after administration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>1.e
2.b
3.d,
4.d
5.d
6.a
7.c
8.b
9.b
10.a
11.d
12.d
13.b
14.b</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>